UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Pursuant
to
Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of earliest event reported) February 12, 2009
PRESSURE
BIOSCIENCES, INC.
(Exact
Name of Registrant as Specified in its Charter)
MASSACHUSETTS
(State or Other Jurisdiction of Incorporation)
0-21615
|
|
04-2652826
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
14 Norfolk Avenue, South Easton, MA
|
|
02375
|
(Address
of Principal Executive Offices)
|
|
(Zip Code)
|
(508)
230-1828
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (
see
General Instruction A.2. below):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
1.01
|
Entry
into a Material Definitive
Agreement.
|
Securities
Purchase Agreement
On
February 12, 2009, pursuant to the terms of a Securities Purchase Agreement
entered into as of February 12, 2009 (the “
Securities Purchase
Agreement
”), Pressure BioSciences, Inc. (the “
Company
”) closed a
private placement to 35 accredited investors (“
Private Placement
”),
pursuant to which the Company issued and sold an aggregate of 156,980 units,
each unit consisting of (i) one share of a newly created series of preferred
stock, designated “Series A Convertible Preferred Stock,” par value $0.01 per
share (the “
Series A
Preferred Stock
”), (ii) a warrant to purchase, at the purchaser’s
election to be made within 7 days of the closing, either 10 shares of Company
common stock, par value $0.01 per share (“
Common Stock
”), at an
exercise price equal to $1.25 per share, with a term expiring 15 months after
the date of closing (“
15 Month Common Stock
Warrant
”), or one share of Series A Preferred Stock at an exercise price
equal to $12.50 per share, with a term expiring 15 months after the date of
closing (“
15 Month
Preferred Stock Warrant
”); and (iii) a warrant to purchase 10 shares of
Common Stock at an exercise price equal to $2.00 per share, with a term expiring
30 months after the date of closing (the “
30 Month Common Stock
Warrants
”). The purchase price for each unit was $11.50
(the “
Purchase
Price
”), resulting in aggregate gross proceeds to the Company of
$1,805,270.
The
Securities Purchase Agreement contains customary representations and warranties
and covenants from the Company and each purchaser.
In
connection with the Private Placement and the Securities Purchase Agreement, the
Company also agreed that if it completes a subsequent equity financing within
one year from the initial closing of the Private Placement, it will offer each
purchaser the opportunity to exchange the units purchased in the Private
Placement for the equity securities issued in such subsequent financing, subject
to compliance with applicable rules and regulations.
This
description of the Securities Purchase Agreement does not purport to be complete
and is qualified in its entirety by reference to the Securities Purchase
Agreement, a copy of which is attached to this report as Exhibit 4.1 and is
incorporated herein by reference.
Series
A Preferred Stock
Dividends
. The
Series A Preferred Stock will pay a cumulative dividend at the rate of 5% per
annum of the Purchase Price, payable semi-annually on June 30 and December 31,
commencing on June 30, 2009 (with the first payment to be pro-rated based on the
number of days occurring between the date of issuance and June 30,
2009). Dividends may be paid in cash or in shares of Common Stock at
the Company’s option, subject to certain conditions.
Liquidation
Preference
. In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Company, the holders of Series A Preferred
Stock will be paid out of the assets of the Company available for distribution
to the Company’s stockholders before any payment shall be paid to the holders of
Common Stock, an amount per share equal to the Purchase Price, plus accrued and
unpaid dividends. Unless the holders of a majority of the outstanding
shares of Series A Preferred Stock elect otherwise, a merger or consolidation
(other than one in which stockholders of the Company own a majority by voting
power of the outstanding shares of the surviving or acquiring corporation) and a
sale, lease, transfer or other disposition of all or substantially all of the
Company’s assets will be treated as a liquidation of the Company thereby
triggering the liquidation preference.
Voluntary
Conversion
. Each share of Series A Preferred Stock is
convertible into 10 shares of Common Stock at any time at the option of the
holder, subject to adjustment for stock splits, stock dividends,
recapitalizations and similar transactions (the “
Conversion Ratio
”).
Unless waived under certain circumstances by the holder of Series A Preferred
Stock, such holder’s shares of Series A Preferred Stock may not be converted if
upon such conversion the holder’s beneficial ownership would exceed certain
thresholds.
Mandatory
Conversion
. Each share of Series A Preferred Stock will
automatically be converted into shares of Common Stock at the Conversion Ratio
then in effect: (i) if, after 12 months from the closing of the
Private Placement, the Common Stock trades on the Nasdaq Capital Market (or
other primary trading market or exchange on which the Common Stock is then
traded) at a price equal to $4.00 for 20 out of 30 consecutive trading days with
average daily trading volume of at least 10,000 shares or (ii) upon a registered
public offering by the Company at a per share price equal to $2.30 with
aggregate gross proceeds to the Company of not less than $10
million. Unless waived under certain circumstances by the holder of
the Series A Preferred Stock, such holder’s Series A Preferred Stock may not be
converted if upon such conversion the holder’s beneficial ownership would exceed
certain thresholds.
Voting
Rights
. The holders of Series A Preferred Stock are not
entitled to vote on any matters presented to the stockholders of the Company for
their action or consideration at any meeting of stockholders of the Company (or
by written consent of stockholders in lieu of meeting), except that the holders
of Series A Preferred Stock may vote separately as a class on any matters that
would amend, alter or repeal any provision of the Company’s Restated Articles of
Organization, as amended, in a manner that adversely affects the powers,
preferences or rights of the Series A Preferred Stock and such holders may also
vote on any matters required by law.
Redemption
. At
any time after February 11, 2014, upon 30 days written notice, the Company will
have the right to redeem the outstanding shares of Series A Preferred Stock at a
price equal to the Purchase Price, plus all accrued and unpaid dividends
thereon. The redemption price may be paid in two annual
installments.
This
description of the Series A Preferred Stock does not purport to be complete and
is qualified in its entirety by reference to the Company’s Articles of
Amendment, together with the Certificate of Designation of Series A Convertible
Preferred Stock, a copy of which is attached to this report as Exhibit 3.1 and
is incorporated herein by reference.
Warrants
The
warrants have the following exercise prices and terms: (i) the 15
Month Common Stock Warrants have an exercise price equal to $1.25 per share,
with a term expiring 15 months after the date of closing; (ii) the 15 Month
Preferred Stock Warrants have an exercise price equal to $12.50 per share, with
a term expiring 15 months after the date of closing; and (iii) the 30 Month
Common Stock Warrants have an exercise price equal to $2.00 per share, with a
term expiring 30 months after the date of closing.
Unless waived under
certain circumstances by the holder of the warrant, such holder’s warrant may
not be exercised if upon such exercise the holder’s beneficial ownership would
exceed certain thresholds.
The 15
Month Common Stock Warrants permit the holder to conduct a “cashless exercise”
at any time after six months from the date of issuance of the warrant if (i)
there is no effective registration statement for the resale of the underlying
Common Stock at the time of exercise and (ii) the underlying shares of Common
Stock may not be resold without restriction under Rule 144 of the Securities Act
of 1933, as amended (the “
Securities
Act
”). Each of the 15 Month Preferred Stock Warrants, 15 Month
Common Stock Warrants and the 30 Month Common Stock Warrants also permit the
holder to conduct a “cashless exercise” at any time after the holder of the
warrant becomes an “affiliate” (as defined in the Securities Purchase Agreement)
of the Company. In the event of a cashless exercise, the
Company would receive no proceeds from the sale of Common Stock or Series A
Preferred Stock, as the case may be, in connection with such
exercise.
The
warrant exercise price and/or number of shares issuable upon exercise of the
applicable warrant will be subject to adjustment for stock dividends, stock
splits or similar capital reorganizations, as set forth in the
warrants.
Subject
to the terms and conditions of the applicable warrants, the Company has the
right to call for cancellation the 15 Month Common Stock Warrants and the 15
Month Preferred Stock Warrants if the volume weighted average price of the
Common Stock on the Nasdaq Capital Market (or other primary trading market or
exchange on which the Common Stock is then traded) equals or exceeds $1.75 for
either (i) 10 consecutive trading days or (ii) 15 out of 25 consecutive trading
days. Subject to the terms and conditions of the 30 Month
Common Stock Warrant, the Company has the right to call for cancellation the 30
Month Common Stock Warrant if the volume weighted average price for the Common
Stock on the Nasdaq Capital Market (or other primary trading market or exchange
on which the Common Stock is then traded) equals or exceeds $2.80 for either (i)
10 consecutive trading days or (ii) 15 out of 25 consecutive trading
days.
This
description of the 15 Month Common Stock Warrants, 15 Month Preferred Stock
Warrants and the 30 Month Common Stock Warrants does not purport to be complete
and is qualified in its entirety by reference to the applicable warrants, copies
of which are attached to this report as Exhibits 4.2, 4.3 and 4.4 respectively,
and are incorporated herein by reference.
Registration
Rights Agreement
In
connection with the Private Placement, the Company has agreed to prepare and
file a Registration Statement on Form S-3 (the “Registration Statement”)
covering the resale of the shares of Common Stock underlying the 15 Month Common
Stock Warrant. The Company agreed to file the Registration Statement
with the Securities and Exchange Commission no later than 60 days following the
closing the Private Placement, and further agreed to use its commercially
reasonable efforts to cause such Registration Statement to be declared effective
as promptly as possible after the filing thereof and to keep the Registration
Statement continuously effective under the Securities Act until all shares
covered by such Registration Statement have been sold, or may be sold without
volume restrictions pursuant to Rule 144 (or any successor Rule under the
Securities Act). The Company also granted piggyback registration
rights (including shares of Series A Preferred Stock issuable upon exercise of
the 15 Month Preferred Stock Warrants) with respect to all of the Common Stock
issuable in connection with any conversion of Series A Preferred Stock, all of
the Common Stock issuable upon exercise of the 30 Month Common Stock Warrants,
and any shares of Common Stock issuable upon exercise of the 15 Month Common
Stock Warrant that were not registered on Form S-3 due to any limitation on the
number of shares the Company could register on Form S-3 under applicable SEC
guidance.
This
description of the Registration Rights Agreement does not purport to be complete
and is qualified in its entirety by reference to the Registration Rights
Agreement, a copy of which is attached to this report as Exhibit 4.5 and is
incorporated herein by reference.
Advance
from Distributor
In
connection with the Private Placement, prior to the closing, the Company
received $200,000 from one of its distributors to be held in the escrow account
for the Private Placement. The distributor requested, and the Company
agreed, that the $200,000 be used as payment for anticipated future purchases of
the Company’s pressure cycling technology (PCT) instrument and consumable
products, and not for an investment in the Private Placement.
Item
3.02 Unregistered
Sales of Equity Securities
Item
5.03 Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal
Year
Effective
on February 12, 2009, the Company amended its Restated Articles of Organization,
as amended, by filing with the Secretary of State of the Commonwealth of
Massachusetts Articles of Amendment creating a new series of preferred stock,
designated “Series A Convertible Preferred Stock,” par value $0.01 per
share. The material terms of Series A Preferred Stock are described
in Item 1.01 of this Current Report on Form 8-K, and the information in Item
1.01 of this Current Report on Form 8-K is incorporated herein by this
reference.
Item
8.01 Other
Events
On
February 18, 2009, the Company announced that its unaudited stockholders’ equity
as of January 31, 2009 was $1,972,661. The total number of issued and
outstanding shares of common stock of the Company as of January 31, 2009 was
2,195,283.
Item
9.01
Financial Statements and
Exhibits
(d)
Exhibits
Exhibit
Number
|
Exhibit
Description
|
3.1
|
Articles
of Amendment to the Company’s Restated Articles of Organization, as
amended
|
4.1
|
Securities
Purchase Agreement entered into as of February 12, 2009, between the
Company and several purchasers
|
4.2
|
Form
of 15 Month Common Stock Warrant
|
4.3
|
Form
of 15 Month Preferred Stock Warrant
|
4.4
|
Form
of 30 Month Common Stock Warrant
|
4.5
|
Registration
Rights Agreement
|
99.1
|
Press
Release dated February 18, 2009, announcing completion of Private
Placement
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
PRESSURE
BIOSCIENCES, INC.
|
|
|
|
|
|
|
By:
|
|
|
|
|
Richard
T. Schumacher,
|
|
|
|
President
and Chief Executive Officer
|
|
|
|
|
|
EXHIBIT
INDEX
Exhibit
Number
|
Exhibit
Description
|
3.1
|
Articles
of Amendment to the Company’s Restated Articles of Organization, as
amended
|
4.1
|
Securities
Purchase Agreement entered into as of February 12, 2009, between the
Company and several purchasers
|
4.2
|
Form
of 15 Month Common Stock Warrant
|
4.3
|
Form
of 15 Month Preferred Stock Warrant
|
4.4
|
Form
of 30 Month Common Stock Warrant
|
4.5
|
Registration
Rights Agreement
|
99.1
|
Press
Release dated February 18, 2009, announcing completion of Private
Placement
|
CERTIFICATE
OF DESIGNATION
OF
SERIES
A CONVERTIBLE PREFERRED STOCK
OF
PRESSURE
BIOSCIENCES, INC.
(Pursuant
to Section 6.02 of the Massachusetts Business Corporation Act, Chapter
156D
of
the Massachusetts General Laws)
A.
Designation and
Amount
.
The
shares of the series of Preferred Stock shall be designated as “Series A
Convertible Preferred Stock” (the “
Series A Preferred Stock
”) and
the number of shares constituting the Series A Preferred Stock shall be
608,696. Such number of shares may be increased or decreased by
resolution of the Board of Directors; provided, that no decrease shall reduce
the number of shares of Series A Preferred Stock to a number less than the
number of shares then outstanding plus the number of shares reserved for
issuance upon the exercise of outstanding options, rights or warrants or upon
the conversion of any outstanding securities issued by the Corporation
convertible into Series A Preferred Stock.
1.
Dividends
.
From and
after the date of the issuance of any shares of Series A Preferred Stock,
dividends at the rate per annum of five percent (5%) of the Series A Original
Issue Price (as defined below) for each share of Series A Preferred Stock shall
accrue on such shares of Series A Preferred Stock (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other
similar recapitalization with respect to the Series A Preferred Stock) (the
“
Accruing
Dividends
”). Accruing Dividends shall accrue from day to day
and shall be paid semi-annually on the 30
th
day of
June and the 31
st
day of
December each year (with the first payment of Accruing Dividends on a
semi-annual payment date to be prorated based on the number of days occurring
between the date on which each share of Series A Preferred Stock was issued (the
“
Series A Original Issue
Date
”) and such semi-annual payment date). The Accruing
Dividends may be paid either in cash or in shares of Common Stock as determined
in the sole discretion of the Board of Directors. For purposes of the
payment of the Accruing Dividends in shares of Common Stock, each share of
Common Stock shall be deemed to have a value equal to one tenth (1/10
th
) of the
Series A Original Issue Price of such shares of Series A Preferred Stock with
respect to which such Accruing Dividends is being paid (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other
similar recapitalization with respect to the Common Stock). The
Corporation shall not declare, pay or set aside any dividends on shares of any
other class or series of capital stock of the Corporation (other than dividends
on shares of Common Stock payable in shares of Common Stock) unless (in addition
to the obtaining of any consents required elsewhere in the Articles of
Organization) the holders of the Series A Preferred Stock then outstanding shall
first receive, or simultaneously receive, a dividend on each outstanding share
of Series A Preferred Stock in an amount at least equal to the greater of (i)
the amount of the aggregate Accruing Dividends then accrued on such share of
Series A Preferred Stock and not previously paid and (ii) (A) in the case of a
dividend on Common Stock or any class or series that is convertible into Common
Stock, that dividend per share of Series A Preferred Stock as would equal the
product of (1) the dividend payable on each share of such class or series
determined, if applicable, as if all shares of such class or series had been
converted into Common Stock and (2) the number of shares of Common Stock
issuable upon conversion of a share of Series A Preferred Stock, in each case
calculated on the record date for determination of holders entitled to receive
such dividend or (B) in the case of a dividend on any class or series that is
not convertible into Common Stock, at a rate per share of Series A Preferred
Stock determined by (1) dividing the amount of the dividend payable on each
share of such class or series of capital stock by the original issuance price of
such class or series of capital stock (subject to appropriate adjustment in the
event of any stock dividend, stock split, combination or other similar
recapitalization with respect to such class or series) and (2) multiplying such
fraction by an amount equal to the Series A Original Issue Price (as defined
below); provided that, if the Corporation declares, pays or sets aside, on the
same date, a dividend on shares of more than one class or series of capital
stock of the Corporation, the dividend payable to the holders of Series A
Preferred Stock pursuant to this
Section 1
shall be
calculated based upon the dividend on the class or series of capital stock that
would result in the highest Series A Preferred Stock dividend.
2.
Liquidation, Dissolution or
Winding Up; Certain Mergers, Consolidations and Asset Sales
.
2.1.
Payments to Holders of
Series A Preferred Stock
. In the event of any voluntary or
involuntary liquidation, dissolution or winding up of the Corporation, the
holders of shares of Series A Preferred Stock then outstanding shall be entitled
to be paid out of the assets of the Corporation available for distribution to
its stockholders before any payment shall be made to the holders of Common Stock
by reason of their ownership thereof, an amount per share equal to the greater
of (i) the Series A Original Issue Price, plus any Accruing Dividends accrued
but unpaid thereon, together with any other dividends accrued but unpaid thereon
or (ii) such amount per share as would have been payable had all shares of
Series A Preferred Stock been converted into Common Stock pursuant to
Section 4
immediately
prior to such liquidation, dissolution or winding up (the amount payable
pursuant to this sentence is hereinafter referred to as the “
Series A Liquidation
Amoun
t”). If upon any such liquidation, dissolution or winding
up of the Corporation, the assets of the Corporation available for distribution
to its stockholders shall be insufficient to pay the holders of shares of Series
A Preferred Stock the full amount to which they shall be entitled under this
Subsection 2.1
,
the holders of shares of Series A Preferred Stock shall share ratably in any
distribution of the assets available for distribution in proportion to the
respective amounts which would otherwise be payable in respect of the shares
held by them upon such distribution if all amounts payable on or with respect to
such shares were paid in full. The “
Series A Original Issue Price”
for each share of Series A Preferred Stock shall mean an amount equal to
the greater of: (i) $11.50; (ii) an amount equal to the volume weighted average
price for the Corporation’s Common Stock on the Trading Market for the ten (10)
Trading Days preceding the Series A Original Issue Date on which such shares of
Series A Preferred Stock are issued multiplied by ten (10); and (iii) an amount
equal to the closing bid price of the Common Stock as reported by the Trading
Market on the Trading Day immediately preceding the Series A Original Issue Date
on which such shares of Series A Preferred Stock are issued multiplied by ten
(10), plus $2.50; in each case subject to appropriate adjustment in the event of
any stock dividend, stock split, combination or other similar recapitalization
with respect to the Series A Preferred Stock. “
Trading Day
” means a day on
which the Common Stock is traded on a Trading Market, and “
Trading Market
” means the
NASDAQ Capital Market or if the NASDAQ Capital Market is not the primary market
on which the Common Stock is then traded, such other markets or exchanges on
which the Common Stock is listed or quoted for trading on the Issuance
Date.
2.2.
Payments to Holders of
Common Stock
. In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Corporation, after the payment of
all preferential amounts required to be paid to the holders of shares of Series
A Preferred Stock, the remaining assets of the Corporation available for
distribution to its stockholders shall be distributed among the holders of
shares of Common Stock, pro rata based on the number of shares held by each such
holder.
2.3.
Deemed Liquidation
Events
.
2.3.1.
Definition
. Each
of the following events shall be considered a “
Deemed Liquidation Event
”
unless the holders of at least a majority of the outstanding shares of Series A
Preferred Stock elect otherwise by written notice sent to the Corporation at
least five (5) days prior to the effective date of any such event:
(a)
a merger or consolidation in which
|
(i)
|
the
Corporation is a constituent party
or
|
|
(ii)
|
a
subsidiary of the Corporation is a constituent party and the Corporation
issues shares of its capital stock pursuant to such merger or
consolidation,
|
except
any such merger or consolidation involving the Corporation or a subsidiary in
which the shares of capital stock of the Corporation outstanding immediately
prior to such merger or consolidation continue to represent, or are converted
into or exchanged for shares of capital stock that represent, immediately
following such merger or consolidation, at least a majority, by voting power, of
the capital stock of (1) the surviving or resulting corporation or (2) if the
surviving or resulting corporation is a wholly owned subsidiary of another
corporation immediately following such merger or consolidation, the parent
corporation of such surviving or resulting corporation (
provided that
, for
the purpose of this
Subsection 2.3.1
, all
shares of Common Stock issuable upon (x) exercise of rights, options or warrants
to subscribe for, purchase or otherwise acquire Common Stock or Convertible
Securities (as defined below) (“
Options
”) outstanding
immediately prior to such merger or consolidation, or (y) conversion of any
evidences of indebtedness, shares or other securities directly or indirectly
convertible into or exchangeable for Common Stock, but excluding Options (“
Convertible Securities
”)
outstanding immediately prior to such merger or consolidation, shall be deemed
to be outstanding immediately prior to such merger or consolidation and, if
applicable, converted or exchanged in such merger or consolidation on the same
terms as the actual outstanding shares of Common Stock are converted or
exchanged); or
(b) the
sale, lease, transfer, exclusive license or other disposition, in a single
transaction or series of related transactions, by the Corporation or any
subsidiary of the Corporation of all or substantially all the assets of the
Corporation and its subsidiaries taken as a whole, or the sale or disposition
(whether by merger or otherwise) of one or more subsidiaries of the Corporation
if substantially all of the assets of the Corporation and its subsidiaries taken
as a whole are held by such subsidiary or subsidiaries, except where such sale,
lease, transfer, exclusive license or other disposition is to a wholly owned
subsidiary of the Corporation.
2.3.2.
Effecting a Deemed
Liquidation Event
.
(a) The
Corporation shall not have the power to effect a Deemed Liquidation Event
referred to in
Subsection
2.3.1(a)(i)
unless the agreement or plan of merger or consolidation for
such transaction (the “
Merger
Agreement
”) provides that the consideration payable to the stockholders
of the Corporation shall be allocated among the holders of capital stock of the
Corporation in accordance with
Subsections 2.1
and
2.2
.
(b) In
the event of a Deemed Liquidation Event referred to in
Subsection
2.3.1(a)(ii)
or
2.3.1(b)
, if the
Corporation does not effect a dissolution of the Corporation under the
Massachusetts Business Corporation Act within 90 days after such Deemed
Liquidation Event, then (i) the Corporation shall send a written notice to each
holder of Series A Preferred Stock no later than the 90th day after the Deemed
Liquidation Event advising such holders of their right (and the requirements to
be met to secure such right) pursuant to the terms of the following
clause (ii)
to
require the redemption of such shares of Series A Preferred Stock, and (ii) if
the holders of at least a majority of the then outstanding shares of Series A
Preferred Stock so request in a written instrument delivered to the Corporation
not later than 120 days after such Deemed Liquidation Event, the Corporation
shall use the consideration received by the Corporation for such Deemed
Liquidation Event (net of any retained liabilities associated with the assets
sold or technology licensed, as determined in good faith by the Board of
Directors of the Corporation), together with any other assets of the Corporation
available for distribution to its stockholders (the “
Available Proceeds
”), to the
extent legally available therefor, on the 150th day after such Deemed
Liquidation Event, to redeem all outstanding shares of Series A Preferred Stock
at a price per share equal to the Series A Liquidation
Amount. Notwithstanding the foregoing, in the event of a redemption
pursuant to the preceding sentence, if the Available Proceeds are not sufficient
to redeem all outstanding shares of Series A Preferred Stock, the Corporation
shall redeem a pro rata portion of each holder’s shares of Series A Preferred
Stock to the fullest extent of such Available Proceeds, based on the respective
amounts which would otherwise be payable in respect of the shares to be redeemed
if the Available Proceeds were sufficient to redeem all such shares, and shall
redeem the remaining shares to have been redeemed as soon as practicable after
the Corporation has funds legally available therefor. The provisions
of
Subsections
6.2
through
6.4
shall apply, with
such necessary changes in the details thereof as are necessitated by the
context, to the redemption of the Series A Preferred Stock pursuant to this
Subsection
2.3.2(b)
. Prior to the distribution or redemption provided for
in this
Subsection
2.3.2(b)
, the Corporation shall not expend or dissipate the consideration
received for such Deemed Liquidation Event, except to discharge expenses
incurred in connection with such Deemed Liquidation Event or in the ordinary
course of business.
2.3.3.
Amount Deemed Paid or
Distributed
. The amount deemed paid or distributed to the
holders of capital stock of the Corporation upon any such merger, consolidation,
sale, transfer, exclusive license, other disposition or redemption shall be the
cash or the value of the property, rights or securities paid or distributed to
such holders by the Corporation or the acquiring person, firm or other
entity. If the amount deemed paid or distributed under this
Subsection 2.3.3 is made in property other than in cash, the value of such
distribution shall be the fair market value of such property, determined as
follows:
(a) For
securities not subject to investment letters or other similar restrictions on
free marketability,
(i) if
traded on the NASDAQ Capital Market or other securities exchange, the value
shall be deemed to be the average of the closing prices of the securities on
such exchange or market over the 30-period ending three days prior to the
closing of such transaction;
(ii) if
actively traded over-the-counter, the value shall be deemed to be the average of
the closing bid prices over the 30-day period ending three days prior to the
closing of such transaction; or
(iii) if
there is no active public market, the value shall be the fair market value
thereof, as determined in good faith by the Board of Directors of the
Corporation.
(b) The
method of valuation of securities subject to investment letters or other similar
restrictions on free marketability (other than restrictions arising solely by
virtue of a stockholder’s status as an affiliate or former affiliate) shall take
into account an appropriate discount (as determined in good faith by the Board
of Directors of the Corporation) from the market value as determined pursuant to
clause (a) above so as to reflect the approximate fair market value
thereof. The value of such property, rights or securities shall be
determined in good faith by the Board of Directors of the
Corporation.
2.3.4.
Allocation of
Escrow
. In the event of a Deemed Liquidation Event pursuant to
Subsection 2.3.1(a)(i), if any portion of the consideration payable to the
stockholders of the Corporation is placed into escrow and/or is payable to the
stockholders of the Corporation subject to contingencies, the Merger Agreement
shall provide that (a) the portion of such consideration that is not placed in
escrow and not subject to any contingencies (the “
Initial Consideration
”) shall
be allocated among the holders of capital stock of the Corporation in accordance
with Subsections 2.1 and 2.2 as if the Initial Consideration were the only
consideration payable in connection with such Deemed Liquidation Event and (b)
any additional consideration which becomes payable to the stockholders of the
Corporation upon release from escrow or satisfaction of contingencies shall be
allocated among the holders of capital stock of the Corporation in accordance
with Subsections 2.1 and 2.2 after taking into account the previous payment of
the Initial Consideration as part of the same transaction.
3.
Voting
.
3.1.
General
. The
holders of Series A Preferred Stock shall not be entitled to vote on any matter
presented to the stockholders of the Corporation for their action or
consideration at any meeting of stockholders of the Corporation (or by written
consent of stockholders in lieu of meeting), except as otherwise expressly
provided for in
Section 3.2
below or
required by law.
3.2.
Series A Preferred Stock
Protective Provisions
. At any time when the number of shares
of Series A Preferred Stock outstanding is equal to or greater than 20% of the
total number of shares of Series A Preferred Stock issued on the first date any
shares of Series A Preferred Stock were issued (with such numbers subject to
appropriate adjustment in the event of any stock dividend, stock split,
combination or other similar recapitalization with respect to the Series A
Preferred Stock), the Corporation shall not, either directly or indirectly by
amendment, merger, consolidation or otherwise, do any of the following without
(in addition to any other vote required by law or the Articles of Organization)
the written consent or affirmative vote of the holders of at least as majority
of the then outstanding shares of Series A Preferred Stock, given in writing or
by vote at a meeting, consenting or voting (as the case may be) separately as a
class amend, alter or repeal any provision of the Articles of Organization in a
manner that adversely affects the powers, preferences or rights of the Series A
Preferred Stock; provided, however, the authorization of another series of
Preferred Stock with rights senior to or pari passu with those of the Series A
Preferred Stock as to dividends, liquidation, redemption or voting, or the
authorization of additional shares of Series A Preferred Stock or Common Stock
shall not constitute an amendment that adversely affects the Series A Preferred
Stock.
4.
Optional
Conversion
.
The
holders of the Series A Preferred Stock shall have conversion rights as follows
(the “
Conversion
Rights
”):
4.1.
Right to
Convert
.
4.1.1.
Conversion
Ratio
. Subject to the limitations set forth in
Section 4.1.2
, each
share of Series A Preferred Stock shall be convertible, at the option of the
holder thereof, at any time and from time to time, and without the payment of
additional consideration by the holder thereof, into such number of fully paid
and nonassessable shares of Common Stock as is determined by dividing the Series
A Original Issue Price for such share of Series A Preferred Stock by the Series
A Conversion Price (as defined below) in effect at the time of
conversion. The
“Series A Conversion Price”
for each share of Series A Preferred Stock shall initially be equal to one tenth
(1/10
th
) of the
Series A Original Issue Price for such share of Series A Preferred
Stock. Such initial Series A Conversion Price, and the rate at which
shares of Series A Preferred Stock may be converted into shares of Common Stock,
shall be subject to adjustment as provided below.
4.1.2. Shares
of Series A Preferred Stock held by each holder of record thereof may not be
converted pursuant to
Section 4.1.1
to the
extent that, after giving effect to such conversion, such holder (together with
any person that, directly or indirectly through one or more intermediaries,
controls or is controlled by or is under common control with a person, as such
terms are used in and construed under Rule 144 under the Securities Act of 1933,
as amended and the rules and regulations promulgated thereunder (each an “
Affiliate
”), and any other
person or entity acting as a group together with such holder or any of such
holder’s Affiliates) would beneficially own in excess of the Beneficial
Ownership Limitation (as defined below). For purposes of the
foregoing sentence, the number of shares of Common Stock beneficially owned by
such holder of record and its Affiliates shall include the number of shares of
Common Stock issuable upon conversion of such holder’s Series A Preferred Stock
with respect to which shares of Series A Preferred Stock the holder is
converting pursuant to
Section 4.1.1
, but
shall exclude the number of shares of Common Stock which would be issuable upon
exercise or conversion of the unexercised or non-converted portion of any other
securities of the Corporation (including, without limitation, options and
warrants) that are subject to a limitation on conversion or exercise analogous
to the limitation contained herein and are beneficially owned by such holder or
any of its Affiliates. Except as set forth in the preceding sentence,
for purposes of this
Section 4.1.2
,
beneficial ownership shall be calculated in accordance with Section 13(d) of the
Securities Exchange Act of 1934, as amended (the “
Exchange Act
”), and each
holder of record shall be solely responsible for any schedules required to be
filed in accordance therewith. To the extent that the limitation
contained in this
Section 4.1.2
applies, the determination of whether each holder of record’s shares of Series A
Preferred Stock are convertible into shares of Common Stock (in relation to
other securities owned by such holder together with any Affiliates) shall be
made by such holder and shall be provided in writing to the Corporation at the
time of such conversion or at such other times as may be reasonably requested by
the Corporation. Upon written request of the record holder of shares
of Series A Preferred Stock, the Corporation shall provide such holder with the
number of then outstanding shares of Common Stock. The Corporation
shall have no obligation to verify or confirm the accuracy of the holder’s
determination. In addition, a determination as to any group status as
contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act. The “
Beneficial Ownership
Limitation
” shall be 4.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common
Stock upon conversion of the shares of Series A Preferred Stock. The
Beneficial Ownership Limitation provisions of this
Section 4.1.2
may be
waived by the holder of record, at the election of such holder, upon not less
than sixty-one (61) days prior written notice to the Corporation (which notice
period, if requested by the holder of record, the Corporation may waive in its
sole discretion) to increase the Beneficial Ownership Limitation to 9.99%,
14.99% or 19.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon
conversion of the shares of Series A Preferred Stock, and the provisions of this
Section 4.1.2
shall continue to apply. Upon a waiver of the Beneficial Ownership
Limitation from 4.99% to 9.99%, or from 9.99% to 14.99%, as the case may be, the
holder of record may further waive the Beneficial Ownership Limitation from
9.99% to 14.99%, or from 14.99% to 19.99%, as applicable, by written notice to
the Corporation not less than sixty-one (61) days in advance of such waiver
(which notice period, if requested by the holder of record, the Corporation may
waive in its sole discretion). Upon the change by the holder of
record of the Beneficial Ownership Limitation from 14.99% to 19.99%, the
Beneficial Ownership Limitation may not be further waived by such
Holder.
4.1.3.
Termination of Conversion
Rights
. In the event of a notice of redemption of any shares
of Series A Preferred Stock pursuant to
Section 6
, the
Conversion Rights of the shares designated for redemption shall terminate at the
close of business on the last full day preceding the date fixed for redemption,
unless the redemption price is not fully paid on such redemption date, in which
case the Conversion Rights for such shares shall continue until such price is
paid in full. In the event of a liquidation, dissolution or winding
up of the Corporation or a Deemed Liquidation Event, the Conversion Rights shall
terminate at the close of business on the last full day preceding the date fixed
for the payment of any such amounts distributable on such event to the holders
of Series A Preferred Stock.
4.2.
Fractional
Shares
. No fractional shares of Common Stock shall be issued
upon conversion of the Series A Preferred Stock. In lieu of any
fractional shares to which the holder would otherwise be entitled, the
Corporation shall pay cash equal to such fraction multiplied by the fair market
value of a share of Common Stock as determined in good faith by the Board of
Directors of the Corporation. Whether or not fractional shares would
be issuable upon such conversion shall be determined on the basis of the total
number of shares of Series A Preferred Stock the holder is at the time
converting into Common Stock and the aggregate number of shares of Common Stock
issuable upon such conversion.
4.3.
Mechanics of
Conversion
.
4.3.1.
Notice of
Conversion
. In order for a holder of Series A Preferred Stock
to voluntarily convert shares of Series A Preferred Stock into shares of Common
Stock, such holder shall surrender the certificate or certificates for such
shares of Series A Preferred Stock (or, if such registered holder alleges that
such certificate has been lost, stolen or destroyed, a lost certificate
affidavit and agreement reasonably acceptable to the Corporation to indemnify
the Corporation against any claim that may be made against the Corporation on
account of the alleged loss, theft or destruction of such certificate), at the
office of the transfer agent for the Series A Preferred Stock (or at the
principal office of the Corporation if the Corporation serves as its own
transfer agent), together with written notice that such holder elects to convert
all or any number of the shares of the Series A Preferred Stock represented by
such certificate or certificates and, if applicable, any event on which such
conversion is contingent. Such notice shall state such holder’s name
or the names of the nominees in which such holder wishes the certificate or
certificates for shares of Common Stock to be issued. If required by
the Corporation, certificates surrendered for conversion shall be endorsed or
accompanied by a written instrument or instruments of transfer, in form
satisfactory to the Corporation, duly executed by the registered holder or his,
her or its attorney duly authorized in writing. The close of business
on the date of receipt by the transfer agent (or by the Corporation if the
Corporation serves as its own transfer agent) of such certificates (or lost
certificate affidavit and agreement) and notice shall be the time of conversion
(the “
Conversion Time
”),
and the shares of Common Stock issuable upon conversion of the shares
represented by such certificate shall be deemed to be outstanding of record as
of such date. The Corporation shall, as soon as practicable after the
Conversion Time, (i) issue and deliver to such holder of Series A Preferred
Stock, or to his, her or its nominees, a certificate or certificates for the
number of full shares of Common Stock issuable upon such conversion in
accordance with the provisions hereof and a certificate for the number (if any)
of the shares of Series A Preferred Stock represented by the surrendered
certificate that were not converted into Common Stock, (ii) pay in cash such
amount as provided in
Subsection 4.2
in
lieu of any fraction of a share of Common Stock otherwise issuable upon such
conversion and (iii) pay all accrued but unpaid dividends on the shares of
Series A Preferred Stock converted.
4.3.2.
Reservation of
Shares
. The Corporation shall at all times when the Series A
Preferred Stock shall be outstanding, reserve and keep available out of its
authorized but unissued capital stock, for the purpose of effecting the
conversion of the Series A Preferred Stock, such number of its duly authorized
shares of Common Stock as shall from time to time be sufficient to effect the
conversion of all outstanding Series A Preferred Stock; and if at any time the
number of authorized but unissued shares of Common Stock shall not be sufficient
to effect the conversion of all then outstanding shares of the Series A
Preferred Stock, the Corporation shall take such corporate action as may be
necessary to increase its authorized but unissued shares of Common Stock to such
number of shares as shall be sufficient for such purposes, including, without
limitation, engaging in best efforts to obtain the requisite stockholder
approval of any necessary amendment to the Articles of
Organization. Before taking any action which would cause an
adjustment reducing the Series A Conversion Price below the then par value of
the shares of Common Stock issuable upon conversion of the Series A Preferred
Stock, the Corporation will take any corporate action which may, in the opinion
of its counsel, be necessary in order that the Corporation may validly and
legally issue fully paid and nonassessable shares of Common Stock at such
adjusted Series A Conversion Price.
4.3.3.
Effect of
Conversion
. All shares of Series A Preferred Stock which shall
have been surrendered for conversion as herein provided shall no longer be
deemed to be outstanding and all rights with respect to such shares shall
immediately cease and terminate at the Conversion Time, except only the right of
the holders thereof to receive shares of Common Stock in exchange therefor, to
receive payment in lieu of any fraction of a share otherwise issuable upon such
conversion as provided in
Subsection 4.2
and to
receive payment of any dividends accrued but unpaid on the shares of Series A
Preferred Stock so converted. Any shares of Series A Preferred Stock
so converted shall be retired and cancelled and may not be reissued as shares of
such series, and the Corporation may thereafter take such appropriate action
(without the need for stockholder action) as may be necessary to reduce the
authorized number of shares of Series A Preferred Stock
accordingly.
4.3.4.
No Further
Adjustment
. Upon any such conversion, no adjustment to the
Series A Conversion Price shall be made for any accrued but unpaid dividends on
the Series A Preferred Stock surrendered for conversion or on the Common Stock
delivered upon conversion.
4.3.5.
Taxes
. The
Corporation shall pay any and all issue and other similar taxes that may be
payable in respect of any issuance or delivery of shares of Common Stock upon
conversion of shares of Series A Preferred Stock pursuant to this
Section
4
. The Corporation shall not, however, be required to pay any
tax which may be payable in respect of any transfer involved in the issuance and
delivery of shares of Common Stock in a name other than that in which the shares
of Series A Preferred Stock so converted were registered, and no such issuance
or delivery shall be made unless and until the person or entity requesting such
issuance has paid to the Corporation the amount of any such tax or has
established, to the satisfaction of the Corporation, that such tax has been
paid.
4.4.
Adjustment for Stock Splits
and Combinations
. If the Corporation shall at any time or from
time to time after the Series A Original Issue Date effect a subdivision of the
outstanding Common Stock, the Series A Conversion Price in effect immediately
before that subdivision shall be proportionately decreased so that the number of
shares of Common Stock issuable on conversion of each share of such series shall
be increased in proportion to such increase in the aggregate number of shares of
Common Stock outstanding. If the Corporation shall at any time or
from time to time after the Series A Original Issue Date combine the outstanding
shares of Common Stock, the Series A Conversion Price in effect immediately
before the combination shall be proportionately increased so that the number of
shares of Common Stock issuable on conversion of each share of such series shall
be decreased in proportion to such decrease in the aggregate number of shares of
Common Stock outstanding. Any adjustment under this subsection shall
become effective at the close of business on the date the subdivision or
combination becomes effective.
4.5.
Adjustment for Certain
Dividends and Distributions
. In the event the Corporation at
any time or from time to time after the Series A Original Issue Date shall make
or issue, or fix a record date for the determination of holders of Common Stock
entitled to receive, a dividend or other distribution payable on the Common
Stock in additional shares of Common Stock, then and in each such event the
Series A Conversion Price in effect immediately before such event shall be
decreased as of the time of such issuance or, in the event such a record date
shall have been fixed, as of the close of business on such record date, by
multiplying the Series A Conversion Price then in effect by a
fraction:
|
(1)
|
the
numerator of which shall be the total number of shares of Common Stock
issued and outstanding immediately prior to the time of such issuance or
the close of business on such record date,
and
|
|
(2)
|
the
denominator of which shall be the total number of shares of Common Stock
issued and outstanding immediately prior to the time of such issuance or
the close of business on such record date plus the number of shares of
Common Stock issuable in payment of such dividend or
distribution.
|
Notwithstanding
the foregoing, (a) if such record date shall have been fixed and such dividend
is not fully paid or if such distribution is not fully made on the date fixed
therefor, the Series A Conversion Price shall be recomputed accordingly as of
the close of business on such record date and thereafter the Series A Conversion
Price shall be adjusted pursuant to this subsection as of the time of actual
payment of such dividends or distributions; and (b) that no such adjustment
shall be made if the holders of Series A Preferred Stock simultaneously receive
a dividend or other distribution of shares of Common Stock in a number equal to
the number of shares of Common Stock as they would have received if all
outstanding shares of Series A Preferred Stock had been converted into Common
Stock on the date of such event.
4.6.
Adjustments for Other
Dividends and Distributions
. In the event the Corporation at
any time or from time to time after the Series A Original Issue Date shall make
or issue, or fix a record date for the determination of holders of Common Stock
entitled to receive, a dividend or other distribution payable in securities of
the Corporation (other than a distribution of shares of Common Stock in respect
of outstanding shares of Common Stock) or in other property and the provisions
of
Section 1
do
not apply to such dividend or distribution, then and in each such event the
holders of Series A Preferred Stock shall receive, simultaneously with the
distribution to the holders of Common Stock, a dividend or other distribution of
such securities or other property in an amount equal to the amount of such
securities or other property as they would have received if all outstanding
shares of Series A Preferred Stock had been converted into Common Stock on the
date of such event.
4.7.
Adjustment for Merger or
Reorganization, etc
. Subject to the provisions of
Subsection 2.3
, if
there shall occur any reorganization, recapitalization, reclassification,
consolidation or merger involving the Corporation in which the Common Stock (but
not the Series A Preferred Stock) is converted into or exchanged for securities,
cash or other property (other than a transaction covered by
Subsections 4.5
or
4.6
), then,
following any such reorganization, recapitalization, reclassification,
consolidation or merger, each share of Series A Preferred Stock shall thereafter
be convertible in lieu of the Common Stock into which it was convertible prior
to such event into the kind and amount of securities, cash or other property
which a holder of the number of shares of Common Stock of the Corporation
issuable upon conversion of one share of Series A Preferred Stock immediately
prior to such reorganization, recapitalization, reclassification, consolidation
or merger would have been entitled to receive pursuant to such transaction; and,
in such case, appropriate adjustment (as determined in good faith by the Board
of Directors of the Corporation) shall be made in the application of the
provisions in this
Section 4
with
respect to the rights and interests thereafter of the holders of the Series A
Preferred Stock, to the end that the provisions set forth in this
Section 4
(including
provisions with respect to changes in and other adjustments of the Series A
Conversion Price) shall thereafter be applicable, as nearly as reasonably may
be, in relation to any securities or other property thereafter deliverable upon
the conversion of the Series A Preferred Stock.
4.8.
Certificate as to
Adjustments
. Upon the occurrence of each adjustment or
readjustment of the Series A Conversion Price pursuant to this
Section 4
, the
Corporation at its expense shall, as promptly as reasonably practicable but in
any event not later than ten (10) days thereafter, compute such adjustment or
readjustment in accordance with the terms hereof and furnish to each holder of
Series A Preferred Stock a certificate setting forth such adjustment or
readjustment (including the kind and amount of securities, cash or other
property into which the Series A Preferred Stock is convertible) and showing in
detail the facts upon which such adjustment or readjustment is
based. The Corporation shall, as promptly as reasonably practicable
after the written request at any time of any holder of Series A Preferred Stock
(but in any event not later than ten (10) days thereafter), furnish or cause to
be furnished to such holder a certificate setting forth (i) the Series A
Conversion Price then in effect, and (ii) the number of shares of Common Stock
and the amount, if any, of other securities, cash or property which then would
be received upon the conversion of Series A Preferred Stock.
4.9.
Notice of Record
Date
. In the event:
(a) the
Corporation shall take a record of the holders of its Common Stock (or other
capital stock or securities at the time issuable upon conversion of the Series A
Preferred Stock) for the purpose of entitling or enabling them to receive any
dividend or other distribution, or to receive any right to subscribe for or
purchase any shares of capital stock of any class or any other securities, or to
receive any other security; or
(b) of
any capital reorganization of the Corporation, any reclassification of the
Common Stock of the Corporation, or any Deemed Liquidation Event;
or
(c) of
the voluntary or involuntary dissolution, liquidation or winding-up of the
Corporation,
then, and
in each such case, the Corporation will send or cause to be sent to the holders
of the Series A Preferred Stock a notice specifying, as the case may be, (i) the
record date for such dividend, distribution or right, and the amount and
character of such dividend, distribution or right, or (ii) the effective date on
which such reorganization, reclassification, consolidation, merger, transfer,
dissolution, liquidation or winding-up is proposed to take place, and the time,
if any is to be fixed, as of which the holders of record of Common Stock (or
such other capital stock or securities at the time issuable upon the conversion
of the Series A Preferred Stock) shall be entitled to exchange their shares of
Common Stock (or such other capital stock or securities) for securities or other
property deliverable upon such reorganization, reclassification, consolidation,
merger, transfer, dissolution, liquidation or winding-up, and the amount per
share and character of such exchange applicable to the Series A Preferred Stock
and the Common Stock. Such notice shall be sent at least ten (10)
days prior to the record date or effective date for the event specified in such
notice.
5.
Mandatory
Conversion
.
5.1.
Trigger
Events
.
5.1.1. Upon
(a) the closing of the sale of shares of Common Stock to the public at a price
of at least $2.30
per share (subject to
appropriate adjustment in the event of any stock dividend, stock split,
combination or other similar recapitalization with respect to the Common Stock),
in a firm-commitment underwritten public offering pursuant to an effective
registration statement under the Securities Act of 1933, as amended (the “
Securities Act
”), resulting in
at least $10,000,000 of gross proceeds to the Corporation, (b) such time, on or
after February 12, 2010, the shares of Common Stock trade on the Nasdaq Capital
Market, or any other trading market on which the shares of Common Stock are then
traded, with a sale price at any time during the trading day of at least $4.00
for at least twenty (20) trading days out of thirty (30) consecutive trading
days with average daily trading volume for such twenty (20) trading days of at
least 10,000 shares, or (c) the date and time, or the occurrence of an event,
specified by vote or written consent of the holders of at least a majority of
the then outstanding shares of Series A Preferred Stock (the time of such
closing or the date and time specified or the time of the event specified in
such vote or written consent is referred to herein as the “
Mandatory Conversion Time
”),
(i) all outstanding shares of Series A Preferred Stock held by each holder
thereof, subject to the Beneficial Ownership Limitation (as defined in
Section 5.1.2
below),
shall automatically be converted into shares of Common Stock at the then
effective Series A Conversion Price, and (ii) such shares may not be reissued by
the Corporation.
5.1.2. Shares
of Series A Preferred Stock held by each holder of record thereof shall not be
converted pursuant to
Section 5.1.1
to the
extent that, after giving effect to such conversion, such holder (together with
any of such holder’s Affiliates and any other person or entity acting as a group
together with such holder or any of such holder’s Affiliates) would beneficially
own in excess of the Beneficial Ownership Limitation (as defined
below). For purposes of the foregoing sentence, the number of shares
of Common Stock beneficially owned by such holder of record and its Affiliates
shall include the number of shares of Common Stock issuable upon conversion of
such holder’s Series A Preferred Stock, but shall exclude the number of shares
of Common Stock which would be issuable upon exercise or conversion of the
unexercised or non-converted portion of any other securities of the Corporation
(including, without limitation, options and warrants) that are subject to a
limitation on conversion or exercise analogous to the limitation contained
herein and are beneficially owned by such holder or any of its
Affiliates. Except as set forth in the preceding sentence, for
purposes of this
Section 5.1.2
,
beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act, and each holder of record shall be solely responsible for any
schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this
Section 5.1.2
applies, the determination of whether each holder of record’s shares of Series A
Preferred Stock are convertible into shares of Common Stock (in relation to
other securities owned by such holder together with any Affiliates) shall be
made by such holder and shall be provided in writing to the Corporation within
ten (10) days of receipt of a written request from the Company for such
determination, which shall indicate the number of shares of Common Stock then
outstanding, or at such other times as may be reasonably requested by the
Corporation. The Corporation shall have no obligation to verify or
confirm the accuracy of the holder’s determination. In addition, a
determination as to any group status as contemplated above shall be determined
in accordance with Section 13(d) of the Exchange Act. The “
Beneficial Ownership
Limitation
” shall be 4.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common
Stock upon conversion of the shares of Series A Preferred Stock. The
Beneficial Ownership Limitation provisions of this
Section 5.1.2
may be
waived by the holder of record, at the election of such holder, upon not less
than sixty-one (61) days prior written notice to the Corporation (which notice
period, if requested by the holder of record, the Corporation may waive in its
sole discretion) to increase the Beneficial Ownership Limitation to 9.99%,
14.99% or 19.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon
conversion of the shares of Series A Preferred Stock, and the provisions of this
Section 5.1.2
shall continue to apply. Upon a waiver of the Beneficial Ownership
Limitation from 4.99% to 9.99%, or from 9.99% to 14.99%, as the case may be, the
holder of record may further waive the Beneficial Ownership Limitation from
9.99% to 14.99%, or from 14.99% to 19.99%, as applicable, by written notice to
the Corporation not less than sixty-one (61) days in advance of such waiver
(which notice period, if requested by the holder of record, the Corporation may
waive in its sole discretion). Upon the change by the holder of
record of the Beneficial Ownership Limitation from 14.99% to 19.99%, the
Beneficial Ownership Limitation may not be further waived by such
Holder.
5.2.
Procedural
Requirements
. All holders of record of shares of Series A
Preferred Stock shall be sent written notice of the Mandatory Conversion Time
and the place designated for mandatory conversion of all such shares of Series A
Preferred Stock pursuant to this
Section
5
. Such notice need not be sent in advance of the occurrence
of the Mandatory Conversion Time. Upon receipt of such notice, each
holder of shares of Series A Preferred Stock shall surrender his, her or its
certificate or certificates for all such shares (or, if such holder alleges that
such certificate has been lost, stolen or destroyed, a lost certificate
affidavit and agreement reasonably acceptable to the Corporation to indemnify
the Corporation against any claim that may be made against the Corporation on
account of the alleged loss, theft or destruction of such certificate) to the
Corporation at the place designated in such notice. If so required by
the Corporation, certificates surrendered for conversion shall be endorsed or
accompanied by written instrument or instruments of transfer, in form
satisfactory to the Corporation, duly executed by the registered holder or by
his, her or its attorney duly authorized in writing. All rights with
respect to the Series A Preferred Stock converted pursuant to
Section 5.1
,
including the rights, if any, to receive notices and vote (other than as a
holder of Common Stock), will terminate at the Mandatory Conversion Time
(notwithstanding the failure of the holder or holders thereof to surrender the
certificates at or prior to such time), except only the rights of the holders
thereof, upon surrender of their certificate or certificates (or lost
certificate affidavit and agreement) therefor, to receive the items provided for
in the next sentence of this
Subsection
5.2
. As soon as practicable after the Mandatory Conversion
Time and the surrender of the certificate or certificates (or lost certificate
affidavit and agreement) for Series A Preferred Stock, the Corporation shall
issue and deliver to such holder, or to his, her or its nominees, a certificate
or certificates for the number of full shares of Common Stock issuable on such
conversion in accordance with the provisions hereof, together with cash as
provided in
Subsection
4.2
in lieu of any fraction of a share of Common Stock otherwise issuable
upon such conversion and the payment of any accrued but unpaid dividends on the
shares of Series A Preferred Stock converted. Such converted Series A
Preferred Stock shall be retired and cancelled and may not be reissued as shares
of such series, and the Corporation may thereafter take such appropriate action
(without the need for stockholder action) as may be necessary to reduce the
authorized number of shares of Series A Preferred Stock
accordingly.
6.
Redemption
.
6.1.
Redemption
. Shares
of Series A Preferred Stock may be redeemed by the Corporation out of funds
lawfully available therefor at a price equal to the Series A Original Issue
Price per share, plus all accrued but unpaid dividends thereon
(the “
Redemption Price
”), in two
annual installments commencing at least 30 days after written notice by the
Corporation to the holders of the then outstanding shares of Series A Preferred
Stock at any time on or after February 12, 2014. The date of each
such installment shall be referred to as a “
Redemption
Date
”. On each Redemption Date, the Corporation shall redeem,
on a pro rata basis in accordance with the number of shares of Series A
Preferred Stock owned by each holder, that number of outstanding shares of
Series A Preferred Stock determined by dividing (i) the total number of shares
of Series A Preferred Stock outstanding immediately prior to such Redemption
Date by (ii) the number of remaining Redemption Dates (including the Redemption
Date to which such calculation applies). If the Corporation does not
have sufficient funds legally available to redeem on any Redemption Date all
shares of Series A Preferred Stock to be redeemed on such Redemption Date, the
Corporation shall redeem a pro rata portion of each holder’s redeemable shares
of such capital stock out of funds legally available therefor, based on the
respective amounts which would otherwise be payable in respect of the shares to
be redeemed if the legally available funds were sufficient to redeem all such
shares, and shall redeem the remaining shares to have been redeemed as soon as
practicable after the Corporation has funds legally available
therefore.
6.2.
Redemption
Notice
. The Corporation shall send written notice of the
mandatory redemption (the “
Redemption Notice
”) to each
holder of record of Series A Preferred Stock not less than 30 days prior to each
Redemption Date. Each Redemption Notice shall state:
(a) the
number of shares of Series A Preferred Stock held by the holder that the
Corporation shall redeem on the Redemption Date specified in the Redemption
Notice;
(b) the
Redemption Date and the Redemption Price;
(c) the
date upon which the holder’s right to convert such shares terminates (as
determined in accordance with
Subsection 4.1
);
and
(d) that
the holder is to surrender to the Corporation, in the manner and at the place
designated, his, her or its certificate or certificates representing the shares
of Series A Preferred Stock to be redeemed.
6.3.
Surrender of Certificates;
Payment
. On or before the applicable Redemption Date, each
holder of shares of Series A Preferred Stock to be redeemed on such Redemption
Date, unless such holder has exercised his, her or its right to convert such
shares as provided in
Section 4
, shall
surrender the certificate or certificates representing such shares (or, if such
registered holder alleges that such certificate has been lost, stolen or
destroyed, a lost certificate affidavit and agreement reasonably acceptable to
the Corporation to indemnify the Corporation against any claim that may be made
against the Corporation on account of the alleged loss, theft or destruction of
such certificate) to the Corporation, in the manner and at the place designated
in the Redemption Notice, and thereupon the Redemption Price for such shares
shall be payable to the order of the person whose name appears on such
certificate or certificates as the owner thereof. In the event less
than all of the shares of Series A Preferred Stock represented by a certificate
are redeemed, a new certificate representing the unredeemed shares of Series A
Preferred Stock shall promptly be issued to such holder.
6.4.
Rights Subsequent to
Redemption
. If the Redemption Notice shall have been duly
given, and if on the applicable Redemption Date the Redemption Price payable
upon redemption of the shares of Series A Preferred Stock to be redeemed on such
Redemption Date is paid or tendered for payment or deposited with an independent
payment agent so as to be available therefor in a timely manner, then
notwithstanding that the certificates evidencing any of the shares of Series A
Preferred Stock so called for redemption shall not have been surrendered,
dividends with respect to such shares of Series A Preferred Stock shall cease to
accrue after such Redemption Date and all rights with respect to such shares
shall forthwith after the Redemption Date terminate, except only the right of
the holders to receive the Redemption Price without interest upon surrender of
their certificate or certificates therefor.
7.
Redeemed or Otherwise
Acquired Shares
. Any shares of Series A Preferred Stock that
are redeemed or otherwise acquired by the Corporation or any of its subsidiaries
shall be automatically and immediately cancelled and retired and shall not be
reissued, sold or transferred. Neither the Corporation nor any of its
subsidiaries may exercise any voting or other rights granted to the holders of
Series A Preferred Stock following redemption.
8.
Waiver
. Any
of the rights, powers, preferences and other terms of the Series A Preferred
Stock set forth herein may be waived on behalf of all holders of Series A
Preferred Stock by the affirmative written consent or vote of the holders of at
least a majority of the shares of Series A Preferred Stock then
outstanding.
9.
Notices
. Any
notice required or permitted by the provisions of this Article Fourth to be
given to a holder of shares of Series A Preferred Stock shall be mailed, postage
prepaid, to the post office address last shown on the records of the
Corporation, or given by electronic communication in compliance with the
provisions of the Massachusetts Business Corporation Act, and shall be deemed
sent upon such mailing or electronic transmission.
SECURITIES
PURCHASE AGREEMENT
This
Securities Purchase Agreement (this “
Agreement
”)
is dated as of February 12, 2009, by and among Pressure BioSciences, Inc., a
Massachusetts corporation (the “
Company
”),
and each purchaser identified on the signature pages hereto (each, including its
successors and assigns, a “
Purchaser
”
and collectively the “
Purchasers
”).
WHEREAS,
the Company has determined that it is in its best interests to obtain equity
financing through the issuance and sale of its securities with such securities
consisting of units (the “
Units
”)
comprised of (i) one share of Series A Convertible Preferred Stock, $.01 par
value (the “
Preferred
Stock
”), (ii) a warrant to purchase, at the Purchaser’s election, either
ten shares of Common Stock, $.01 par value (“
15-Month Common
Warrant
”), or one share of Preferred Stock (the “
15-Month
Preferred Warrant
”), and (iii) a warrant to purchase ten shares of Common
Stock (the “
30-Month Common
Warrant
”); and
WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to
Section 4(2) of the Securities Act of 1933, as amended (the “
Securities
Act
”), and Rule 506 promulgated thereunder, the Company desires to issue
and sell to each Purchaser, and each Purchaser, severally and not jointly,
desires to purchase from the Company, the Units, as more fully described in this
Agreement.
NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement,
and for other good and valuable consideration the receipt and adequacy of which
are hereby acknowledged, the Company and each Purchaser agree as
follows:
ARTICLE
I.
DEFINITIONS
1.1
Definitions
. In
addition to the terms defined elsewhere in this Agreement, for all purposes of
this Agreement, the following terms have the meanings set forth in this
Section
1.1
:
“
Affiliate
”
means any Person that, directly or indirectly through one or more
intermediaries, controls or is controlled by or is under common control with a
Person as such terms are used in and construed under Rule 144 under the
Securities Act.
“
Articles of
Amendment
” means the Articles of Amendment to the Company’s Restated
Articles of Organization, as amended, in the form of
Exhibit A
attached
hereto, that includes a Certificate of Designation setting forth the rights,
preferences, powers, privileges, restrictions, qualifications and limitations of
the Preferred Stock.
“
Business
Day
” means any day except Saturday, Sunday, any day which shall be a
federal legal holiday in the United States, or any day on which banking
institutions in the State of New York are authorized or required by law or other
governmental action to close.
“
Closing
”
and “
Closings
”
means each of the closings of the purchase and sale of the Units pursuant to
Section
2.3
. In the event there is more than one closing, the term
“
Closing
”
shall apply to each such closing unless otherwise specified
“
Closing
Date
” means the date on which the Company closes the purchase and sale of
the Units. In the event there is more than one Closing, the term
“
Closing
Date
” shall apply to each such Closing unless otherwise
specified.
“
Commission
”
means the Securities and Exchange Commission.
“
Common
Stock
” means the common stock of the Company, par value $0.01 per share,
and any other class of securities into which such securities may hereafter be
reclassified or changed into.
“
Common Stock
Equivalents
” means any securities of the Company or the Subsidiaries
which would entitle the holder thereof to acquire at any time Common Stock,
including, without limitation, any debt, preferred stock, rights, options,
warrants, stock appreciation rights, restricted stock units, or other instrument
that are at any time convertible into or exercisable or exchangeable for, or
otherwise entitles the holder thereof to receive, Common Stock.
“
Common Warrant
Shares
” means the shares of Common Stock issuable upon exercise of the
15-Month Common Warrants and 30-Month Common Warrants.
“
Company
Counsel
” means Pepper Hamilton LLP, with offices located at 125 High
Street, 15
th
Floor,
Oliver Street Tower, Boston, Massachusetts, 02110.
“
Conversion
Shares
” means such shares of Common Stock which, from time to time, have
been issued, or may be issuable, upon conversion of the Preferred
Stock.
“
Disclosure
Schedules
” means the Disclosure Schedules of the Company delivered
concurrently herewith.
“
Effective
Date
” has the meaning set forth in the Registration Rights
Agreement.
“
Escrow
Agent
” means Pepper Hamilton LLP, with offices located at 125 High
Street, 15
th
Floor,
Oliver Street Tower, Boston, Massachusetts, 02110.
“
Escrow
Agreement
” means the Escrow Agreement among the Company and the
Purchasers in the form of
Exhibit B
attached
hereto.
“
Exchange
Act
” means the Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder.
“
Liens
”
means a lien, charge, security interest, encumbrance, right of first refusal,
preemptive right or other restriction.
“
Material Adverse
Effect
” shall have the meaning assigned to such term in
Section
3.1(b)
.
“
Next
Financing
” shall have the meaning assigned to such term in
Section
4.7
.
“
Per Unit Purchase
Price
” means an amount equal to the greater of:
|
(b)
|
an
amount equal to the volume weighted average price for the Company’s Common
Stock on the Trading Market for the ten (10) Trading Days preceding the
Closing Date with respect to which the particular Units are being
purchased, multiplied by ten (10);
and
|
|
(c)
|
an
amount equal to the closing bid price of the Common Stock as reported by
the Trading Market on the Trading Day immediately preceding the Closing
Date with respect to which the particular Units are being purchased,
multiplied by ten (10), plus $2.50.
|
“
Person
”
means an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability company, joint
stock company, government (or an agency or subdivision thereof), or other entity
of any kind.
“
Preferred
Stock
” means the Series A Convertible Preferred Stock of the Company,
$0.01 par value, issued or issuable to each Purchaser pursuant to this Agreement
with such rights, preferences, powers, privileges, restrictions, qualifications
and limitations as are set forth in the Certificate of Designation included in
the Articles of Amendment.
“
Preferred Warrant
Shares
” means the shares of Preferred Stock issuable upon exercise of the
15-Month Preferred Warrants.
“
Proceeding
”
means an action, claim, suit, investigation or proceeding (including, without
limitation, an investigation or partial proceeding, such as a deposition),
whether commenced or threatened.
“
Registration
Rights Agreement
” means the Registration Rights Agreement, dated the date
hereof, among the Company and the Purchasers, in the form of
Exhibit C
attached
hereto.
“
Registration
Statement
” means a registration statement meeting the requirements set
forth in the Registration Rights Agreement and covering the resale by the
Purchasers of all or part of the Common Warrant Shares issuable upon exercise of
the 15-Month Common Warrants.
“
Required
Approvals
” shall have the meaning ascribed to such term in
Section
3.1(e)
.
“
Rule 144
”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as
such rule may be amended from time to time, or any similar rule or regulation
hereafter adopted by the Commission having substantially the same effect as such
rule.
“
SEC
Reports
” shall have the meaning ascribed to such term in
Section
3.1(h)
.
“
Securities
”
means, as context requires, the Preferred Stock, the Warrants, the Conversion
Shares, the Warrant Shares, and any combination of the foregoing or all of the
foregoing.
“
Securities
Act
” means the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder.
“
Subscription
Amount
” means, as to each Purchaser, the aggregate amount to be paid for
Units purchased hereunder as specified below such Purchaser’s name on the
signature page of this Agreement and next to the heading “Subscription Amount,”
in United States dollars and in immediately available funds.
“
Subsidiary
”
means any subsidiary of the Company as set forth on
Schedule
3.1(a)
.
“
Trading
Day
” means a day on which the Common Stock is traded on a Trading
Market.
“
Trading
Market
” means the NASDAQ Capital Market or if the NASDAQ Capital Market
is not the primary market on which the Common Stock is then traded, such other
markets or exchanges on which the Common Stock is listed or quoted for trading
on the date in question.
“
Transaction
Documents
” means this Agreement, the Escrow Agreement, the Registration
Rights Agreement and any other documents or agreements executed in connection
with the transactions contemplated hereunder.
“
Transfer
Agent
” means Computershare Trust Company, with a mailing address of 350
Indiana Street, Suite 800, Golden, CO 80401 and a telephone number of
(303) 262-0600.
“
Unit
”
means (i) one share of Preferred Stock, (ii) a 15-Month Common Warrant or
15-Month Preferred Warrant, as the case may be, and (iii) a 30-Month Common
Warrant.
“
Warrants
”
means collectively the 15-Month Common Warrants, the 15-Month Preferred Warrants
and the 30-Month Common Warrants delivered, as the case may be, to the
Purchasers at the Closing in accordance with
Section 2.2(a)
hereof, which warrants shall be, respectively, in the forms of
Exhibit D
,
Exhibit E
and
Exhibit F
attached
hereto.
“
Warrant
Shares
” means collectively the Common Warrant Shares and the Preferred
Warrant Shares.
ARTICLE
II.
PURCHASE
AND SALE
2.1
Escrow.
Prior
to the Closing, each Purchaser shall deliver to the Escrow Agent, via wire
transfer, immediately available funds equal to its Subscription Amount to be
held and released pursuant to the terms of the Escrow Agreement. The
Subscription Amount will be deposited by the Escrow Agent in a non-interest
bearing escrow account. The Company will pay interest on the
Subscription Amount when the Subscription Amount is released from the escrow in
an amount equal to five percent (5%) per annum, pro rated on a daily basis for
each day during which the Subscription Amount is held in escrow. The
Subscription Amounts may be released to the Company, at the direction and in the
discretion of the Company, at an initial Closing after the Company has received
aggregate Subscription Amounts from Purchasers equal to at least
$2,000,000. Thereafter, Subscription Amounts may be released to the
Company from time to time at each subsequent Closing. Subscription
Amounts shall be returned to a Purchaser if there is no Closing with respect to
such Purchaser’s Subscription Amount before February 12, 2009, in accordance
with the terms of the Escrow Agreement.
2.2
Articles of
Amendment
. On or before the initial Closing, the Company shall
adopt and file with the Secretary of the Commonwealth of Massachusetts the
Articles of Amendment.
2.3
Closing
.
(a) On
each Closing Date, upon the terms and subject to the conditions set forth
herein, the Company agrees to sell, and each Purchaser, severally and not
jointly, agrees to purchase, at the Per Unit Purchase Price that number of Units
set forth opposite each Purchaser’s name on the signature page to this
Agreement, up to an aggregate of $3,500,000 of Units. At the Closing,
the Escrow Agent shall release to the Company each Purchaser’s Subscription
Amount and the Company shall record in the name of each Purchaser its respective
shares of Preferred Stock and shall deliver to each Purchaser a 30-Month Common
Warrant as determined pursuant to Section 2.4(a)(v), and the Company and each
Purchaser shall deliver the other items set forth in Section 2.4 deliverable at
the Closing. Upon satisfaction of the conditions set forth in
Sections 2.4 and 2.5, the Closing shall occur at the offices of the Company
Counsel or remotely via the exchange of documents and signatures or at such
other location or by such other means as the parties shall mutually
agree.
(b)
Within 7 days after each Closing Date, each Purchaser shall notify the Company
in writing (each, a “
Warrant Election
Notice
”) of its election to receive (i) a 15-Month Common Warrant and/or
(ii) a 15-Month Preferred Warrant, as determined pursuant to Section
2.4(a)(iv).
(c)
The
initial Closing
of the purchase and sale of the Units shall not take place until such time as
the Escrow Agent has received at least $2,000,000 in Subscription
Amounts. After the Escrow Agent has received such Subscription
Amounts, the Company may select, in its sole discretion, a date for the initial
Closing to occur, which may not be later than February 12,
2009. After the initial Closing and from time to time until February
12, 2009, the Company may sell, on the same terms and conditions as those
contained in this Agreement, up to the remaining aggregate of $3,500,000 of
Units, if any, with the Per Unit Purchase Price being determined on the basis of
such subsequent Closing Date.
2.4
Deliveries
.
(a) On or
prior to the Closing Date (except as otherwise required below), the Company
shall deliver or cause to be delivered to each Purchaser the
following:
|
(i)
|
this
Agreement duly executed by the
Company;
|
|
(ii)
|
the
Escrow Agreement duly executed by the Company and the Escrow
Agent;
|
|
(iii)
|
in
the discretion of the Company, either (A) a copy of the irrevocable
instructions to the Transfer Agent instructing the Transfer Agent to
deliver, on an expedited basis, a certificate evidencing the number of
shares of Preferred Stock contained in such Purchaser’s Units, or (B) a
certificate evidencing the number of shares of Preferred Stock contained
in such Purchaser’s Units, (in each case determined by dividing such
Purchaser’s Subscription Amount by the Per Unit Purchase Price), and in
each case registered in the name of such
Purchaser;
|
|
(iv)
|
within
7 days after receiving such Purchaser’s Warrant Election Notice, (a) a
15-Month Common Warrant, if applicable, registered in the name of such
Purchaser to purchase up to a number of Common Warrant Shares equal to ten
(10) times the number of the Purchaser’s Units for which such Purchaser
elects in the Warrant Election Notice to receive a 15-Month Common
Warrant, and/or (b) a 15-Month Preferred Warrant, if applicable,
registered in the name of such Purchaser to purchase up to a number of
Preferred Warrant Shares equal to the number of the Purchaser’s Units for
which such Purchaser elects in the Warrant Election Notice to receive a
15-Month Preferred Warrant;
provided
that, for the
purposes of clarity, the Purchaser may elect to receive, with respect to
each of its Units, either a 15-Month Common Warrant or a 15-Month
Preferred Warrant, and not both such
Warrants;
|
|
(v)
|
a
30-Month Common Warrant registered in the name of such Purchaser to
purchase up to a number of Common Warrant Shares equal to ten (10) times
the number of shares of Preferred Stock contained in such Purchaser’s
Units;
|
|
(vi)
|
a
check in the amount of the interest accrued on the Subscription Amounts
held in escrow based upon an interest rate of five percent (5%) per annum
and prorated on a daily basis for each day during which the Subscription
Amount has been held in escrow;
|
|
(vii)
|
the
Registration Rights Agreement duly executed by the Company;
and
|
|
(viii)
|
a
legal opinion of Company Counsel in customary form regarding the issuance
of the Units.
|
(b) On or
prior to the Closing Date, each Purchaser shall deliver or cause to be delivered
to the Company the following:
|
(i)
|
this
Agreement duly executed by such
Purchaser;
|
|
(ii)
|
the
Escrow Agreement duly executed by such
Purchaser;
|
|
(iii)
|
such
Purchaser’s Subscription Amount by wire transfer to the account as
specified in the Escrow Agreement;
|
|
(iv)
|
the
Registration Rights Agreement duly executed by such Purchaser;
and
|
|
(v)
|
if
the Purchaser is a U.S. citizen, resident for U.S. federal income tax
purposes, or otherwise subject to U.S. federal income tax, an IRS Form W-9
completed with respect to such Purchaser in accordance with the
instructions accompanying such
form.
|
On the
Closing Date, the Escrow Agent shall deliver or cause to be delivered to the
Company the Subscription Amounts from each Purchaser.
2.5
Closing
Conditions
.
(a) The
obligations of the Company hereunder in connection with the Closing are subject
to the following conditions being met:
(i) the
accuracy in all material respects when made and on the Closing Date of the
representations and warranties of the Purchasers contained herein;
(ii) all
obligations, covenants and agreements of the Purchasers required to be performed
at or prior to the Closing Date shall have been performed;
(iii) the
delivery by the Purchasers of the items set forth in
Section 2.2(b)
of
this Agreement; and
(iv) the
receipt by the Company of not less than $2,000,000 in Subscription
Amounts.
(b) The
respective obligations of each Purchaser hereunder in connection with the
Closing are subject to the following conditions being met:
(i) the
accuracy in all material respects when made and on the Closing Date of the
representations and warranties of the Company contained herein;
(ii) all
obligations, covenants and agreements of the Company required to be performed at
or prior to the Closing Date shall have been performed;
(iii) the
delivery by the Company of the items set forth in
Section 2.2(a)
of
this Agreement; and
(iv) the
receipt by the Company of not less than $2,000,000 in Subscription
Amounts.
ARTICLE
III.
REPRESENTATIONS
AND WARRANTIES
3.1
Representations and
Warranties of the Company
. Except as set forth in the
Disclosure Schedules or disclosed in the SEC Reports, which Disclosure Schedules
shall be deemed a part hereof and shall qualify any representation or otherwise
made herein to the extent of the disclosure contained in the corresponding
section of the Disclosure Schedules, the Company hereby makes the following
representations and warranties to each Purchaser:
(a)
Subsidiaries
. All
of the direct and indirect subsidiaries of the Company are set forth on
Schedule
3.1(a)
. The Company owns, directly or indirectly, all of the
capital stock or other equity interests of each Subsidiary free and clear of any
Liens, and all of the issued and outstanding shares of capital stock of each
Subsidiary are validly issued and are fully paid, non-assessable and free of
preemptive and similar rights to subscribe for or purchase
securities.
(b)
Organization and
Qualification
. Each of the Company and each of the
Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its
incorporation or organization (as applicable), with the requisite power and
authority to own and use its properties and assets and to carry on its business
as currently conducted. Neither the Company nor any Subsidiary is in
violation or default of any of the provisions of its respective certificate or
articles of incorporation, bylaws or other organizational or charter
documents. Each of the Company and each of the Subsidiaries is duly
qualified to conduct business and is in good standing as a foreign corporation
or other entity in each jurisdiction in which the nature of the business
conducted or property owned by it makes such qualification necessary, except
where the failure to be so qualified or in good standing, as the case may be,
would
not, individually or in the
aggregate, h
ave or
reasonably be expected
to result in (i) a material adverse effect on the legality, validity or
enforceability of any Transaction Document, (ii) a material adverse effect on
the results of operations, assets, business
,
prospects
or condition (financial or otherwise) of the Company and the
Subsidiaries, taken as a whole, or (iii) a material adverse effect on the
Company’s ability to perform in any material respect on a timely basis its
obligations under any Transaction Document (any of (i), (ii) or (iii), a “
Material Adverse
Effect
”).
(c)
Authorization;
Enforcement
. The Company has the requisite corporate power and
authority to enter into and to consummate the transactions contemplated by each
of the Transaction Documents and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of each of the
Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all
necessary corporate action on the part of the Company and no further action is
required by the Company, its board of directors or its stockholders in
connection therewith other than the Required Approvals. Each
Transaction Document has been (or upon delivery will have been) duly executed by
the Company and, when delivered in accordance with the terms hereof and thereof,
will constitute the valid and binding obligation of the Company enforceable
against the Company in accordance with its terms except (i) as limited by
general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting
enforcement of creditors’ rights generally, (ii) as limited by laws relating to
the availability of specific performance, injunctive relief or other equitable
remedies and (iii) insofar as indemnification and contribution provisions may be
limited by applicable law.
(d)
No
Conflicts
. The execution, delivery, and performance of the
Transaction Documents by the Company, the issuance and sale of the Units, and
the consummation by the Company of the other transactions contemplated hereby
and thereby do not and will not (i) conflict with or violate any provision of
the Company’s or any Subsidiary’s certificate or articles of incorporation,
bylaws or other organizational or charter documents, or (ii) conflict with, or
constitute a default (or an event that with notice or lapse of time or both
would become a default) under, result in the creation of any Lien upon any of
the properties or assets of the Company or any Subsidiary, or give to others any
rights of termination, amendment, acceleration or cancellation (with or without
notice, lapse of time or both) of, any agreement, credit facility, debt or other
instrument (evidencing a Company or Subsidiary debt or otherwise) or other
understanding to which the Company or any Subsidiary is a party or by which any
property or asset of the Company or any Subsidiary is bound or affected, or
(iii) subject to the Required Approvals, conflict with or result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other
restriction of any court or governmental authority to which the Company or a
Subsidiary is subject (including federal and state securities laws and
regulations), or by which any property or asset of the Company or a Subsidiary
is bound or affected; except in the case of each of clauses (ii) and (iii), such
as
would
not, individually or in the
aggregate,
have or
reasonably be expected
to result in a Material Adverse Effect.
(e)
Filings, Consents and
Approvals
. The Company is not required to obtain any consent,
waiver, authorization, or order of, give any notice to, or make any filing or
registration with, any court or other federal, state, local or other
governmental authority or other Person in connection with the execution,
delivery, and performance by the Company of the Transaction Documents, other
than (i) the filing of the Articles of Amendment with, and the acceptance of
such filing by, the Secretary of the Commonwealth of Massachusetts, (ii) filings
required pursuant to
Section 4.3
of this
Agreement, (iii) the filing with, and the declaration of effectiveness by, the
Commission of the Registration Statement, (iv) application(s) and
notification(s) to each applicable Trading Market for the listing of the
Securities for trading thereon in the time and manner required thereby, and (v)
the filing of Form D with the Commission and such filings as are required to be
made under applicable state securities laws (collectively, the “
Required
Approvals
”).
(f)
Issuance of
Units
. The shares of Preferred Stock constituting a part of
the Units are duly authorized and, when issued and paid for in accordance with
the applicable Transaction Documents, will be duly and validly issued, fully
paid and nonassessable, free and clear of all Liens imposed by the Company other
than restrictions on transfer provided for in the Transaction Documents,
applicable federal and state securities laws and liens or encumbrances created
by or imposed by a Purchaser. The Warrants, constituting a part of
the Units have been duly authorized and constitute the binding obligation of the
Company enforceable against the Company in accordance with its terms except (i)
as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other
equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law. The Preferred Stock
issuable upon exercise of the 15-Month Preferred Warrants, and the Common Stock
issuable upon (x) conversion of the shares of Preferred Stock issued as part of
the Units, (y) exercise of the 15-Month Common Warrants and 30-Month Common
Warrants, and (z) conversion of the shares of Preferred Stock issuable upon
exercise of the 15-Month Preferred Warrants, have in each case been duly
reserved for issuance, and upon issuance in accordance with the terms of the
Company’s Restated Articles of Organization, as amended, and the terms of the
Warrants, as applicable, will be validly issued, fully paid and nonassessable
and free of restrictions on transfer other than restrictions on transfer under
the Transaction Documents, applicable federal and state securities laws and
liens or encumbrances created by or imposed by a Purchaser.
(g)
Capitalization
. The
number of shares and type of all authorized, issued and outstanding capital
stock of the Company as of December 31, 2008, are set forth on
Schedule
3.1(g)
. No Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate in the
transactions contemplated by the Transaction Documents. Except as set
forth on
Schedule
3.1(g)
, or as a result of the purchase and sale of the Units pursuant to
the terms of this Agreement, there are no outstanding options, warrants, scrip
rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities, rights, or obligations convertible into or
exercisable or exchangeable for, or giving any Person any right to subscribe for
or acquire, any shares of Common Stock, or contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may
become bound to issue additional shares of Common Stock or Common Stock
Equivalents. The issuance and sale of the Units will not obligate the
Company to issue shares of Common Stock or other securities to any Person (other
than the Purchasers) and will not result in a right of any holder of Company
securities to adjust the exercise, conversion, exchange or reset price under any
of such securities.
(h)
SEC Reports; Financial
Statements
. The Company has filed all reports, schedules,
forms, statements and other documents required to be filed by the Company under
the Securities Act and the Exchange Act, including pursuant to Section 13(a) or
15(d) thereof, for the two years preceding the date hereof (or such shorter
period as the Company was required by law or regulation to file such material)
(the foregoing materials, including the exhibits thereto and documents
incorporated by reference therein, being collectively referred to herein as the
“
SEC
Reports
”) on a timely basis or has received a valid extension of such
time of filing and has filed any such SEC Reports prior to the expiration of any
such extension. As of their respective dates, the SEC Reports
complied in all material respects with the requirements of the Securities Act
and the Exchange Act, as applicable, and none of the SEC Reports, when filed,
contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not
misleading.
The
financial
statements of the Company included in the SEC Reports comply in all material
respects with applicable accounting requirements and the rules and regulations
of the Commission with respect thereto as in effect at the time of
filing.
Such
financial
statements have been prepared in accordance with United States generally
accepted accounting principles applied on a consistent basis during the periods
involved (“
GAAP
”),
except as may be otherwise specified in such financial statements or the notes
thereto and except that unaudited financial statements may not contain all
footnotes required by GAAP, and fairly present in all material respects the
financial position of the Company and its consolidated subsidiaries as of and
for the dates thereof and the results of operations and cash flows for the
periods then ended, subject, in the case of unaudited statements, to normal,
immaterial, year-end audit adjustments and absence of footnotes
thereto.
(i)
Material Changes;
Undisclosed Events, Liabilities or Developments
. Except as set
forth on
Schedule
3.1(i)
, s
ince
the date of the latest
Current Report on Form 8-K filed by the Company prior to the date hereof, (i)
there has been no event, occurrence or development that has had or that could
reasonably be expected to result in a Material Adverse Effect, (ii) the Company
has not incurred any liabilities (contingent or otherwise) other than (A) trade
payables and accrued expenses incurred in the ordinary course of business
consistent with past practice and (B) liabilities not required to be reflected
in the Company’s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of
accounting, and (iv) the Company has not declared or made any dividend or
distribution of cash or other property to its stockholders or purchased,
redeemed or made any agreements to purchase or redeem any shares of its capital
stock.
(j)
Certain
Fees
. Except as set forth on
Schedule 3.1(j)
, no
brokerage or finder’s fees or commissions are or will be payable by the Company
to any broker, financial advisor or consultant, finder, placement agent,
investment banker, bank or other Person with respect to the transactions
contemplated by the Transaction Documents.
(k)
Disclosure
. Except
with regard to the identity of the Purchasers set forth on
Schedule 3.1(k)
and
except with respect to the material terms and conditions of the transactions
contemplated by the Transaction Documents which may constitute material,
non-public information until such time as the Company files a Current Report on
Form 8-K or issues a press release disclosing the terms of the transaction
contemplated by the Transaction Documents, the Company confirms that neither it
nor any other Person acting on its behalf has provided any of the Purchasers or
their agents or counsel with any information that it believes constitutes or
might constitute material, non-public information. The Company
understands and confirms that the Purchasers will rely on the foregoing
representation in effecting transactions in securities of the
Company. All disclosure furnished by or on behalf of the Company to
the Purchasers regarding the Company, its business, and the transactions
contemplated hereby, including the Disclosure Schedules to this Agreement, is
true and correct and does not contain any untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements made
therein, in light of the circumstances under which they were made, not
misleading.
3.2
Representations and
Warranties of the Purchasers
. Each Purchaser, for itself,
himself or herself and for no other Purchaser, hereby represents and warrants as
follows:
(a)
Organization;
Authority
. If a corporation, partnership, limited liability
company, trust or other entity, (i) such Purchaser is an entity duly organized,
validly existing, and in good standing under the laws of the jurisdiction of its
organization with full right, corporate or partnership power and authority to
enter into and to consummate the transactions contemplated by the Transaction
Documents and otherwise to carry out its obligations hereunder and thereunder;
and (ii) the execution, delivery, and performance by such Purchaser of the
transactions contemplated by this Agreement have been duly authorized by all
necessary corporate or similar action on the part of such
Purchaser. If an individual, such Purchaser has full legal capacity
to execute and deliver this Agreement and the other Transaction Documents to
which he or she is a party and to consummate the transactions contemplated by
the Transaction Documents and otherwise to carry out his or her obligations
hereunder and thereunder. Each Transaction Document to which such
Purchaser is a party has been duly executed by the Purchaser, and when delivered
by such Purchaser in accordance with the terms hereof, will constitute the valid
and legally binding obligation of such Purchaser, enforceable against such
Purchaser in accordance with its terms, except (i) as limited by general
equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of
creditors’ rights generally, (ii) as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable
remedies and (iii) insofar as indemnification and contribution provisions may be
limited by applicable law.
(b)
Own
Account
. Such Purchaser understands that the Securities are
“restricted securities” and have not been registered under the Securities Act or
any applicable state or other securities law and is acquiring the Securities as
principal for its own account and not with a view to or for distributing or
reselling such Securities or any part thereof in violation of the Securities Act
or any applicable state or other securities law, has no present intention of
distributing any of such Securities in violation of the Securities Act or any
applicable state or other securities law, and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding
the distribution of such Securities (this representation and warranty not
limiting such Purchaser’s right to sell the Securities pursuant to the
Registration Statement or otherwise in compliance with applicable federal and
state securities laws) in violation of the Securities Act or any applicable
state or other securities law. Such Purchaser is acquiring the
Securities hereunder in the ordinary course of its business.
(c)
Purchaser
Status
. At the time such Purchaser was offered the Securities
such Purchaser was, on the date hereof it is, and on the applicable Closing Date
it will be, an “accredited investor” as defined in Rule 501(a) under the
Securities Act. No Purchaser is required to be registered as a
broker-dealer under Section 15 of the Exchange Act.
(d)
Experience of Such
Purchaser
. Such Purchaser, either alone or together with such
Purchaser’s representatives, has such knowledge, sophistication, and experience
in business and financial matters so as to be capable of evaluating the merits
and risks of the prospective investment in the Securities, and has so evaluated
the merits and risks of such investment. Such Purchaser is able to
bear the economic risk of an investment in the Securities and, at the present
time, is able to afford a complete loss of such investment.
(e)
General
Solicitation
. Such Purchaser is not purchasing the Securities
as a result of any advertisement, article, notice, or other communication
regarding the Securities published in any newspaper, magazine or similar media
or broadcast over television or radio or presented at any seminar or any other
general solicitation or general advertisement.
(f)
Provision of
Information
. Such Purchaser has been afforded (i) the opportunity to ask
such questions as it has deemed necessary of, and to receive answers from,
representatives of the Company concerning the terms and conditions of the
Securities and the finances, operations and business of the Company; and (ii)
the opportunity to request such additional information which the Company
possesses or can acquire without unreasonable effort or expense. All
of such Purchaser’s questions have been answered to its satisfaction and such
Purchaser has received all of such requested additional
information.
(g)
Certain
Fees
. No brokerage or finder’s fees or commissions are or will
be payable by such Purchaser to any broker, financial advisor or consultant,
finder, placement agent, investment banker, bank, or other Person with respect
to the transactions contemplated by the Transaction Documents.
(h)
Residency
. The
residence or principal place of business of such Purchaser is set forth below on
such Purchaser’s signature page to this Agreement, and all communications
between such Purchaser and the Company regarding the transactions contemplated
by this Agreement took place within or from the state of such residence or
principal place of business.
(i)
Acknowledgement
. Each
Purchaser acknowledges that the Company has relied upon the representations and
warranties of the Purchasers set forth in
Section 3.2
in its
determination that no registration under the Securities Act is required for the
offer and sale of the Securities by the Company to the Purchasers as
contemplated by this Agreement.
(j)
Transactions in Common
Stock
.
(i) Each
Purchaser represents, warrants and covenants that, at no time in the thirty (30)
days preceding the date hereof and through the date of the Closing, such
Purchaser and, to the Purchaser’s knowledge, its Affiliates have not engaged in,
directed or otherwise participated in, and shall not engage in, direct or
otherwise participate in, any transactions, whether directly or indirectly
through or with another Person, involving securities of the Company (including
without limitation the Common Stock) to maintain or otherwise affect, or that
are intended to maintain or otherwise affect, the trading price of the Common
Stock.
(ii) Each
Purchaser represents, warrants and covenants that, at no time in the thirty (30)
days preceding the date hereof and through the date of the Closing, such
Purchaser and, to the Purchaser’s knowledge, its Affiliates have not engaged,
and shall not engage, in any short-selling of Common Stock, and that such
Purchaser shall not use any of the Securities acquired pursuant to this
Agreement to cover any short position in the Common Stock if doing so would be
in violation of any applicable federal or state securities laws. For
the six (6) months following the Closing, the Purchaser shall not, and shall
cause its Affiliates not to, engage in any short-selling of Common
Stock.
(iii) Each
Purchaser shall indemnify the Company for any and all losses, damages, costs and
expenses (including attorneys’ fees) that the Company may incur as a result of
any breach by the Purchaser of this Section 3.2(j).
ARTICLE
IV.
OTHER
AGREEMENTS OF THE PARTIES
4.1
Transfer
Restrictions
.
(a) The
Securities may only be disposed of in compliance with state and federal
securities laws. In connection with any transfer of Securities other
than pursuant to an effective registration statement or Rule 144, or to the
Company, the Company may require the transferor thereof to provide to the
Company an opinion of counsel selected by the transferor and reasonably
acceptable to the Company, the form and substance of which opinion shall be
reasonably satisfactory to the Company, to the effect that such transfer does
not require registration of such transferred Securities under the Securities
Act. As a condition of transfer, any such transferee shall agree in
writing to be bound by the terms of this Agreement and shall have the rights of
a Purchaser under this Agreement.
(b) Certificates
evidencing any Securities will contain the following legend or such other legend
as may be reasonably appropriate under the Securities Act for so long as the
Company determines that such legend is reasonably appropriate under the
Securities Act:
THIS
SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR
THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM
REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN
AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO
SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE
COMPANY.
4.2
Furnishing of
Information
. As long as any Purchaser owns Securities and the
Company remains subject to the requirements of the Exchange Act, the Company
covenants to timely file (or obtain extensions in respect thereof and file
within the applicable grace period) all reports required to be filed by the
Company after the date hereof pursuant to the Exchange Act. As long
as any Purchaser owns Securities, if the Company is not required to file reports
pursuant to the Exchange Act, it will prepare and furnish to the Purchasers and
make publicly available in accordance with Rule 144(c) such information as is
required for the Purchasers to sell the Securities under Rule 144.
4.3
Securities Laws Disclosure;
Publicity
. Promptly following the Closing and in accordance
with federal securities laws and regulations, the Company shall file a Current
Report on Form 8-K, disclosing the material terms of the transactions
contemplated hereby and filing the Transaction Documents as exhibits
thereto. The Company intends to and may issue press releases with
respect to the transactions contemplated hereby without the prior consent of
each Purchaser. Notwithstanding the foregoing, the Company shall not
publicly disclose the name of any Purchaser, or include the name of any
Purchaser in any filing with the Commission or any regulatory agency or Trading
Market, without the prior written consent of such Purchaser, except (i) as
required by federal securities law in connection with (A) any registration
statement contemplated by the Registration Rights Agreement, (B) the Current
Report on Form 8-K required by this
Section 4.3
, (C) any
filing required by the Commission, (D) any filing required by state securities
laws and regulations as set forth in
Section 4.5
, and (E)
the filing of final Transaction Documents (including signature pages thereto)
with the Commission and (ii) to the extent such disclosure is required by law or
Trading Market regulations, in which case the Company shall provide the
Purchasers with prior notice of such disclosure permitted under this clause
(ii). No Purchaser shall issue any press release or otherwise make
any public statement with respect to the transactions contemplated hereby
without the prior consent of the Company, which consent shall not unreasonably
be withheld or delayed, except if such disclosure is required by law, in which
case the Purchaser shall promptly provide the Company with prior notice of such
public statement or communication.
4.4
Use of
Proceeds
. The Company shall use the net proceeds from the sale
of the Securities hereunder for general corporate working capital and corporate
purposes, including, but not limited to sales and marketing expenses, general
and administrative expenses, research and development expenses and the expenses
of the transaction contemplated by the Transaction Documents.
4.5
Form D; Blue Sky
Filings
. The Company shall timely file a Form D with respect
to the Securities as required under Regulation D under the Securities Act and
shall provide a copy thereof, promptly upon request of any Purchaser. The
Company shall take such action as the Company shall reasonably determine is
necessary in order to obtain an exemption for, or to qualify the Securities for,
sale to the Purchasers at the Closing under applicable securities or “Blue Sky”
laws of the states of the United States, and shall provide evidence of such
actions promptly upon request of any Purchaser. Each Purchaser shall
take all commercially reasonable actions that are reasonably requested by the
Company related to, or to effectuate, the filing of a Form D or any filing
required pursuant to the “Blue Sky” laws of the states of the United States
which, for purposes of clarity, shall not include the payment of any fees by
such Purchaser.
4.6
Registration of Warrant
Shares
. Not later than 60 days following the Closing Date, the
Company shall use its commercially reasonable efforts to prepare and file with
the Commission a Registration Statement on Form S-3 covering the resale of the
Common Warrant Shares (subject to the limitations set forth in the Registration
Rights Agreement), and upon such filing the Company shall use its commercially
reasonable efforts to cause the Registration Statement to be declared effective
under the Securities Act as promptly as possible after the filing thereof, all
in accordance with the terms and conditions of the Registration Rights
Agreement.
4.7
Subsequent
Placements
.
(a) If
the Company consummates an equity financing (the “
Next
Financing
”) prior to the first anniversary of the initial Closing Date,
each Purchaser may exchange all, but not less than all, of his, her or its Units
for the equity securities issued in such Next Financing (the “
Next Financing
Securities
”), and shall become subject to the terms and conditions of
such Next Financing;
provided
that the exchange of
the Purchaser’s Units for Next Financing Securities is permitted under the rules
and regulations of the Trading Market then in effect. The number of
Next Financing Securities into which a Purchaser’s Units may be exchanged shall
be determined by dividing (a) the aggregate Per Unit Purchase Price at which the
Units being exchanged were issued, by (b) the price per Next Financing Security
at which such securities were issued in the Next Financing.
(b) The
Company shall provide the Purchasers written notice (the “
Exchange
Notice
”) of any proposed Next Financing at least ten (10) days prior to
the closing of such Next Financing. Such notice shall include the
terms and conditions of such Financing, including the consideration to be paid
to the Company for the issuance of the Next Financing Securities. If
a Purchaser shall decide to exchange his, her or its Units for Next Financing
Securities, such Purchaser shall notify the Company in writing within ten (10)
days after receipt of the Exchange Notice.
(c) In
order to exchange Units for Next Financing Securities, each Purchaser shall be
required to execute all agreements executed by the investors in the Next
Financing (which in the sole discretion of the Company are reasonably applicable
to such Purchaser) and to deliver the certificate or certificates representing
their shares of Series A Preferred Stock and their Warrants, duly endorsed for
transfer or accompanied by a duly endorsed stock power (or, if such Purchaser
alleges that such certificate or Warrant has been lost, stolen or destroyed, a
lost certificate affidavit and agreement reasonably acceptable to the Company to
indemnify the Company against any claim that may be made against the Company on
account of the alleged loss, theft or destruction of such certificate) to the
Company at the place designated in the Exchange Notice. Each
exchanging Purchaser also shall be required to execute and deliver such
additional instruments and undertake such other actions as the Company may
reasonably require to transfer such Units and issue Next Financing Securities in
exchange therefore in accordance with the terms and conditions of the Next
Financing.
ARTICLE
V.
MISCELLANEOUS
5.1
Fees and
Expenses
. Except as expressly set forth in the Transaction
Documents to the contrary, each party shall pay the fees and expenses of its
advisers, counsel, accountants and other experts, if any, and all other expenses
incurred by such party incident to the negotiation, preparation, execution,
delivery and performance of this Agreement. The Company shall pay all
Transfer Agent fees, stamp taxes and other taxes and duties levied in connection
with the delivery of any Shares to the Purchasers.
5.2
Entire
Agreement
. The Transaction Documents and all of the
confidentiality agreements by and between the Company and the Purchasers
together with the exhibits and schedules thereto, contain the entire
understanding of the parties with respect to the subject matter hereof and
thereof and supersede all prior agreements and understandings, oral or written,
with respect to such matters, which the parties acknowledge have been merged
into such documents, exhibits and schedules.
5.3
Notices
. Any
and all notices or other communications or deliveries required or permitted to
be provided hereunder shall be in writing and shall be deemed given and
effective on the earliest of (a) the date of transmission, if such notice or
communication is delivered via facsimile at the facsimile number set forth on
the signature pages attached hereto prior to 5:30 p.m. (New York City time) on a
Trading Day, (b) the next Trading Day after the date of transmission, if such
notice or communication is delivered via facsimile at the facsimile number set
forth on the signature pages attached hereto on a day that is not a Trading Day
or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second
Trading Day following the date of mailing, if sent by internationally recognized
overnight courier service, or (d) upon actual receipt by the party to whom such
notice is required to be given. The address for such notices and
communications shall be as set forth on the signature pages attached
hereto.
5.4
Amendments;
Waivers
. No provision of this Agreement may be waived or
amended except in a written instrument signed, in the case of an amendment, by
the Company and all of the Purchasers or, in the case of a waiver, by the party
against whom enforcement of any such waived provision is sought. No
waiver of any default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the future or a
waiver of any subsequent default or a waiver of any other provision, condition
or requirement hereof, nor shall any delay or omission of any party to exercise
any right hereunder in any manner impair the exercise of any such
right.
5.5
Headings
. The
headings herein are for convenience only, do not constitute a part of this
Agreement and shall not be deemed to limit or affect any of the provisions
hereof.
5.6
Successors and
Assigns
. This Agreement shall be binding upon and inure to the
benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or
obligations hereunder without the prior written consent of the
Purchasers. Subject to compliance with federal and state securities
laws and the restrictions on transfers and assignments under the exemptions from
registration upon which the Company is relying to offer, issue and sell the
Securities, any Purchaser may assign any or all of its rights under this
Agreement to any Person to whom such Purchaser assigns or transfers any
Securities, provided such transferee agrees in writing to be bound, with respect
to the transferred Securities, by the provisions of the Transaction Documents
that apply to the “Purchasers.”
5.7
No Third Party
Beneficiaries
. This Agreement is intended for the benefit of
the parties hereto and their respective successors and permitted assigns and is
not for the benefit of, nor may any provision hereof be enforced by, any other
Person.
5.8
Governing
Law
. All questions concerning the construction, validity,
enforcement and interpretation of the Transaction Documents shall be governed by
and construed and enforced in accordance with the internal laws of the
Commonwealth of Massachusetts, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning
the interpretations, enforcement, and defense of the transactions contemplated
by this Agreement and any other Transaction Documents (whether brought against a
party hereto or its respective affiliates, directors, officers, shareholders,
employees, or agents) shall be commenced exclusively in the state and federal
courts sitting in the Commonwealth of Massachusetts. Each party hereby
irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of Boston for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein (including with respect to the enforcement of any of the
Transaction Documents), and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject
to the jurisdiction of any such court, that such suit, action or proceeding is
improper or is an inconvenient venue for such proceeding. Each party
hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by mailing a copy thereof
via registered or certified mail or overnight delivery (with evidence of
delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall
be deemed to limit in any way any right to serve process in any other manner
permitted by law. The parties hereby waive all rights to a trial by
jury. If either party shall commence an action or proceeding to
enforce any provisions of the Transaction Documents, then the prevailing party
in such action or proceeding shall be reimbursed by the other party for its
reasonable attorneys’ fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such action or
proceeding.
5.9
Execution
. This
Agreement may be executed in two or more counterparts, all of which when taken
together shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the
other party, it being understood that both parties need not sign the same
counterpart. In the event that any signature is delivered by
facsimile transmission or by e-mail delivery of a “.pdf” format data file, such
signature shall create a valid and binding obligation of the party executing (or
on whose behalf such signature is executed) with the same force and effect as if
such facsimile or “.pdf” signature page were an original thereof.
5.10
Severability
. If
any term, provision, covenant or restriction of this Agreement is held by a
court of competent jurisdiction to be invalid, illegal, void or unenforceable,
the remainder of the terms, provisions, covenants and restrictions set forth
herein shall remain in full force and effect and shall in no way be affected,
impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same
or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the
intention of the parties that they would have executed the remaining terms,
provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.
5.11
Remedies
. In
addition to being entitled to exercise all rights provided herein or granted by
law, including recovery of damages, each of the Purchasers and the Company will
be entitled to specific performance under the Transaction
Documents. The parties agree that monetary damages may not be
adequate compensation for any loss incurred by reason of any breach of
obligations contained in the Transaction Documents and hereby agrees to waive
and not to assert in any action for specific performance of any such obligation
the defense that a remedy at law would be adequate.
5.12
Independent Nature of
Purchasers’ Obligations and Rights
. The obligations of each
Purchaser under any Transaction Document are several and not joint with the
obligations of any other Purchaser, and no Purchaser shall be responsible in any
way for the performance or non-performance of the obligations of any other
Purchaser under any Transaction Document. Nothing contained herein or
in any other Transaction Document, and no action taken by any Purchaser pursuant
thereto, shall be deemed to constitute the Purchasers as a partnership, an
association, a joint venture or any other kind of entity, or create a
presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the
Transaction Documents. Each Purchaser shall be entitled to
independently protect and enforce its rights, including without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents,
and it shall not be necessary for any other Purchaser to be joined as an
additional party in any proceeding for such purpose. Each Purchaser
has been represented by its own separate legal counsel in their review and
negotiation of the Transaction Documents.
5.13
Construction
. The
parties agree that each of them and/or their respective counsel has reviewed and
had an opportunity to revise the Transaction Documents and, therefore, the
normal rule of construction to the effect that any ambiguities are to be
resolved against the drafting party shall not be employed in the interpretation
of the Transaction Documents or any amendments hereto.
[signature
pages follow]
IN WITNESS WHEREOF, the parties hereto
have caused this Securities Purchase Agreement to be duly executed by their
respective authorized signatories as of the date first indicated
above.
Pressure Biosciences
Inc.
|
|
Address
for Notice:
|
By:
|
|
|
14
Norfolk Avenue
|
|
Name: Richard
T. Schumacher
Title: President
and Chief Executive Officer
|
|
Easton,
MA 02375
Facsimile: (508)
580-1829
Attention: Richard
T. Schumacher
|
With
a copy to (which shall not constitute notice):
Pepper
Hamilton LLP
125
High Street
Oliver
Street Tower
15
th
Floor
Boston,
MA 02110
Facsimile: 617-956-4351
Attention: Steven
R. London
|
|
|
[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK
SIGNATURE
PAGE FOR PURCHASER FOLLOWS]
[PURCHASER
SIGNATURE PAGES TO PRESSURE BIOSCIENCES INC. SECURITIES
PURCHASE
AGREEMENT]
IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement
to be duly executed by their respective authorized signatories as of the date
first indicated above.
Signature of Authorized Signatory of Purchaser:
|
|
Name of Authorized Signatory:
|
|
Title of Authorized Signatory:
|
|
Email Address of Purchaser:
|
|
Address for Notice of Purchaser:
|
|
|
|
|
|
Address for Delivery of Units for Purchaser (if not same as address for notice):
|
|
Subscription Amount: $__________________
Units:
_______________________
[TO BE COMPLETED BY THE COMPANY AT
THE CLOSING BASED UPON THE PER UNIT PURCHASE PRICE]
Taxpayer
Identification Number:
[PROVIDE THIS UNDER SEPARATE
COVER]
[SIGNATURE
PAGES CONTINUE]
*
|
All
of the exhibits and schedules to this agreement have been omitted pursuant
to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish
supplementally to the SEC, upon request, a copy of any omitted exhibit or
schedule provided however that the Company may request confidential
treatment pursuant to Rule 24-2 of the Exchange Act for any schedule or
exhibit so furnished.
|
NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE
BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS
EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE
SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
15-MONTH
COMMON STOCK PURCHASE WARRANT
PRESSURE
BIOSCIENCES INC.
WARRANT
NO. B-__
Warrant
Shares:
_____ Initial
Exercise Date: February 12, 2009
THIS
15-MONTH COMMON STOCK PURCHASE WARRANT (the “
Warrant
”)
certifies that, for value received, _____________ (the “
Holder
”)
is entitled, upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time on or after the date hereof (the
“
Initial
Exercise Date
”) and on or prior to the close of business on May 12, 2010,
which is 15 months after the Initial Exercise Date, or sooner in accordance with
Section 3(b)
or
Section 5(c)
(the “
Termination
Date
”) but not thereafter, to subscribe for and purchase from Pressure
BioSciences Inc., a Massachusetts corporation (the “
Company
”),
up to ______ shares (the “
Warrant
Shares
”) of common stock, par value $0.01 per share (the “
Common
Stock
”), of the Company. The purchase price of one share of
Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in
Section
2(b)
.
1.
Definitions
. Capitalized
terms used and not otherwise defined herein shall have the meanings set forth in
that certain Securities Purchase Agreement, dated February 12, 2009 (the “
Purchase
Agreement
”), by and among the Company and the purchasers signatory
thereto.
2.
Exercise
.
a)
Exercise of
Warrant
. Exercise of the purchase rights represented by this
Warrant may be made, in whole or in part, at any time or times on or after the
Initial Exercise Date and on or before the Termination Date by delivery to the
Company of a duly executed Notice of Exercise (in the form annexed hereto, the
“
Notice of
Exercise
”) (or such other office or agency of the Company as it may
designate by notice in writing to the registered Holder at the address of such
Holder appearing on the books of the Company), this Warrant, and payment of the
aggregate Exercise Price of the Warrant Shares thereby purchased by wire
transfer or cashier’s check drawn on a United States bank.
b)
Exercise
Price
. The exercise price per share of the Common Stock under
this Warrant shall be $1.25,
subject to adjustment
hereunder (the “
Exercise
Price
”).
c)
Cashless
Exercise
.
i. If
at any time after six (6) months from the date of issuance of this Warrant (x)
there is no effective Registration Statement (as defined in that certain
Registration Rights Agreement, dated February 12, 2009, by and among the Company
and the other parties thereto) registering, or no current prospectus under such
Registration Statement available for, the resale of all of the Warrant Shares by
the Holder, and (y) the Warrant Shares not registered under such Registration
Statement and not provided for in any such prospectus thereunder may not be
resold without restriction by the Holder pursuant to Rule 144 under the
Securities Act (such Warrant Shares, the “
Restricted
Warrant Shares
”), then this Warrant may also be exercised at such time by
means of a “cashless exercise” only with respect to such Restricted Warrant
Shares, in which case the Holder shall be entitled to receive that number of
Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where:
|
(A)
=
|
the
volume weighted average price (“
VWAP
”)
on the Trading Day immediately preceding the date of such election (with
the date of such election being deemed to be the date on which the Company
receives the Holder’s duly executed Notice of Exercise and this
Warrant);
|
|
(B)
=
|
the
Exercise Price, as adjusted; and
|
|
(X)
=
|
the
number of Restricted Warrant Shares issuable upon exercise of this Warrant
in accordance with the terms of this Warrant by means of a cash exercise
rather than a cashless exercise.
|
Notwithstanding
the foregoing provisions of this
Section 2(c)(i)
, this
Warrant may be exercised only (A) first in accordance with
Section 2(a)
by
payment of the Exercise Price in cash with respect to the Warrant Shares that
are not Restricted Warrant Shares, and only after this Warrant has been so
exercised with respect to all such Warrant Shares this Warrant may be exercised
(B) in accordance with this
Section 2(c)(i)
by
means of cashless exercise with respect to the Restricted Warrant
Shares.
ii. At
any time that the Holder is an Affiliate of the Company, this Warrant may also
be exercised by means of a “cashless exercise” with respect to all Warrant
Shares, in which case the Holder shall be entitled to receive that number of
Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where:
|
(A)
=
|
the
VWAP on the Trading Day immediately preceding the date of such election
(with the date of such election being deemed to be the date on which the
Company receives the Holder’s duly executed Notice of Exercise and this
Warrant);
|
|
(B)
=
|
the
Exercise Price, as adjusted; and
|
|
(X)
=
|
the
number of Warrant Shares issuable upon exercise of this Warrant in
accordance with the terms of this Warrant by means of a cash exercise
rather than a cashless exercise.
|
d)
Holder’s
Restrictions
. The Company shall not effect any exercise of
this Warrant, and a Holder shall not have the right to exercise any portion of
this Warrant, pursuant to
Section 2
, to the
extent that after giving effect to such issuance after exercise as set forth in
the applicable Notice of Exercise, such Holder (together with such Holder’s
Affiliates, and any other person or entity acting as a group together with such
Holder or any of such Holder’s Affiliates) would beneficially own in excess of
the Beneficial Ownership Limitation (as defined below). For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially
owned by such Holder and its Affiliates shall include the number of shares of
Common Stock issuable upon exercise of this Warrant with respect to which such
determination is being made, but shall exclude the number of shares of Common
Stock which would be issuable upon (A) exercise of the remaining, non-exercised
portion of this Warrant beneficially owned by such Holder or any of its
Affiliates and (B) exercise or conversion of the unexercised or non-converted
portion of any other securities of the Company (including, without limitation,
shares of Series A Convertible Preferred Stock, options and any other warrants)
subject to a limitation on conversion or exercise analogous to the limitation
contained herein beneficially owned by such Holder or any of its
Affiliates. Except as set forth in the preceding sentence, for
purposes of this
Section 2(d)
,
beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act, it being acknowledged by the Holder that the Company is not
representing to such Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and such Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this
Section 2(d)
applies,
the determination of whether this Warrant is exercisable in full or in part (in
relation to other securities owned by such Holder together with any Affiliates)
shall be made by the Holder, and the submission of a Notice of Exercise shall be
deemed to be each Holder’s determination of whether this Warrant is exercisable
(in relation to other securities owned by such Holder together with any
Affiliates), in each case subject to such aggregate percentage limitation, and
the Company shall have no obligation to verify or confirm the accuracy of such
determination. In addition, a determination as to any group status as
contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act. Upon the written request of the Holder, the Company
shall within two (2) Trading Days confirm in writing to such Holder the number
of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to
the conversion or exercise of securities of the Company, including this Warrant,
by such Holder or its Affiliates since the date as of which such number of
outstanding shares of Common Stock was reported. The “
Beneficial
Ownership Limitation
” shall be 4.99% of the number of shares of the
Common Stock outstanding immediately after giving effect to the issuance of
shares of Common Stock issuable upon exercise of this Warrant. The
Beneficial Ownership Limitation provisions of this
Section 2(d)
may be
waived by the Holder, at the election of such Holder, upon not less than
sixty-one (61) days prior written notice to the Company (which notice period, if
requested by the Holder, may be waived by the Company in its sole discretion) to
increase the Beneficial Ownership Limitation to 9.99%, 14.99% or 19.99% of the
number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon exercise of this Warrant, and the
provisions of this
Section 2(d)
shall
continue to apply. Upon a waiver of the Beneficial Ownership
Limitation from 4.99% to 9.99%, or from 9.99% to 14.99%, as the case may be, the
Holder may further waive the Beneficial Ownership Limitation from 9.99% to
14.99%, or from 14.99% to 19.99%, as applicable, by written notice to the
Company not less than sixty-one (61) days in advance of such waiver (which
notice period, if requested by the Holder, may be waived by the Company in its
sole discretion). Upon the change by the Holder of the Beneficial
Ownership Limitation from 14.99% to 19.99%, the Beneficial Ownership Limitation
may not be further waived by such Holder. The limitations contained
in this paragraph shall apply to a successor holder of this
Warrant.
e)
Mechanics of
Exercise
.
i.
Authorization of Warrant
Shares
. The Company covenants that all Warrant Shares which
may be issued upon the exercise of the purchase rights represented by this
Warrant will, upon such exercise, be duly authorized, validly issued, fully paid
and nonassessable and free from all taxes, liens and charges created by the
Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).
ii.
Delivery of Certificates
Upon Exercise
. Certificates for shares purchased hereunder
shall be transmitted by the Transfer Agent to the Holder by crediting the
account of the Holder’s prime broker with the Depository Trust Company through
its Deposit Withdrawal Agent Commission (“
DWAC
”)
system if the Company is a participant in such system, and otherwise by the
Company or by the Transfer Agent by physical delivery to the address specified
by the Holder in the Notice of Exercise promptly, or if required by law, within
three (3) Trading Days, from the delivery to the Company of the duly executed
Notice of Exercise, surrender of this Warrant and payment of the aggregate
Exercise Price as set forth above (
or an exercise
pursuant to
Section 2(c)
) (
“
Warrant Share
Delivery Date
”). This Warrant shall be deemed to have been
exercised, the Warrant Shares shall be deemed to have been issued, and the
Holder or any other person so designated to be named therein shall be deemed to
have become a holder of record of such shares of Common Stock for all purposes,
on the date the Company receives the duly executed Notice of Exercise, Warrant
and Exercise Price
(unless such exercise is
pursuant to
Section 2(c)
in which case receipt of the Exercise Price is not
applicable),
and all taxes required to be paid by the Holder,
if any, pursuant to
Section 2(e)(v)
prior
to the issuance of such shares, have been paid.
iii.
Delivery of New Warrants
Upon Exercise
. If this Warrant shall have been exercised in
part, the Company shall, at the time of delivery of the certificate or
certificates representing Warrant Shares if prior to the Termination Date,
deliver to Holder a new Warrant evidencing the right of Holder to purchase the
unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.
iv.
No Fractional Shares or
Scrip
. No fractional shares or scrip representing fractional
shares shall be issued upon the exercise of this Warrant. As to any
fraction of a share which Holder would otherwise be entitled to purchase upon
such exercise, the Company shall at its election, either pay a cash adjustment
in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.
v.
Charges, Taxes and
Expenses
. Issuance of certificates for Warrant Shares shall be
made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such certificate, all of which
taxes and expenses shall be paid by the Company, and such certificates shall be
issued in the name of the Holder or in such name or names as may be directed by
the Holder;
provided,
however
, that in the event certificates for Warrant Shares are to be
issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached
hereto duly executed by the Holder; and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax
incidental thereto.
vi.
Closing of
Books
. The Company will not close its stockholder books or
records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.
3.
Certain
Events
.
a)
Adjustments for Stock
Dividends and Splits
. If the Company, at any time while this Warrant is
outstanding: (A) pays a stock dividend or otherwise m
akes
a distribution or distributions on shares of
its Common Stock or any other equity or equity equivalent securities payable in
shares of Common Stock (which, for avoidance of doubt, shall not include any
shares of Common Stock issued by the Company upon exercise of this Warrant), (B)
subdivides outstanding shares of Common Stock into a larger number of shares,
(C) combines (including by way of reverse stock split) outstanding shares of
Common Stock into a smaller number of shares, or (D) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then
in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury
shares, if any) outstanding immediately before such event and of which the
denominator shall be the number of shares of Common Stock outstanding
immediately after such event and the number of shares issuable upon exercise of
this Warrant shall be proportionately adjusted. Any adjustment made
pursuant to this
Section 3(a)
shall
become effective immediately after the record date for the determination of
stockholders entitled to receive such dividend or distribution and shall become
effective immediately after the effective date in the case of a subdivision,
combination or re-classification.
b)
Fundamental
Transaction
. If, at any time while this Warrant is outstanding, (A) the
Company effects any merger or consolidation of the Company (or a subsidiary of
the Company and the Company issues shares of its capital stock pursuant to such
merger or consolidation) with or into another Person in which the shares of
capital stock of the Company outstanding immediately prior to such merger or
consolidation do not continue to represent, or are not converted into or
exchanged for shares of capital stock that represent, immediately following such
merger or consolidation, at least a majority, by voting power, of the capital
stock of the surviving or resulting entity, or if the surviving or resulting
entity is a wholly owned subsidiary of another entity immediately following such
merger or consolidation, the parent entity of such surviving or resulting
entity, (B) the Company effects any sale of all or substantially all of its
assets in one or a series of related transactions, (C) any tender offer or
exchange offer (whether by the Company or another Person) is completed pursuant
to which holders of Common Stock are permitted to tender or exchange their
shares for other securities, cash or property, or (D) the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other
securities, cash or property (each “
Fundamental
Transaction
”), then, the Holder may exercise this Warrant subject to and
conditioned upon the completion or closing of such Fundamental Transaction, and
upon such completion or closing of such Fundamental Transaction, this Warrant
shall terminate and shall no longer be exerciseable.
c)
Calculations
. All
calculations under this
Section 3
shall be
made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this
Section 3
, the number
of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury
shares, if any) issued and outstanding.
d)
Notice to
Holder
.
i.
Adjustment to Exercise
Price
. Whenever the Exercise Price is adjusted pursuant to any provision
of this
Section
3
, the Company shall promptly mail to the Holder a notice setting forth
the Exercise Price after such adjustment and setting forth a brief statement of
the facts requiring such adjustment.
ii.
Notice to Allow Exercise by
Holder
. If (A) the Company shall declare a dividend (or any other
distribution in whatever form) on the Common Stock; (B) the Company shall
declare a special nonrecurring cash dividend on or a redemption of the Common
Stock; (C) the Company shall authorize the granting to all holders of the Common
Stock rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights; (D) the approval of any stockholders of the
Company shall be required in connection with any reclassification of the Common
Stock, any consolidation or merger to which the Company is a party, any sale or
transfer of all or substantially all of the assets of the Company, any
compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property
, or any Fundamental
Transaction
; (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company; then, in
each case, the Company shall cause to be mailed to the Holder at its last
address as it shall appear upon the Warrant Register (as defined below) of the
Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is
to be taken for the purpose of such dividend, distribution, redemption, rights
or warrants, or if a record is not to be taken, the date as of which the holders
of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange
is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to
exchange their shares of the Common Stock for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer or
share exchange; provided that the failure to mail such notice or any defect
therein or in the mailing thereof shall not affect the validity of the corporate
action required to be specified in such notice
if
Holder is allowed to determine in its discretion that the Company must deem the
Warrant exercised immediately prior to and contingent upon the occurrence of the
events described in (A), (B), (C), (D) or (E) above
. The
Holder is entitled to exercise this Warrant during the 20-day period commencing
on the date of such notice of the record or effective date of the event
triggering such notice.
4.
Transfer of
Warrant
.
a)
Transferability
. Subject
to compliance with any applicable securities laws and the conditions set forth
in
Section 4(d)
hereof and to the provisions of
Section 4.1
of the
Purchase Agreement, this Warrant and all rights hereunder (including, without
limitation, any registration rights) are transferable, in whole or in part, upon
surrender of this Warrant at the principal office of the Company or its
designated agent, together with a written assignment of this Warrant
substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon
the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in
the name of the assignee or assignees and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a
new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. A Warrant, if properly assigned,
may be exercised by a new holder for the purchase of Warrant Shares without
having a new Warrant issued.
b)
New Warrants
. This
Warrant may be divided or combined with other Warrants upon presentation hereof
at the aforesaid office of the Company, together with a written notice
specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance
with
Section
4(a)
, as to any transfer which may be involved in such division or
combination, the Company shall execute and deliver a new Warrant or Warrants in
exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice.
c)
Warrant Register
. The
Company shall register this Warrant, upon records to be maintained by the
Company for that purpose (the “
Warrant
Register
”), in the name of the record Holder hereof from time to
time. The Company may deem and treat the registered Holder of this
Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice
to the contrary reasonably satisfactory to the Company.
d)
Transfer
Restrictions
.
If
, at the
time of the surrender of this Warrant in connection with
any transfer of this Warrant, the transfer of this Warrant shall not be
registered pursuant to an effective
registration
statement under the Securities Act
and
under applicable state securities or blue sky laws, the
Company may require, as a condition of allowing such transfer, that (i) the
Holder or transferee of this Warrant, as the case may be, furnish to the Company
a written opinion of counsel (which opinion shall be in form, substance and
scope customary for opinions of counsel in comparable transactions) to the
effect that such transfer may be made without
registration under
the Securities Act and under applicable state securities
or blue sky laws, and (ii) the Holder or transferee execute and deliver to the
Company an investment letter in form and substance acceptable to the Company,
and (iii) the transferee be an “accredited investor” as defined in Rule 501(a)
promulgated under the Securities Act or a “qualified institutional buyer” as
defined in Rule 144A(a) promulgated under the Securities
Act.
5.
Right to
Call
.
a)
Call
Conditions
. The Company may call for cancellation this
Warrant, subject to the limitations discussed in
Section 5(b)
, if the
volume weighted average price for the Common Stock on the Trading Market equals
or exceeds $1.75 for either (i) ten (10) consecutive Trading Days or (ii)
fifteen (15) out of twenty-five (25) consecutive Trading Days.
b)
Callable Warrant
Shares
. The Company shall not have the right to call any
portion of this Warrant, pursuant to this
Section 5
, to the
extent that, after giving effect to the issuance of Warrant Shares after
exercise of this Warrant, such Holder (together with such Holder’s Affiliates,
and any other person or entity acting as a group together with such Holder or
any of such Holder’s Affiliates) would beneficially own in excess of the
Beneficial Ownership Limitation (as defined below). For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned
by such Holder and its Affiliates shall include the number of shares of Common
Stock issuable upon exercise of this Warrant with respect to which such right to
call determination is being made, but shall exclude the number of shares of
Common Stock which would be issuable upon (A) exercise of the remaining portion,
if any, of this Warrant with respect to which such right to call determination
is not being made beneficially owned by such Holder or any of its Affiliates and
(B) exercise or conversion of the unexercised or non-converted portion of any
other securities of the Company (including, without limitation, shares of Series
A Convertible Preferred Stock, options and any other warrants) subject to a
limitation on conversion or exercise analogous to the limitation contained
herein beneficially owned by such Holder or any of its
Affiliates. Except as set forth in the preceding sentence, for
purposes of this
Section 5(b)
,
beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act, it being acknowledged by the Holder that the Company is not
representing to such Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and such Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this
Section 5(b)
applies,
the determination of whether this Warrant may be called by the Company in full
or in part (in relation to other securities owned by such Holder together with
any Affiliates) shall be made by the Holder, and the submission of a Notice of
Exercise shall be deemed to be each Holder’s determination of whether this
Warrant is exercisable (in relation to other securities owned by such Holder
together with any Affiliates), in each case subject to such aggregate percentage
limitation, and the Company shall have no obligation to verify or confirm the
accuracy of such determination. In addition, a determination as to
any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act. Upon the written request of the
Holder, the Company shall within two (2) Trading Days confirm in writing to such
Holder the number of shares of Common Stock then outstanding. In any
case, the number of outstanding shares of Common Stock shall be determined after
giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by such Holder or its Affiliates since the date as of
which such number of outstanding shares of Common Stock was
reported. The “
Beneficial
Ownership Limitation
” shall be 4.99% of the number of shares of the
Common Stock outstanding immediately after giving effect to the issuance of
shares of Common Stock issuable upon exercise of this Warrant. The
Beneficial Ownership Limitation provisions of this
Section 5(b)
may be
waived by the Holder, at the election of such Holder, upon not less than
sixty-one (61) days prior written notice to the Company (which notice period, if
requested by the Holder, may be waived by the Company in its sole discretion) to
increase the Beneficial Ownership Limitation to 9.99%, 14.99% or 19.99% of the
number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon exercise of this Warrant, and the
provisions of this
Section 5(b)
shall
continue to apply. Upon a waiver of the Beneficial Ownership
Limitation from 4.99% to 9.99%, or from 9.99% to 14.99%, as the case may be, the
Holder may further waive the Beneficial Ownership Limitation from 9.99% to
14.99%, or from 14.99% to 19.99%, as applicable, by written notice to the
Company not less than sixty-one (61) days in advance of such waiver (which
notice period, if requested by the Holder, may be waived by the Company in its
sole discretion). Upon the change by the Holder of the Beneficial
Ownership Limitation from 14.99% to 19.99%, the Beneficial Ownership Limitation
may not be further waived by such Holder. The limitations contained
in this
Section
5(b)
shall apply to a successor holder of this Warrant.
c)
Call
Procedure
. To exercise this right, the Company shall deliver
to the Holder a written notice (a “
Call
Notice
”) indicating therein that this Warrant must be exercised by a date
specified in the Call Notice, which date shall be at least twelve (12) Business
Days after the date of the Call Notice, and which date shall be extended for a
Holder providing written notice of waiver of the Beneficial Ownership Limitation
to the sixty-first (61
st
) day
following the date such Holder provides such sixty-one (61) days notice or to
such earlier date on which the Company has waived such sixty-one (61) day
notice) (such date, the “
Call
Date
”). If the Holder does not exercise this Warrant by the
Call Date, then on the date immediately following the Call Date this Warrant
shall terminate and shall no longer be exerciseable.
6.
Miscellaneous
.
a)
No Rights as Shareholder
Until Exercise
. This Warrant does not entitle the Holder to
any voting rights or other rights as a shareholder of the Company prior to the
exercise hereof as set forth in
Section
2(e)(ii)
.
b)
Loss, Theft, Destruction or
Mutilation of Warrant
. The Company covenants that upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft,
destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or
security reasonably satisfactory to it and upon surrender and cancellation of
such Warrant or stock certificate, if mutilated, the Company will make and
deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate.
c)
Saturdays, Sundays,
Holidays, etc
. If the last or appointed day for the taking of
any action or the expiration of any right required or granted herein shall not
be a Business Day, then such action may be taken or such right may be exercised
on the next succeeding Business Day.
d)
Authorized
Shares
.
The
Company covenants that during the period the Warrant is outstanding, it will
reserve from its authorized and unissued Common Stock a sufficient number of
shares to provide for the issuance of the Warrant Shares upon the exercise of
any purchase rights under this Warrant
, including
as the Warrant is adjusted pursuant to
Section 3
above
The Company further covenants
that its issuance of this Warrant shall constitute full authority to its
officers who are charged with the duty of executing stock certificates to
execute and issue the necessary certificates for the Warrant Shares upon the
exercise of the purchase rights under this Warrant. The Company will
take all such commercially reasonable action as may be necessary to assure that
such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon
which the Common Stock may be listed.
Except
and to the extent as waived or consented to by the Holder, the Company shall not
by any action, including, without limitation, amending its articles of
organization or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all
such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the
Company will (a) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to such increase in
par value, (b) take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and nonassessable
Warrant Shares upon the exercise of this Warrant, and (c) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof as may be necessary
to enable the Company to perform its obligations under this
Warrant.
Before
taking any action which would result in an adjustment in the number of Warrant
Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents
thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof.
e)
Jurisdiction
. All
questions concerning the construction, validity, enforcement and interpretation
of this Warrant shall be determined in accordance with the provisions of the
Purchase Agreement.
f)
Governing
Law
. This Warrant shall be governed by and construed and
enforced in accordance with the internal laws of the Commonwealth of
Massachusetts, with regard to the principles of conflicts of law
thereof.
g)
Restrictions
. The
Holder acknowledges that the Warrant Shares acquired upon the exercise of this
Warrant, if not registered, will have restrictions upon resale imposed by state
and federal securities laws.
h)
Nonwaiver and
Expenses
. No course of dealing or any delay or failure to
exercise any right hereunder on the part of Holder shall operate as a waiver of
such right or otherwise prejudice Holder’s rights, powers or remedies,
notwithstanding the fact that all rights hereunder terminate on the Termination
Date. If the Company willfully and knowingly fails to comply with any
provision of this Warrant, which results in any material damages to the Holder,
the Company shall pay to Holder such amounts as shall be sufficient to cover any
costs and expenses including, but not limited to, reasonable attorneys’ fees,
including those of appellate proceedings, incurred by Holder in collecting any
amounts due pursuant hereto or in otherwise enforcing any of its rights, powers
or remedies hereunder.
i)
Notices
. Any
notice, request or other document required or permitted to be given or delivered
to the Holder by the Company shall be delivered in accordance with the notice
provisions of the Purchase Agreement.
j)
Successors and
Assigns
. Subject to applicable securities laws, this Warrant
and the rights and obligations evidenced hereby shall inure to the benefit of
and be binding upon the successors of the Company and the successors and
permitted assigns of Holder. The provisions of this Warrant are
intended to be for the benefit of all Holders from time to time of this Warrant
and shall be enforceable by any such Holder or holder of Warrant
Shares.
k)
Amendment
. This
Warrant may be modified or amended or the provisions hereof waived with the
written consent of the Company and the Holder.
l)
Severability
. Wherever
possible, each provision of this Warrant shall be interpreted in such manner as
to be effective and valid under applicable law, but if any provision of this
Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions of
this Warrant.
m)
Headings
. The
headings used in this Warrant are for the convenience of reference only and
shall not, for any purpose, be deemed a part of this Warrant.
********************
IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
officer thereunto duly authorized as of the date first above
indicated.
|
PRESSURE
BIOSCIENCES INC.
|
|
|
|
|
By:
|
|
|
|
Name:
Richard T. Schumacher
|
|
|
Title:
President and Chief Executive
Officer
|
NOTICE OF
EXERCISE
TO: PRESSURE
BIOSCIENCES INC.
(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company
pursuant to the terms of the attached Warrant (only if exercised in full), and
tenders herewith payment of the Exercise Price in full, together with all
applicable transfer taxes, if any.
(2)
Payment shall take the form of (check applicable box):
o
in lawful money of the
United States; or
o
[if permitted] the
cancellation of such number of Warrant Shares as is necessary, in accordance
with the formula set forth in
Section 2(c)(i)
, to
exercise this Warrant with respect to the maximum number of Warrant Shares
purchasable pursuant to the cashless exercise procedure set forth in
Section 2(c)(i)
;
or
o
[if permitted] the
cancellation of such number of Warrant Shares as is necessary, in accordance
with the formula set forth in
Section 2(c)(ii)
, to
exercise this Warrant with respect to the maximum number of Warrant Shares
purchasable pursuant to the cashless exercise procedure set forth in
Section
2(c)(ii)
.
(3)
Please issue a certificate or certificates representing said Warrant Shares in
the name of the undersigned or in such other name as is specified
below:
_______________________________
The
Warrant Shares shall be delivered to the following DWAC Account Number or by
physical delivery of a certificate to:
_______________________________
_______________________________
_______________________________
(4) Accredited
Investor. The undersigned is an “accredited investor” as defined in
Regulation D promulgated under the Securities Act of 1933, as
amended.
[SIGNATURE
OF HOLDER]
Name of
Investing Entity:
________________________________________________________________________
Signature
of Authorized Signatory of Investing Entity:
_________________________________________________
Name of
Authorized Signatory:
___________________________________________________________________
Title of
Authorized Signatory:
____________________________________________________________________
Date:
________________________________________________________________________________________
ASSIGNMENT
FORM
(To
assign the foregoing Warrant, execute
this form
and supply required information.
Do not
use this form to exercise the Warrant.)
FOR VALUE
RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all
rights evidenced thereby are hereby assigned to
_______________________________________________
whose address is
_______________________________________________________________.
_______________________________________________________________
Dated: ______________,
_______
Holder’s
Signature: _____________________________
Holder’s
Address:
_____________________________
_____________________________
Signature
Guaranteed: ___________________________________________
NOTE: The
signature to this Assignment Form must correspond with the name as it appears on
the face of the Warrant, without alteration or enlargement or any change
whatsoever, and must be guaranteed by a bank or trust
company. Officers of corporations and those acting in a fiduciary or
other representative capacity should file proper evidence of authority to assign
the foregoing Warrant.
NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE
BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS
EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE
SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
15-MONTH
PREFERRED STOCK PURCHASE WARRANT
PRESSURE
BIOSCIENCES INC.
WARRANT
NO. A-__
Warrant
Shares: _____
|
Initial
Exercise Date: February 12,
2009
|
THIS
15-MONTH PREFERRED STOCK PURCHASE WARRANT (the “
Warrant
”)
certifies that, for value received, _____________ (the “
Holder
”)
is entitled, upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time on or after the date hereof (the
“
Initial
Exercise Date
”) and on or prior to the close of business on May 12, 2010,
which is 15 months after the Initial Exercise Date, or sooner in accordance with
Section 3(b)
or
Section 5(b)
(the “
Termination
Date
”) but not thereafter, to subscribe for and purchase from Pressure
BioSciences Inc., a Massachusetts corporation (the “
Company
”),
up to ______ shares (the “
Warrant
Shares
”) of Series A Convertible Preferred Stock, par value $0.01 per
share (the “
Preferred
Stock
”), of the Company. The purchase price of one share of
Preferred Stock under this Warrant shall be equal to the Exercise Price, as
defined in
Section
2(b)
.
1.
Definitions
. Capitalized
terms used and not otherwise defined herein shall have the meanings set forth in
that certain Securities Purchase Agreement, dated February 12, 2009 (the “
Purchase
Agreement
”), by and among the Company and the purchasers signatory
thereto.
2.
Exercise
.
a)
Exercise of
Warrant
. Exercise of the purchase rights represented by this
Warrant may be made, in whole or in part, at any time or times on or after the
Initial Exercise Date and on or before the Termination Date by delivery to the
Company of a duly executed Notice of Exercise (in the form annexed hereto, the
“
Notice of
Exercise
”) (or such other office or agency of the Company as it may
designate by notice in writing to the registered Holder at the address of such
Holder appearing on the books of the Company), this Warrant, and payment of the
aggregate Exercise Price of the Warrant Shares thereby purchased by wire
transfer or cashier’s check drawn on a United States bank.
b)
Exercise
Price
. The exercise price per share of the Preferred Stock
under this Warrant shall be $12.50,
subject to adjustment
hereunder (the “
Exercise
Price
”).
c)
Cashless
Exercise
. At any time that the Holder is an Affiliate of the
Company, this Warrant may also be exercised by means of a “cashless exercise”
with respect to all Warrant Shares, in which case the Holder shall be entitled
to receive that number of Warrant Shares equal to the quotient obtained by
dividing [(A-B) (X)] by (A), where:
|
(A)
=
|
the
volume weighted average price on the Trading Day immediately preceding the
date of such election (with the date of such election being deemed to be
the date on which the Company receives the Holder’s duly executed Notice
of Exercise and this Warrant);
|
|
(B)
=
|
the
Exercise Price, as adjusted; and
|
|
(X)
=
|
the
number of Warrant Shares issuable upon exercise of this Warrant in
accordance with the terms of this Warrant by means of a cash exercise
rather than a cashless exercise.
|
d)
Mechanics of
Exercise
.
i.
Authorization of Warrant
Shares
. The Company covenants that all Warrant Shares which
may be issued upon the exercise of the purchase rights represented by this
Warrant will, upon such exercise, be duly authorized, validly issued, fully paid
and nonassessable and free from all taxes, liens and charges created by the
Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).
ii.
Delivery of Certificates
Upon Exercise
. Certificates for shares purchased hereunder
shall be transmitted by the Company or by the Transfer Agent by physical
delivery to the address specified by the Holder in the Notice of Exercise
promptly, or if required by law, within three (3) Trading Days, from the
delivery to the Company of the duly executed Notice of Exercise, surrender of
this Warrant and payment of the aggregate Exercise Price as set forth above (or
an exercise pursuant to
Section 2(c)
)
(
“
Warrant Share
Delivery Date
”). This Warrant shall be deemed to have been
exercised, the Warrant Shares shall be deemed to have been issued, and the
Holder or any other person so designated to be named therein shall be deemed to
have become a holder of record of such shares of Preferred Stock for all
purposes, on the date the Company receives the duly executed Notice of Exercise,
Warrant and Exercise Price
(unless such exercise
is pursuant to
Section 2(c)
in which case receipt of the Exercise Price is not
applicable),
and all taxes required to be paid by the Holder, if any,
pursuant to
Section
2(d)(v)
prior to the issuance of such shares, have been
paid.
iii.
Delivery of New Warrants
Upon Exercise
. If this Warrant shall have been exercised in
part, the Company shall, at the time of delivery of the certificate or
certificates representing Warrant Shares if prior to the Termination Date,
deliver to Holder a new Warrant evidencing the right of Holder to purchase the
unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.
iv.
No Fractional Shares or
Scrip
. No fractional shares or scrip representing fractional
shares shall be issued upon the exercise of this Warrant. As to any
fraction of a share which Holder would otherwise be entitled to purchase upon
such exercise, the Company shall at its election, either pay a cash adjustment
in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.
v.
Charges, Taxes and
Expenses
. Issuance of certificates for Warrant Shares shall be
made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such certificate, all of which
taxes and expenses shall be paid by the Company, and such certificates shall be
issued in the name of the Holder or in such name or names as may be directed by
the Holder;
provided,
however
, that in the event certificates for Warrant Shares are to be
issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached
hereto duly executed by the Holder; and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax
incidental thereto.
vi.
Closing of
Books
. The Company will not close its stockholder books or
records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.
3.
Certain
Events
.
a)
Adjustments for Stock
Dividends and Splits
. If the Company, at any time while this Warrant is
outstanding: (A) pays a stock dividend or otherwise m
akes
a distribution or distributions on shares of
its Preferred Stock or any other equity or equity equivalent securities payable
in shares of Preferred Stock (which, for avoidance of doubt, shall not include
any shares of Preferred Stock issued by the Company upon exercise of this
Warrant), (B) subdivides outstanding shares of Preferred Stock into a larger
number of shares, (C) combines (including by way of reverse stock split)
outstanding shares of Preferred Stock into a smaller number of shares, or (D)
issues by reclassification of shares of the Preferred Stock any shares of
capital stock of the Company, then in each case the Exercise Price shall be
multiplied by a fraction of which the numerator shall be the number of shares of
Preferred Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of
Preferred Stock outstanding immediately after such event and the number of
shares issuable upon exercise of this Warrant shall be proportionately
adjusted. Any adjustment made pursuant to this
Section 3(a)
shall
become effective immediately after the record date for the determination of
stockholders entitled to receive such dividend or distribution and shall become
effective immediately after the effective date in the case of a subdivision,
combination or re-classification.
b)
Fundamental
Transaction
. If, at any time while this Warrant is outstanding, (A) the
Company effects any merger or consolidation of the Company (or a subsidiary of
the Company and the Company issues shares of its capital stock pursuant to such
merger or consolidation) with or into another Person in which the shares of
capital stock of the Company outstanding immediately prior to such merger or
consolidation do not continue to represent, or are not converted into or
exchanged for shares of capital stock that represent, immediately following such
merger or consolidation, at least a majority, by voting power, of the capital
stock of the surviving or resulting entity, or if the surviving or resulting
entity is a wholly owned subsidiary of another entity immediately following such
merger or consolidation, the parent entity of such surviving or resulting
entity, (B) the Company effects any sale of all or substantially all of its
assets in one or a series of related transactions, (C) any tender offer or
exchange offer (whether by the Company or another Person) is completed pursuant
to which holders of the Company’s common stock, par value $0.01 per share (the
“
Common
Stock
”) or the Preferred Stock are permitted to tender or exchange their
shares for other securities, cash or property, or (D) the Company effects any
reclassification of the Common Stock or the Preferred Stock or any compulsory
share exchange pursuant to which the Common Stock or the Preferred Stock, as the
case may be, is effectively converted into or exchanged for other securities,
cash or property (each “
Fundamental
Transaction
”), then, the Holder may exercise this Warrant subject to and
conditioned upon the completion or closing of such Fundamental Transaction, and
upon such completion or closing of such Fundamental Transaction, this Warrant
shall terminate and shall no longer be exerciseable.
c)
Calculations
. All
calculations under this
Section 3
shall be
made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this
Section 3
, the number
of shares of Preferred Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Preferred Stock (excluding
treasury shares, if any) issued and outstanding.
d)
Notice to
Holder
.
i.
Adjustment to Exercise
Price
. Whenever the Exercise Price is adjusted pursuant to any provision
of this
Section
3
, the Company shall promptly mail to the Holder a notice setting forth
the Exercise Price after such adjustment and setting forth a brief statement of
the facts requiring such adjustment.
ii.
Notice to Allow Exercise by
Holder
. If (A) the Company shall declare a dividend (or any other
distribution in whatever form) on the Common Stock or the Preferred Stock; (B)
the Company shall declare a special nonrecurring cash dividend on or a
redemption of the Common Stock or the Preferred Stock; (C) the Company shall
authorize the granting to all holders of the Common Stock or the Preferred Stock
rights or warrants to subscribe for or purchase any shares of capital stock of
any class or of any rights; (D) the approval of any stockholders of the Company
shall be required in connection with any reclassification of the Common Stock or
the Preferred Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the
Company, any compulsory share exchange whereby the Common Stock or the Preferred
Stock is converted into other securities, cash or property
, or any Fundamental Transaction
; (E) the Company
shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company; then, in each case, the Company shall cause to
be mailed to the Holder at its last address as it shall appear upon the Warrant
Register (as defined below) of the Company, at least 20 calendar days prior to
the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken,
the date as of which the holders of the Common Stock or the Preferred Stock, as
the case may be, of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange
is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock or the Preferred Stock of record shall
be entitled to exchange their shares of Common Stock or Preferred Stock, as the
case may be, for securities, cash or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to mail such notice or any defect therein or in the
mailing thereof shall not affect the validity of the corporate action required
to be specified in such notice
if Holder is
allowed to determine in its discretion that the Company must deem the Warrant
exercised immediately prior to and contingent upon the occurrence of the events
described in (A), (B), (C), (D) or (E) above
. The Holder is
entitled to exercise this Warrant during the 20-day period commencing on the
date of such notice of the record or effective date of the event triggering such
notice.
4.
Transfer of
Warrant
.
a)
Transferability
. Subject
to compliance with any applicable securities laws and the conditions set forth
in
Section 4(d)
hereof and to the provisions of
Section 4.1
of the
Purchase Agreement, this Warrant and all rights hereunder (including, without
limitation, any registration rights) are transferable, in whole or in part, upon
surrender of this Warrant at the principal office of the Company or its
designated agent, together with a written assignment of this Warrant
substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon
the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in
the name of the assignee or assignees and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a
new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. A Warrant, if properly assigned,
may be exercised by a new holder for the purchase of Warrant Shares without
having a new Warrant issued.
b)
New Warrants
. This
Warrant may be divided or combined with other Warrants upon presentation hereof
at the aforesaid office of the Company, together with a written notice
specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance
with
Section
4(a)
, as to any transfer which may be involved in such division or
combination, the Company shall execute and deliver a new Warrant or Warrants in
exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice.
c)
Warrant Register
. The
Company shall register this Warrant, upon records to be maintained by the
Company for that purpose (the “
Warrant
Register
”), in the name of the record Holder hereof from time to
time. The Company may deem and treat the registered Holder of this
Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice
to the contrary reasonably satisfactory to the Company.
d)
Transfer
Restrictions
.
If
, at the
time of the surrender of this Warrant in connection with
any transfer of this Warrant, the transfer of this Warrant shall not be
registered pursuant to an effective
registration
statement under the Securities Act
and
under applicable state securities or blue sky laws, the
Company may require, as a condition of allowing such transfer, that (i) the
Holder or transferee of this Warrant, as the case may be, furnish to the Company
a written opinion of counsel (which opinion shall be in form, substance and
scope customary for opinions of counsel in comparable transactions) to the
effect that such transfer may be made without
registration under
the Securities Act and under applicable state securities
or blue sky laws, and (ii) the Holder or transferee execute and deliver to the
Company an investment letter in form and substance acceptable to the Company,
and (iii) the transferee be an “accredited investor” as defined in Rule 501(a)
promulgated under the Securities Act or a “qualified institutional buyer” as
defined in Rule 144A(a) promulgated under the Securities
Act.
5.
Right to
Call
.
a)
Call
Conditions
. The Company may call for cancellation this Warrant
if the volume weighted average price for the Common Stock on the Trading Market
equals or exceeds $1.75
for either (i) ten (10)
consecutive Trading Days or (ii) fifteen (15) out of twenty-five (25)
consecutive Trading Days.
b)
Call
Procedure
. To exercise this right, the Company shall deliver
to the Holder a written notice (a “
Call
Notice
”) indicating therein that this Warrant must be exercised by a date
specified in the Call Notice, which date shall be at least twelve (12) Business
Days after the date of the Call Notice (such date, the “
Call
Date
”). If the Holder does not exercise this Warrant by the
Call Date, then on the date immediately following the Call Date this Warrant
shall terminate and shall no longer be exerciseable.
6.
Miscellaneous
.
a)
No Rights as Shareholder
Until Exercise
. This Warrant does not entitle the Holder to
any voting rights or other rights as a shareholder of the Company prior to the
exercise hereof as set forth in
Section
2(d)(ii)
.
b)
Loss, Theft, Destruction or
Mutilation of Warrant
. The Company covenants that upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft,
destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or
security reasonably satisfactory to it and upon surrender and cancellation of
such Warrant or stock certificate, if mutilated, the Company will make and
deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate.
c)
Saturdays, Sundays,
Holidays, etc
. If the last or appointed day for the taking of
any action or the expiration of any right required or granted herein shall not
be a Business Day, then such action may be taken or such right may be exercised
on the next succeeding Business Day.
d)
Authorized
Shares
.
The
Company covenants that during the period the Warrant is outstanding, it will
reserve from its authorized and unissued Preferred Stock a sufficient number of
shares to provide for the issuance of the Warrant Shares upon the exercise of
any purchase rights under this Warrant
, including
as the Warrant is adjusted pursuant to
Section 3
above
The Company further covenants
that its issuance of this Warrant shall constitute full authority to its
officers who are charged with the duty of executing stock certificates to
execute and issue the necessary certificates for the Warrant Shares upon the
exercise of the purchase rights under this Warrant. The Company will
take all such commercially reasonable action as may be necessary to assure that
such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon
which the Common Stock may be listed.
Except
and to the extent as waived or consented to by the Holder, the Company shall not
by any action, including, without limitation, amending its articles of
organization or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all
such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the
Company will (a) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to such increase in
par value, (b) take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and nonassessable
Warrant Shares upon the exercise of this Warrant, and (c) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof as may be necessary
to enable the Company to perform its obligations under this
Warrant.
Before
taking any action which would result in an adjustment in the number of Warrant
Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents
thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof.
e)
Jurisdiction
. All
questions concerning the construction, validity, enforcement and interpretation
of this Warrant shall be determined in accordance with the provisions of the
Purchase Agreement.
f)
Governing
Law
. This Warrant shall be governed by and construed and
enforced in accordance with the internal laws of the Commonwealth of
Massachusetts, with regard to the principles of conflicts of law
thereof.
g)
Restrictions
. The
Holder acknowledges that the Warrant Shares acquired upon the exercise of this
Warrant, if not registered, will have restrictions upon resale imposed by state
and federal securities laws.
h)
Nonwaiver and
Expenses
. No course of dealing or any delay or failure to
exercise any right hereunder on the part of Holder shall operate as a waiver of
such right or otherwise prejudice Holder’s rights, powers or remedies,
notwithstanding the fact that all rights hereunder terminate on the Termination
Date. If the Company willfully and knowingly fails to comply with any
provision of this Warrant, which results in any material damages to the Holder,
the Company shall pay to Holder such amounts as shall be sufficient to cover any
costs and expenses including, but not limited to, reasonable attorneys’ fees,
including those of appellate proceedings, incurred by Holder in collecting any
amounts due pursuant hereto or in otherwise enforcing any of its rights, powers
or remedies hereunder.
i)
Notices
. Any
notice, request or other document required or permitted to be given or delivered
to the Holder by the Company shall be delivered in accordance with the notice
provisions of the Purchase Agreement.
j)
Successors and
Assigns
. Subject to applicable securities laws, this Warrant
and the rights and obligations evidenced hereby shall inure to the benefit of
and be binding upon the successors of the Company and the successors and
permitted assigns of Holder. The provisions of this Warrant are
intended to be for the benefit of all Holders from time to time of this Warrant
and shall be enforceable by any such Holder or holder of Warrant
Shares.
k)
Amendment
. This
Warrant may be modified or amended or the provisions hereof waived with the
written consent of the Company and the Holder.
l)
Severability
. Wherever
possible, each provision of this Warrant shall be interpreted in such manner as
to be effective and valid under applicable law, but if any provision of this
Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions of
this Warrant.
m)
Headings
. The
headings used in this Warrant are for the convenience of reference only and
shall not, for any purpose, be deemed a part of this Warrant.
********************
IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
officer thereunto duly authorized as of the date first above
indicated.
|
PRESSURE
BIOSCIENCES INC.
|
|
|
|
By:
|
|
|
|
Name:
|
Richard
T. Schumacher
|
|
|
Title:
|
President
and Chief Executive Officer
|
NOTICE OF
EXERCISE
TO: PRESSURE
BIOSCIENCES INC.
(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company
pursuant to the terms of the attached Warrant (only if exercised in full), and
tenders herewith payment of the Exercise Price in full, together with all
applicable transfer taxes, if any.
(2)
Payment shall take the form of (check applicable box):
o
in lawful money of the
United States; or
o
[if permitted] the
cancellation of such number of Warrant Shares as is necessary, in accordance
with the formula set forth in
Section 2(c)
, to
exercise this Warrant with respect to the maximum number of Warrant Shares
purchasable pursuant to the cashless exercise procedure set forth in
Section
2(c)
.
(3)
Please issue a certificate or certificates representing said Warrant Shares in
the name of the undersigned or in such other name as is specified
below:
|
________________________________
|
|
The
Warrant Shares shall be delivered to the following DWAC Account Number or by
physical delivery of a certificate to:
|
________________________________
|
|
|
|
|
|
________________________________
|
|
|
|
|
|
________________________________
|
|
(4) Accredited
Investor. The undersigned is an “accredited investor” as defined in
Regulation D promulgated under the Securities Act of 1933, as
amended.
[SIGNATURE
OF HOLDER]
Name of
Investing Entity:
_______________________________________________________________________________
Signature
of Authorized Signatory of Investing Entity:
________________________________________________________
Name of
Authorized Signatory:
___________________________________________________________________________
Title of
Authorized Signatory:
____________________________________________________________________________
Date:
_______________________________________________________________________________________________
ASSIGNMENT
FORM
(To
assign the foregoing Warrant, execute
this form
and supply required information.
Do not
use this form to exercise the Warrant.)
FOR VALUE
RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all
rights evidenced thereby are hereby assigned to
_______________________________________________
whose address is
_______________________________________________________________.
_______________________________________________________________
Dated: ______________,
_______
|
Holder’s
Signature:
|
_____________________________
|
|
|
|
|
Holder’s
Address:
|
_____________________________
|
|
|
|
|
|
_____________________________
|
Signature
Guaranteed: ___________________________________________
NOTE: The
signature to this Assignment Form must correspond with the name as it appears on
the face of the Warrant, without alteration or enlargement or any change
whatsoever, and must be guaranteed by a bank or trust
company. Officers of corporations and those acting in a fiduciary or
other representative capacity should file proper evidence of authority to assign
the foregoing Warrant.
NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE
BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS
EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE
SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
30-MONTH
COMMON STOCK PURCHASE WARRANT
PRESSURE
BIOSCIENCES INC.
WARRANT
NO. C-__
Warrant
Shares: _____
|
Initial
Exercise Date: February 12,
2009
|
THIS
30-MONTH COMMON STOCK PURCHASE WARRANT (the “
Warrant
”)
certifies that, for value received, _____________ (the “
Holder
”)
is entitled, upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time on or after the date hereof (the
“
Initial
Exercise Date
”) and on or prior to the close of business on August 12,
2011, which is 30 months after the Initial Exercise Date, or sooner in
accordance with
Section 3(b)
or
Section 5(c)
(the
“
Termination
Date
”) but not thereafter, to subscribe for and purchase from Pressure
BioSciences Inc., a Massachusetts corporation (the “
Company
”),
up to ______ shares (the “
Warrant
Shares
”) of common stock, par value $0.01 per share (the “
Common
Stock
”), of the Company. The purchase price of one share of
Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in
Section
2(b)
.
1.
Definitions
. Capitalized
terms used and not otherwise defined herein shall have the meanings set forth in
that certain Securities Purchase Agreement, dated February 12, 2009 (the “
Purchase
Agreement
”), by and among the Company and the purchasers signatory
thereto.
2.
Exercise
.
a)
Exercise of
Warrant
. Exercise of the purchase rights represented by this
Warrant may be made, in whole or in part, at any time or times on or after the
Initial Exercise Date and on or before the Termination Date by delivery to the
Company of a duly executed Notice of Exercise (in the form annexed hereto, the
“
Notice of
Exercise
”) (or such other office or agency of the Company as it may
designate by notice in writing to the registered Holder at the address of such
Holder appearing on the books of the Company), this Warrant, and payment of the
aggregate Exercise Price of the Warrant Shares thereby purchased by wire
transfer or cashier’s check drawn on a United States bank.
b)
Exercise
Price
. The exercise price per share of the Common Stock under
this Warrant shall be $2.00,
subject to adjustment
hereunder (the “
Exercise
Price
”).
c)
Cashless
Exercise
. At any time that the Holder is an Affiliate of the
Company, this Warrant may also be exercised by means of a “cashless exercise”
with respect to all Warrant Shares, in which case the Holder shall be entitled
to receive that number of Warrant Shares equal to the quotient obtained by
dividing [(A-B) (X)] by (A), where:
|
(A)
=
|
the
volume weighted average price on the Trading Day immediately preceding the
date of such election (with the date of such election being deemed to be
the date on which the Company receives the Holder’s duly executed Notice
of Exercise and this Warrant);
|
|
(B)
=
|
the
Exercise Price, as adjusted; and
|
|
(X)
=
|
the
number of Warrant Shares issuable upon exercise of this Warrant in
accordance with the terms of this Warrant by means of a cash exercise
rather than a cashless
exercise.
|
d)
Holder’s
Restrictions
. The Company shall not effect any exercise of
this Warrant, and a Holder shall not have the right to exercise any portion of
this Warrant, pursuant to
Section 2
, to the
extent that after giving effect to such issuance after exercise as set forth in
the applicable Notice of Exercise, such Holder (together with such Holder’s
Affiliates, and any other person or entity acting as a group together with such
Holder or any of such Holder’s Affiliates) would beneficially own in excess of
the Beneficial Ownership Limitation (as defined below). For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially
owned by such Holder and its Affiliates shall include the number of shares of
Common Stock issuable upon exercise of this Warrant with respect to which such
determination is being made, but shall exclude the number of shares of Common
Stock which would be issuable upon (A) exercise of the remaining, non-exercised
portion of this Warrant beneficially owned by such Holder or any of its
Affiliates and (B) exercise or conversion of the unexercised or non-converted
portion of any other securities of the Company (including, without limitation,
shares of Series A Convertible Preferred Stock, options and any other warrants)
subject to a limitation on conversion or exercise analogous to the limitation
contained herein beneficially owned by such Holder or any of its
Affiliates. Except as set forth in the preceding sentence, for
purposes of this
Section 2(d)
,
beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act, it being acknowledged by the Holder that the Company is not
representing to such Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and such Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this
Section 2(d)
applies,
the determination of whether this Warrant is exercisable in full or in part (in
relation to other securities owned by such Holder together with any Affiliates)
shall be made by the Holder, and the submission of a Notice of Exercise shall be
deemed to be each Holder’s determination of whether this Warrant is exercisable
(in relation to other securities owned by such Holder together with any
Affiliates), in each case subject to such aggregate percentage limitation, and
the Company shall have no obligation to verify or confirm the accuracy of such
determination. In addition, a determination as to any group status as
contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act. Upon the written request of the Holder, the Company
shall within two (2) Trading Days confirm in writing to such Holder the number
of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to
the conversion or exercise of securities of the Company, including this Warrant,
by such Holder or its Affiliates since the date as of which such number of
outstanding shares of Common Stock was reported. The “
Beneficial
Ownership Limitation
” shall be 4.99% of the number of shares of the
Common Stock outstanding immediately after giving effect to the issuance of
shares of Common Stock issuable upon exercise of this Warrant. The
Beneficial Ownership Limitation provisions of this
Section 2(d)
may be
waived by the Holder, at the election of such Holder, upon not less than
sixty-one (61) days prior written notice to the Company (which notice period, if
requested by the Holder, may be waived by the Company in its sole discretion) to
increase the Beneficial Ownership Limitation to 9.99%, 14.99% or 19.99% of the
number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon exercise of this Warrant, and the
provisions of this
Section 2(d)
shall
continue to apply. Upon a waiver of the Beneficial Ownership
Limitation from 4.99% to 9.99%, or from 9.99% to 14.99%, as the case may be, the
Holder may further waive the Beneficial Ownership Limitation from 9.99% to
14.99%, or from 14.99% to 19.99%, as applicable, by written notice to the
Company not less than sixty-one (61) days in advance of such waiver (which
notice period, if requested by the Holder, may be waived by the Company in its
sole discretion). Upon the change by the Holder of the Beneficial
Ownership Limitation from 14.99% to 19.99%, the Beneficial Ownership Limitation
may not be further waived by such Holder. The limitations contained
in this paragraph shall apply to a successor holder of this
Warrant.
e)
Mechanics of
Exercise
.
i.
Authorization of Warrant
Shares
. The Company covenants that all Warrant Shares which
may be issued upon the exercise of the purchase rights represented by this
Warrant will, upon such exercise, be duly authorized, validly issued, fully paid
and nonassessable and free from all taxes, liens and charges created by the
Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).
ii.
Delivery of Certificates
Upon Exercise
. Certificates for shares purchased hereunder
shall be transmitted by the Transfer Agent to the Holder by crediting the
account of the Holder’s prime broker with the Depository Trust Company through
its Deposit Withdrawal Agent Commission (“
DWAC
”)
system if the Company is a participant in such system, and otherwise by the
Company or by the Transfer Agent by physical delivery to the address specified
by the Holder in the Notice of Exercise promptly, or if required by law, within
three (3) Trading Days, from the delivery to the Company of the duly executed
Notice of Exercise, surrender of this Warrant and payment of the aggregate
Exercise Price as set forth above
(or an exercise
pursuant to
Section 2(c)
) (
“
Warrant Share
Delivery Date
”). This Warrant shall be deemed to have been
exercised, the Warrant Shares shall be deemed to have been issued, and the
Holder or any other person so designated to be named therein shall be deemed to
have become a holder of record of such shares of Common Stock for all purposes,
on the date the Company receives the duly executed Notice of Exercise, Warrant
and Exercise Price (unless such exercise is pursuant to
Section 2(c)
in which
case receipt of the Exercise Price is not applicable)
,
and all taxes required to be paid by the
Holder, if any, pursuant to
Section 2(e)(v)
prior
to the issuance of such shares, have been paid.
iii.
Delivery of New Warrants
Upon Exercise
. If this Warrant shall have been exercised in
part, the Company shall, at the time of delivery of the certificate or
certificates representing Warrant Shares if prior to the Termination Date,
deliver to Holder a new Warrant evidencing the right of Holder to purchase the
unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.
iv.
No Fractional Shares or
Scrip
. No fractional shares or scrip representing fractional
shares shall be issued upon the exercise of this Warrant. As to any
fraction of a share which Holder would otherwise be entitled to purchase upon
such exercise, the Company shall at its election, either pay a cash adjustment
in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.
v.
Charges, Taxes and
Expenses
. Issuance of certificates for Warrant Shares shall be
made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such certificate, all of which
taxes and expenses shall be paid by the Company, and such certificates shall be
issued in the name of the Holder or in such name or names as may be directed by
the Holder;
provided,
however
, that in the event certificates for Warrant Shares are to be
issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached
hereto duly executed by the Holder; and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax
incidental thereto.
vi.
Closing of
Books
. The Company will not close its stockholder books or
records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.
3.
Certain
Events
.
a)
Adjustments for Stock
Dividends and Splits
. If the Company, at any time while this Warrant is
outstanding: (A) pays a stock dividend or otherwise m
akes
a distribution or distributions on shares of
its Common Stock or any other equity or equity equivalent securities payable in
shares of Common Stock (which, for avoidance of doubt, shall not include any
shares of Common Stock issued by the Company upon exercise of this Warrant), (B)
subdivides outstanding shares of Common Stock into a larger number of shares,
(C) combines (including by way of reverse stock split) outstanding shares of
Common Stock into a smaller number of shares, or (D) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then
in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury
shares, if any) outstanding immediately before such event and of which the
denominator shall be the number of shares of Common Stock outstanding
immediately after such event and the number of shares issuable upon exercise of
this Warrant shall be proportionately adjusted. Any adjustment made
pursuant to this
Section 3(a)
shall
become effective immediately after the record date for the determination of
stockholders entitled to receive such dividend or distribution and shall become
effective immediately after the effective date in the case of a subdivision,
combination or re-classification.
b)
Fundamental
Transaction
. If, at any time while this Warrant is outstanding, (A) the
Company effects any merger or consolidation of the Company (or a subsidiary of
the Company and the Company issues shares of its capital stock pursuant to such
merger or consolidation) with or into another Person in which the shares of
capital stock of the Company outstanding immediately prior to such merger or
consolidation do not continue to represent, or are not converted into or
exchanged for shares of capital stock that represent, immediately following such
merger or consolidation, at least a majority, by voting power, of the capital
stock of the surviving or resulting entity, or if the surviving or resulting
entity is a wholly owned subsidiary of another entity immediately following such
merger or consolidation, the parent entity of such surviving or resulting
entity, (B) the Company effects any sale of all or substantially all of its
assets in one or a series of related transactions, (C) any tender offer or
exchange offer (whether by the Company or another Person) is completed pursuant
to which holders of Common Stock are permitted to tender or exchange their
shares for other securities, cash or property, or (D) the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other
securities, cash or property (each “
Fundamental
Transaction
”), then, the Holder may exercise this Warrant subject to and
conditioned upon the completion or closing of such Fundamental Transaction, and
upon such completion or closing of such Fundamental Transaction, this Warrant
shall terminate and shall no longer be exerciseable.
c)
Calculations
. All
calculations under this
Section 3
shall be
made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this
Section 3
, the number
of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury
shares, if any) issued and outstanding.
d)
Notice to
Holder
.
i.
Adjustment to Exercise
Price
. Whenever the Exercise Price is adjusted pursuant to any provision
of this
Section
3
, the Company shall promptly mail to the Holder a notice setting forth
the Exercise Price after such adjustment and setting forth a brief statement of
the facts requiring such adjustment.
ii.
Notice to Allow Exercise by
Holder
. If (A) the Company shall declare a dividend (or any other
distribution in whatever form) on the Common Stock; (B) the Company shall
declare a special nonrecurring cash dividend on or a redemption of the Common
Stock; (C) the Company shall authorize the granting to all holders of the Common
Stock rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights; (D) the approval of any stockholders of the
Company shall be required in connection with any reclassification of the Common
Stock, any consolidation or merger to which the Company is a party, any sale or
transfer of all or substantially all of the assets of the Company, any
compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property
, or any Fundamental
Transaction
; (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company; then, in
each case, the Company shall cause to be mailed to the Holder at its last
address as it shall appear upon the Warrant Register (as defined below) of the
Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is
to be taken for the purpose of such dividend, distribution, redemption, rights
or warrants, or if a record is not to be taken, the date as of which the holders
of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange
is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to
exchange their shares of the Common Stock for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer or
share exchange; provided that the failure to mail such notice or any defect
therein or in the mailing thereof shall not affect the validity of the corporate
action required to be specified in such notice
if
Holder is allowed to determine in its discretion that the Company must deem the
Warrant exercised immediately prior to and contingent upon the occurrence of the
events described in (A), (B), (C), (D) or (E) above
. The
Holder is entitled to exercise this Warrant during the 20-day period commencing
on the date of such notice of the record or effective date of the event
triggering such notice.
4.
Transfer of
Warrant
.
a)
Transferability
. Subject
to compliance with any applicable securities laws and the conditions set forth
in
Section 4(d)
hereof and to the provisions of
Section 4.1
of the
Purchase Agreement, this Warrant and all rights hereunder (including, without
limitation, any registration rights) are transferable, in whole or in part, upon
surrender of this Warrant at the principal office of the Company or its
designated agent, together with a written assignment of this Warrant
substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon
the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in
the name of the assignee or assignees and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a
new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. A Warrant, if properly assigned,
may be exercised by a new holder for the purchase of Warrant Shares without
having a new Warrant issued.
b)
New Warrants
. This
Warrant may be divided or combined with other Warrants upon presentation hereof
at the aforesaid office of the Company, together with a written notice
specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance
with
Section
4(a)
, as to any transfer which may be involved in such division or
combination, the Company shall execute and deliver a new Warrant or Warrants in
exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice.
c)
Warrant Register
. The
Company shall register this Warrant, upon records to be maintained by the
Company for that purpose (the “
Warrant
Register
”), in the name of the record Holder hereof from time to
time. The Company may deem and treat the registered Holder of this
Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice
to the contrary reasonably satisfactory to the Company.
d)
Transfer
Restrictions
.
If
, at the
time of the surrender of this Warrant in connection with
any transfer of this Warrant, the transfer of this Warrant shall not be
registered pursuant to an effective
registration
statement under the Securities Act
and
under applicable state securities or blue sky laws, the
Company may require, as a condition of allowing such transfer, that (i) the
Holder or transferee of this Warrant, as the case may be, furnish to the Company
a written opinion of counsel (which opinion shall be in form, substance and
scope customary for opinions of counsel in comparable transactions) to the
effect that such transfer may be made without
registration under
the Securities Act and under applicable state securities
or blue sky laws, and (ii) the Holder or transferee execute and deliver to the
Company an investment letter in form and substance acceptable to the Company,
and (iii) the transferee be an “accredited investor” as defined in Rule 501(a)
promulgated under the Securities Act or a “qualified institutional buyer” as
defined in Rule 144A(a) promulgated under the Securities
Act.
5.
Right to
Call
.
a)
Call
Conditions
. The Company may call for cancellation this
Warrant, subject to the limitations discussed in
Section 5(b)
, if the
volume weighted average price for the Common Stock on the Trading Market equals
or exceeds $2.80 for either (i) ten (10) consecutive Trading Days or (ii)
fifteen (15) out of twenty-five (25) consecutive Trading Days.
b)
Callable Warrant
Shares
. The Company shall not have the right to call any
portion of this Warrant, pursuant to this
Section 5
, to the
extent that, after giving effect to the issuance of Warrant Shares after
exercise of this Warrant, such Holder (together with such Holder’s Affiliates,
and any other person or entity acting as a group together with such Holder or
any of such Holder’s Affiliates) would beneficially own in excess of the
Beneficial Ownership Limitation (as defined below). For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned
by such Holder and its Affiliates shall include the number of shares of Common
Stock issuable upon exercise of this Warrant with respect to which such right to
call determination is being made, but shall exclude the number of shares of
Common Stock which would be issuable upon (A) exercise of the remaining portion,
if any, of this Warrant with respect to which such right to call determination
is not being made beneficially owned by such Holder or any of its Affiliates and
(B) exercise or conversion of the unexercised or non-converted portion of any
other securities of the Company (including, without limitation, shares of Series
A Convertible Preferred Stock, options and any other warrants) subject to a
limitation on conversion or exercise analogous to the limitation contained
herein beneficially owned by such Holder or any of its
Affiliates. Except as set forth in the preceding sentence, for
purposes of this
Section 5(b)
,
beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act, it being acknowledged by the Holder that the Company is not
representing to such Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and such Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this
Section 5(b)
applies,
the determination of whether this Warrant may be called by the Company in full
or in part (in relation to other securities owned by such Holder together with
any Affiliates) shall be made by the Holder, and the submission of a Notice of
Exercise shall be deemed to be each Holder’s determination of whether this
Warrant is exercisable (in relation to other securities owned by such Holder
together with any Affiliates), in each case subject to such aggregate percentage
limitation, and the Company shall have no obligation to verify or confirm the
accuracy of such determination. In addition, a determination as to
any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act. Upon the written request of the
Holder, the Company shall within two (2) Trading Days confirm in writing to such
Holder the number of shares of Common Stock then outstanding. In any
case, the number of outstanding shares of Common Stock shall be determined after
giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by such Holder or its Affiliates since the date as of
which such number of outstanding shares of Common Stock was
reported. The “
Beneficial
Ownership Limitation
” shall be 4.99% of the number of shares of the
Common Stock outstanding immediately after giving effect to the issuance of
shares of Common Stock issuable upon exercise of this Warrant. The
Beneficial Ownership Limitation provisions of this
Section 5(b)
may be
waived by the Holder, at the election of such Holder, upon not less than
sixty-one (61) days prior written notice to the Company (which notice period, if
requested by the Holder, may be waived by the Company in its sole discretion) to
increase the Beneficial Ownership Limitation to 9.99%, 14.99% or 19.99% of the
number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon exercise of this Warrant, and the
provisions of this
Section 5(b)
shall
continue to apply. Upon a waiver of the Beneficial Ownership
Limitation from 4.99% to 9.99%, or from 9.99% to 14.99%, as the case may be, the
Holder may further waive the Beneficial Ownership Limitation from 9.99% to
14.99%, or from 14.99% to 19.99%, as applicable, by written notice to the
Company not less than sixty-one (61) days in advance of such waiver (which
notice period, if requested by the Holder, may be waived by the Company in its
sole discretion). Upon the change by the Holder of the Beneficial
Ownership Limitation from 14.99% to 19.99%, the Beneficial Ownership Limitation
may not be further waived by such Holder. The limitations contained
in this
Section
5(b)
shall apply to a successor holder of this Warrant.
c)
Call
Procedure
. To exercise this right, the Company shall deliver
to the Holder a written notice (a “
Call
Notice
”) indicating therein that this Warrant must be exercised by a date
specified in the Call Notice, which date shall be at least twelve (12) Business
Days after the date of the Call Notice, and which date shall be extended for a
Holder providing written notice of waiver of the Beneficial Ownership Limitation
to the sixty-first (61
st
) day
following the date such Holder provides such sixty-one (61) days notice or to
such earlier date on which the Company has waived such sixty-one (61) day
notice) (such date, the “
Call
Date
”). If the Holder does not exercise this Warrant by the
Call Date, then on the date immediately following the Call Date this Warrant
shall terminate and shall no longer be exerciseable.
6.
Miscellaneous
.
a)
No Rights as Shareholder
Until Exercise
. This Warrant does not entitle the Holder to
any voting rights or other rights as a shareholder of the Company prior to the
exercise hereof as set forth in
Section
2(e)(ii)
.
b)
Loss, Theft, Destruction or
Mutilation of Warrant
. The Company covenants that upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft,
destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or
security reasonably satisfactory to it and upon surrender and cancellation of
such Warrant or stock certificate, if mutilated, the Company will make and
deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate.
c)
Saturdays, Sundays,
Holidays, etc
. If the last or appointed day for the taking of
any action or the expiration of any right required or granted herein shall not
be a Business Day, then such action may be taken or such right may be exercised
on the next succeeding Business Day.
d)
Authorized
Shares
.
The
Company covenants that during the period the Warrant is outstanding, it will
reserve from its authorized and unissued Common Stock a sufficient number of
shares to provide for the issuance of the Warrant Shares upon the exercise of
any purchase rights under this Warrant
, including
as the Warrant is adjusted pursuant to
Section 3
above
The Company further covenants
that its issuance of this Warrant shall constitute full authority to its
officers who are charged with the duty of executing stock certificates to
execute and issue the necessary certificates for the Warrant Shares upon the
exercise of the purchase rights under this Warrant. The Company will
take all such commercially reasonable action as may be necessary to assure that
such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon
which the Common Stock may be listed.
Except
and to the extent as waived or consented to by the Holder, the Company shall not
by any action, including, without limitation, amending its articles of
organization or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all
such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the
Company will (a) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to such increase in
par value, (b) take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and nonassessable
Warrant Shares upon the exercise of this Warrant, and (c) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof as may be necessary
to enable the Company to perform its obligations under this
Warrant.
Before
taking any action which would result in an adjustment in the number of Warrant
Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents
thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof.
e)
Jurisdiction
. All
questions concerning the construction, validity, enforcement and interpretation
of this Warrant shall be determined in accordance with the provisions of the
Purchase Agreement.
f)
Governing
Law
. This Warrant shall be governed by and construed and
enforced in accordance with the internal laws of the Commonwealth of
Massachusetts, with regard to the principles of conflicts of law
thereof.
g)
Restrictions
. The
Holder acknowledges that the Warrant Shares acquired upon the exercise of this
Warrant, if not registered, will have restrictions upon resale imposed by state
and federal securities laws.
h)
Nonwaiver and
Expenses
. No course of dealing or any delay or failure to
exercise any right hereunder on the part of Holder shall operate as a waiver of
such right or otherwise prejudice Holder’s rights, powers or remedies,
notwithstanding the fact that all rights hereunder terminate on the Termination
Date. If the Company willfully and knowingly fails to comply with any
provision of this Warrant, which results in any material damages to the Holder,
the Company shall pay to Holder such amounts as shall be sufficient to cover any
costs and expenses including, but not limited to, reasonable attorneys’ fees,
including those of appellate proceedings, incurred by Holder in collecting any
amounts due pursuant hereto or in otherwise enforcing any of its rights, powers
or remedies hereunder.
i)
Notices
. Any
notice, request or other document required or permitted to be given or delivered
to the Holder by the Company shall be delivered in accordance with the notice
provisions of the Purchase Agreement.
j)
Successors and
Assigns
. Subject to applicable securities laws, this Warrant
and the rights and obligations evidenced hereby shall inure to the benefit of
and be binding upon the successors of the Company and the successors and
permitted assigns of Holder. The provisions of this Warrant are
intended to be for the benefit of all Holders from time to time of this Warrant
and shall be enforceable by any such Holder or holder of Warrant
Shares.
k)
Amendment
. This
Warrant may be modified or amended or the provisions hereof waived with the
written consent of the Company and the Holder.
l)
Severability
. Wherever
possible, each provision of this Warrant shall be interpreted in such manner as
to be effective and valid under applicable law, but if any provision of this
Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions of
this Warrant.
m)
Headings
. The
headings used in this Warrant are for the convenience of reference only and
shall not, for any purpose, be deemed a part of this Warrant.
********************
IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
officer thereunto duly authorized as of the date first above
indicated.
PRESSURE
BIOSCIENCES INC.
|
|
By:
|
|
|
Name:
|
Richard T. Schumacher
|
|
Title:
|
President and Chief Executive
Officer
|
NOTICE OF
EXERCISE
TO: PRESSURE
BIOSCIENCES INC.
(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company
pursuant to the terms of the attached Warrant (only if exercised in full), and
tenders herewith payment of the Exercise Price in full, together with all
applicable transfer taxes, if any.
(2) Payment
shall take the form of (check applicable box):
¨
in
lawful money of the United States; or
¨
[if
permitted] the cancellation of such number of Warrant Shares as is necessary, in
accordance with the formula set forth in
Section 2(c)
, to
exercise this Warrant with respect to the maximum number of Warrant Shares
purchasable pursuant to the cashless exercise procedure set forth in
Section
2(c)
.
(3) Please
issue a certificate or certificates representing said Warrant Shares in the name
of the undersigned or in such other name as is specified below:
_______________________________
The
Warrant Shares shall be delivered to the following DWAC Account Number or by
physical delivery of a certificate to:
_______________________________
_______________________________
_______________________________
(4) Accredited
Investor. The undersigned is an “accredited investor” as defined in
Regulation D promulgated under the Securities Act of 1933, as
amended.
[SIGNATURE
OF HOLDER]
Name of
Investing Entity:
___________________________________________________________________________________________
Signature
of Authorized Signatory of Investing Entity:
___________________________________________________________________________________________
Name of
Authorized Signatory:
___________________________________________________________________________________________
Title of
Authorized Signatory:
___________________________________________________________________________________________
Date:
____________________________________________
ASSIGNMENT
FORM
(To
assign the foregoing Warrant, execute
this form
and supply required information.
Do not
use this form to exercise the Warrant.)
FOR VALUE
RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all
rights evidenced thereby are hereby assigned to
_______________________________________________
whose address is
_______________________________________________________________________.
_______________________________________________________________________
Dated: ______________,
_______
Holder’s
Signature: _____________________________
Holder’s
Address: _____________________________
_____________________________
Signature
Guaranteed: ___________________________________________
NOTE: The
signature to this Assignment Form must correspond with the name as it appears on
the face of the Warrant, without alteration or enlargement or any change
whatsoever, and must be guaranteed by a bank or trust
company. Officers of corporations and those acting in a fiduciary or
other representative capacity should file proper evidence of authority to assign
the foregoing Warrant.
REGISTRATION
RIGHTS AGREEMENT
This
Registration Rights Agreement (this “
Agreement
”)
is made and entered into as of February 12, 2009, by and among Pressure
BioSciences Inc., a Massachusetts corporation (the “
Company
”),
and the several purchasers signatory hereto (each such purchaser, a “
Purchaser
”
and collectively, the “
Purchasers
”).
This
Agreement is made pursuant to the Securities Purchase Agreement, dated as of the
date hereof, between the Company and each Purchaser (the “
Purchase
Agreement
”).
The
Company and each Purchaser hereby agrees as follows:
1.
Definitions
. Capitalized
terms used and not otherwise defined herein that are defined in the Purchase
Agreement shall have the meanings given such terms in the Purchase
Agreement. As used in this Agreement, the following terms shall have
the following meanings:
“
Advice
”
shall have the meaning set forth in
Section
7(c)
.
“
Commission
”
means the U.S. Securities and Exchange Commission.
“
Common Warrant
Shares
” means the shares of Common Stock issuable upon (i) exercise of
the 15-Month Common Warrants and (ii) exercise of the 30-Month
Warrants.
“
Effectiveness
Date
” means the date on which any Registration Statement required to be
filed hereunder is declared effective by the Commission.
“
Effectiveness
Period
” means, for any particular Registration Statement, the period from
the Effectiveness Date of such Registration Statement until such time as all
Registrable Securities covered by such Registration Statement have been sold, or
may be sold without volume restrictions pursuant to Rule 144 (or any successor
Rule under the Securities Act), as determined by counsel to the Company pursuant
to a written opinion letter to such effect, addressed and acceptable to the
Company’s transfer agent and the affected Holders.
“
Filing
Date
” means the date on which the Company initially files the
Registration Statement with the Commission.
“
Form S-3
”
shall have the meaning set forth in
Section
2
.
“
Holder
” or
“
Holders
”
means the holder or holders, as the case may be, from time to time of
Registrable Securities.
“
Indemnified
Party
” shall have the meaning set forth in
Section
6(c)
.
“
Indemnifying
Party
” shall have the meaning set forth in
Section
6(c)
.
“
Losses
”
shall have the meaning set forth in
Section
6(a)
.
“
Plan of
Distribution
” shall have the meaning set forth in
Section
2
.
“
Prospectus
”
means the prospectus included in a Registration Statement (including, without
limitation, a prospectus that includes any information previously omitted from a
prospectus filed as part of an effective registration statement in reliance upon
Rule 430A promulgated under the Securities Act), as amended or supplemented by
any prospectus supplement, with respect to the terms of the offering of any
portion of the Registrable Securities covered by a Registration Statement, and
all other amendments and supplements to the Prospectus, including post-effective
amendments, and all material incorporated by reference or deemed to be
incorporated by reference in such Prospectus.
“
Registrable
Conversion Shares
” means (i) all of the Common Stock issuable in
connection with any conversion of the Preferred Stock, (ii) any Registrable
Warrant Shares that have not been registered on a Registration Statement
pursuant to
Section
2
, due solely by reason of the maximum number of shares of Common Stock
that the Company may register on Form S-3, and (iii) all of the Common Warrant
Shares issuable upon exercise of the 30-Month Common Warrants. Upon
the sale, pursuant to a Registration Statement
declared effective by the Commission
or an
exemption from registration under the Securities Act
(such that all transfer restrictions and restrictive
legends with respect thereto are removed upon the consummation of such
sale)
, of any of the securities described in the preceding sentence, such
securities shall no longer be Registrable Conversion Shares.
“
Registrable
Securities
” means, collectively, the Registrable Conversion Shares and
the Registrable Warrant Shares.
“
Registrable
Warrant Shares
” means all of the Common Warrant Shares issued or issuable
upon the exercise of the 15-Month Common Warrants. Upon the sale,
pursuant to a Registration Statement
declared
effective by the Commission
or an exemption from registration under the
Securities Act
(such that all transfer
restrictions and restrictive legends with respect thereto are removed upon the
consummation of such sale)
, of any of the securities described in the
preceding sentence, such securities shall no longer be Registrable Warrant
Shares.
“
Registration
Statement
” means the registration statements required to be filed
hereunder and any other registration statement that includes any Registrable
Securities, including (in each case) the Prospectus, amendments and supplements
to such registration statement or Prospectus, including pre- and post-effective
amendments, all exhibits thereto, and all material incorporated by reference or
deemed to be incorporated by reference in such registration
statement.
“
Rule 415
”
means Rule 415 promulgated by the Commission pursuant to the Securities Act, as
such Rule may be amended from time to time, or any similar rule or regulation
hereafter adopted by the Commission having substantially the same purpose and
effect as such Rule.
“
Rule 424
”
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as
such Rule may be amended from time to time, or any similar rule or regulation
hereafter adopted by the Commission having substantially the same purpose and
effect as such Rule.
“
Securities
Act
” means the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder.
“
Selling
Stockholder Questionnaire
” shall have the meaning set forth in
Section
4(a)
.
“
SEC
Guidance
” means (i) any publicly-available written guidance, or rule of
general applicability of the Commission staff, or (ii) written comments,
requirements or requests of the Commission staff to the Company in connection
with the review of the Registration Statements.
2.
Required
Registration
. Within 60 days following the Closing Date, the
Company shall prepare and file with the Commission a Registration Statement
covering the resale of all, or if less than all, such maximum number of the
Registrable Warrant Shares as may be registered by the Company on a Registration
Statement on Form S-3 (“
Form S-3
”)
pursuant to the instructions for Form S-3 and as provided by SEC Guidance on the
Filing Date that are not then registered on an effective Registration Statement
for an offering to be made on a continuous basis pursuant to Rule
415. The Registration Statement shall be on Form S-3 and shall
contain (unless otherwise directed by
Holders of
at least a majority of the
then outstanding
Registrable Warrant Shares
) substantially the “
Plan of
Distribution
” attached hereto as
Annex
A
. Notwithstanding any other provisions of this Agreement, the
Company shall not be required to file a Registration Statement if the Company is
not eligible to use the Form S-3 as specified in General Instruction I.A to Form
S-3 and SEC Guidance. Subject to the terms of this Agreement, the
Company shall use commercially reasonable efforts to cause any Registration
Statement filed pursuant to this
Section 2
to be
declared effective under the Securities Act as promptly as possible after the
filing thereof, but in any event on or prior to the applicable Effectiveness
Date, and shall use commercially reasonable efforts to keep such Registration
Statement continuously effective under the Securities Act until the end of the
applicable Effectiveness Period.
Notwithstanding any other provision of this Agreement,
if any SEC Guidance sets forth a limitation of the number of Registrable Warrant
Shares to be registered on a particular Registration Statement
filed
pursuant to this
Section 2,
the number of Registrable Warrant Shares to be
registered on such Registration Statement will be reduced on a pro rata basis
based on the total number of Registrable Warrant Shares then held by the
Holders.
3.
Piggy Back
Registration
.
(a) If
at any time after the date hereof and as long as Registrable Conversion Shares
remain outstanding, the Company shall file with the Commission a registration
statement of the Company under the Securities Act, relating to an offering for
its own account or the account of others under the Securities Act of any of its
equity securities (a “
Registration
”),
the Company shall send to each Holder a written notice of such determination
and, if within fifteen (15) days after the giving of such notice, each Holder
shall so request in writing, the Company shall include in such registration
statement all of the Registrable Conversion Shares of such Holder, except that
if, in connection with any underwritten Registration for the account of the
Company, the managing underwriter(s) thereof shall impose a limitation on the
number of shares of Common Stock which may be included in a registration
statement because, in such underwriter(s)’ judgment, marketing or other factors
dictate such limitation is necessary to facilitate public distribution, then the
Company shall be obligated to include in such registration statement only such
limited portion of the Registrable Conversion Shares as the underwriter(s) shall
permit, if any.
In the event only a limited
portion of the Registrable Conversion Shares shall be included in a registration
statement, the number of Registrable Conversion Shares to be registered on such
registration statement will be reduced pro rata based on the total number of
Registrable Conversion Shares requested to be included held by such
Holders.
If a Registration in connection with which a Holder
is entitled to registration under this
Section 3(a)
is an
underwritten Registration, then each such Holder shall, unless otherwise agreed
by the Company, offer and sell such Registrable Conversion Shares in an
underwritten offering using the same underwriter(s) and, subject to the
provisions of this Agreement, on the same terms and conditions as other shares
of Common Stock included in such underwritten offering.
(b) Notwithstanding
any other provision of this Agreement, this
Section 3
shall not
apply to, and a Holder’s right to participate in a Registration shall not be
triggered by, the filing of a registration statement (i) covering shares of
Common Stock issued pursuant to a stock option, stock incentive or employee
benefit plan, (ii) on Form S-4 (or successor form) under the Securities Act for
the purpose of offering such securities to another business entity or the
shareholders of such entity in connection with the acquisition of assets or
shares of capital stock, respectively, of such entity, (iii) in connection with
a resale shelf registration filed in connection with an acquisition,
reorganization, recapitalization, merger, consolidation or similar transaction
involving the Company, or (iv) in accordance with
Section 2
,
above.
4.
Registration
Procedures
. In connection with the Company’s registration
obligations hereunder, the Company shall:
(a) Not
less than five (5) Trading Days prior to the filing of each Registration
Statement and not less than one (1) Trading Day prior to the filing of any
related Prospectus or any amendment or supplement thereto, the Company shall,
(i) furnish to each Holder copies of all such documents proposed to be filed,
which documents (other than those incorporated or deemed to be incorporated by
reference) will be subject to the review of such Holders, and (ii) cause its
officers and directors, counsel and independent certified public accountants to
respond to such inquiries as shall be necessary, in the reasonable opinion of
respective counsel to each Holder, to conduct a reasonable investigation within
the meaning of the Securities Act. The Company shall not file a Registration
Statement or any such Prospectus or any amendments or supplements thereto to
which the Holders of a majority of the Registrable Securities shall reasonably
object in good faith, provided that the Company is notified of such objection in
writing no later than five (5) Trading Days after the Holders have been so
furnished copies of a Registration Statement or one (1) Trading Day after the
Holders have been so furnished copies of any related Prospectus or amendments or
supplements thereto. Each Holder agrees to furnish to the Company a completed
questionnaire in the form attached to this Agreement as
Annex B
(a “
Selling
Stockholder Questionnaire
”) not less than two (2) Trading Days prior to
the Filing Date or by the end of the fourth (4
th
)
Trading Day following the date on which such Holder receives draft materials in
accordance with this Section. If any Holder fails to furnish its
Selling Stockholder Questionnaire related to a particular Registration Statement
not less than two (2) Trading Days prior to the Filing Date or by the end of the
fourth (4
th
)
Trading Day following the date on which such Holder receives draft materials in
accordance with this
Section 4
any rights
of such Holder under this Agreement with regard to such Registration Statement,
including without limitation, the right to include such Holder’s Registrable
Securities in such Registration Statement, shall be tolled as to such Holder
until such information is received by the Company.
(b) (i)
Prepare and file with the Commission such amendments, including post-effective
amendments, to a Registration Statement and the Prospectus used in connection
therewith as may be necessary to keep a Registration Statement continuously
effective as to the applicable Registrable Securities for the Effectiveness
Period and prepare and file with the Commission such additional Registration
Statements in order to register for resale under the Securities Act all of the
Registrable Securities; (ii) cause the related Prospectus to be amended or
supplemented by any required Prospectus supplement (subject to the terms of this
Agreement), and as so supplemented or amended to be filed pursuant to Rule 424;
(iii) respond as promptly as reasonably possible to any comments received from
the Commission with respect to a Registration Statement or any amendment thereto
and provide as promptly as reasonably possible to the Holders true and complete
copies of all correspondence from and to the Commission relating to a
Registration Statement (provided that the Company may excise any information
contained therein which would constitute material non-public information as to
any Holder which has not executed a confidentiality agreement with the Company);
and (iv) comply in all material respects with the provisions of the Securities
Act and the Exchange Act with respect to the disposition of all Registrable
Securities covered by a Registration Statement during the applicable period in
accordance (subject to the terms of this Agreement) with the intended methods of
disposition by the Holders thereof set forth in such Registration Statement as
so amended or in such Prospectus as so supplemented.
(c) Notify
each Holder of Registrable Securities to be sold as promptly as reasonably
possible (i)(A) when a Prospectus or any Prospectus supplement or post-effective
amendment to a Registration Statement is proposed to be filed; (B) when the
Commission notifies the Company whether there will be a “review” of such
Registration Statement and whenever the Commission comments in writing on such
Registration Statement; and (C) with respect to a Registration Statement or any
post-effective amendment, when the same has become effective; (ii) of any
request by the Commission or any other Federal or state governmental authority
for amendments or supplements to a Registration Statement or Prospectus or for
additional information; (iii) of the issuance by the Commission or any other
federal or state governmental authority of any stop order suspending the
effectiveness of a Registration Statement covering any or all of the Registrable
Securities or the initiation of any Proceedings for that purpose; (iv) of the
receipt by the Company of any notification with respect to the suspension of the
qualification or exemption from qualification of any of the Registrable
Securities for sale in any jurisdiction, or the initiation or threatening of any
Proceeding for such purpose; and (v) of the occurrence of any event or passage
of time that makes the financial statements included in a Registration Statement
ineligible for inclusion therein or any statement made in a Registration
Statement or Prospectus or any document incorporated or deemed to be
incorporated therein by reference untrue in any material respect or that
requires any revisions to a Registration Statement, Prospectus or other
documents so that, in the case of a Registration Statement or the Prospectus, as
the case may be, it will not contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances under which they were
made, not misleading.
(d) Use
its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal
of (i) any order suspending the effectiveness of a Registration Statement, or
(ii) any suspension of the qualification (or exemption from qualification) of
any of the Registrable Securities for sale in any jurisdiction, at the earliest
practicable moment.
(e) Furnish
to each Holder, without charge, at least one conformed copy of each such
Registration Statement and each amendment thereto, including financial
statements and schedules, all documents incorporated or deemed to be
incorporated therein by reference to the extent requested by such Person, and
all exhibits to the extent requested by such Person (including those previously
furnished or incorporated by reference) promptly after the filing of such
documents with the Commission.
(f) Prior
to any resale of Registrable Securities by a Holder, use its commercially
reasonable efforts to register or qualify or cooperate with the selling Holders
in connection with the registration or qualification (or exemption from the
Registration or qualification) of such Registrable Securities for the resale by
a Holder under the securities or Blue Sky laws of such jurisdictions within the
United States as any Holder reasonably requests in writing, to keep each
registration or qualification (or exemption therefrom) effective during the
Effectiveness Period and to do any and all other acts or things reasonably
necessary to enable the disposition in such jurisdictions of the Registrable
Securities covered by each Registration Statement;
provided
, that the Company
shall not be required to qualify generally to do business in any jurisdiction
where it is not then so qualified, subject the Company to any material tax in
any such jurisdiction where it is not then so subject or file a general consent
to service of process in any such jurisdiction.
(g) Upon
the occurrence of any event contemplated by
Section 4(c)
, as
promptly as reasonably possible under the circumstances taking into account the
Company’s good faith assessment of any adverse consequences to the Company and
its stockholders of the premature disclosure of such event, prepare a supplement
or amendment, including a post-effective amendment, to a Registration Statement
or a supplement to the related Prospectus or any document incorporated or deemed
to be incorporated therein by reference, and file any other required document so
that, as thereafter delivered, neither a Registration Statement nor such
Prospectus will contain an untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made,
not misleading. If the Company notifies the Holders in accordance
with clauses
(iii)
through
(v)
of
Section 4(c)
above to
suspend the use of any Prospectus until the requisite changes to such Prospectus
have been made, then the Holders shall suspend use of such
Prospectus. The Company will use its best efforts to ensure that the
use of the Prospectus may be resumed as promptly as is
practicable. The Company shall be entitled to exercise its right
under this
Section
4(g)
to suspend the availability of a Registration Statement and
Prospectus for a period not to exceed sixty (60) calendar days (which need not
be consecutive days) in any twelve (12) month period.
(h) The
Company may require each selling Holder to furnish to the Company a certified
statement as to the number of shares of Common Stock beneficially owned by such
Holder and, if required by the Commission, the natural persons thereof that have
voting and dispositive control over the Shares. During any periods
that the Company is unable to meet its obligations hereunder with respect to the
registration of the Registrable Securities solely because any Holder fails to
furnish such information within three Trading Days of the Company’s request, any
rights of such Holder under this Agreement, including without limitation, the
right to include such Holder’s Registrable Securities in a Registration
Statement shall be tolled and any Event that may otherwise occur solely because
of such delay shall be suspended as to such Holder only, until such information
is delivered to the Company.
5.
Registration
Expenses
. All fees and expenses incident to the performance of
or compliance with this Agreement by the Company shall be borne by the Company
whether or not any Registrable Securities are sold pursuant to a Registration
Statement. The fees and expenses referred to in the foregoing
sentence shall include, without limitation, (i) all registration and filing fees
(including, without limitation, fees and expenses) (A) with respect to filings
required to be made with any Trading Market on which the Common Stock is then
listed for trading, and (B) in compliance with applicable state securities or
Blue Sky laws reasonably agreed to by the Company in writing (including, without
limitation, fees and disbursements of counsel for the Company in connection with
Blue Sky qualifications or exemptions of the Registrable Securities), (ii)
printing expenses (including, without limitation, expenses of printing
certificates for Registrable Securities, (iii) messenger, telephone and delivery
expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities
Act liability insurance, if the Company so desires such insurance, and (vi) fees
and expenses of all other Persons retained by the Company in connection with the
consummation of the transactions contemplated by this Agreement. In
addition, the Company shall be responsible for all of its internal expenses
incurred in connection with the consummation of the transactions contemplated by
this Agreement (including, without limitation, all salaries and expenses of its
officers and employees performing legal or accounting duties), the expense of
any annual audit and the fees and expenses incurred in connection with the
listing of the Registrable Securities on any securities exchange as required
hereunder. In no event shall the Company be responsible for any broker or
similar commissions of any Holder or, except to the extent provided for in the
Transaction Documents, any legal fees or other costs of the
Holders.
6.
Indemnification
.
(a)
Indemnification by the
Company
. The Company shall, notwithstanding any termination of
this Agreement, indemnify and hold harmless each Holder, the officers,
directors, members, partners, agents, brokers (including brokers who offer and
sell Registrable Securities as principal as a result of a pledge or any failure
to perform under a margin call of Common Stock), investment advisors, and
employees (and any other Persons with a functionally equivalent role of a Person
holding such titles, notwithstanding a lack of such title or any other title) of
each of them, each Person who controls any such Holder (within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act) and the
officers, directors, members, stockholders, partners, agents and employees (and
any other Persons with a functionally equivalent role of a Person holding such
titles, notwithstanding a lack of such title or any other title) of each such
controlling Person, to the fullest extent permitted by applicable law, from and
against any and all losses, claims, damages, liabilities, costs (including,
without limitation, reasonable attorneys’ fees) and expenses (collectively,
“
Losses
”),
as incurred, arising out of or relating to (i) any untrue or alleged untrue
statement of a material fact contained in a Registration Statement, any
Prospectus or any form of prospectus or in any amendment or supplement thereto
or in any preliminary prospectus, or arising out of or relating to any omission
or alleged omission of a material fact required to be stated therein or
necessary to make the statements therein (in the case of any Prospectus or form
of prospectus or supplement thereto, in light of the circumstances under which
they were made) not misleading, or (ii) any violation or alleged violation by
the Company of the Securities Act, Exchange Act or any state securities law, or
any rule or regulation thereunder, in connection with the performance of its
obligations under this Agreement, except to the extent, but only to the extent,
that (A) such untrue statements or omissions are based solely upon information
regarding such Holder furnished in writing to the Company by such Holder
expressly for use therein, or to the extent that such information relates to
such Holder or such Holder’s proposed method of distribution of Registrable
Securities and was reviewed and expressly approved in writing by such Holder
expressly for use in a Registration Statement, such Prospectus or such form of
Prospectus or in any amendment or supplement thereto (it being understood that
each Holder has approved
Annex A
hereto for
this purpose) or (B) in the case of an occurrence of an event of the type
specified in
Section
4(c)(iii)-(v)
, the use by such Holder of an outdated or defective
Prospectus after the Company has notified such Holder in writing that the
Prospectus is outdated or defective and prior to the receipt by such Holder of
the Advice contemplated in
Section
7(c)
. The Company shall notify the Holders promptly of the
institution, threat or assertion of any Proceeding arising from or in connection
with the transactions contemplated by this Agreement of which the Company is
aware.
(b)
Indemnification by
Holders
. Each Holder shall, severally and not jointly, indemnify and hold
harmless the Company, its directors, officers, agents, and employees, each
Person who controls the Company (within the meaning of Section 15 of the
Securities Act and Section 20 of the Exchange Act), and the directors, officers,
agents or employees of such controlling Persons, to the fullest extent permitted
by applicable law, from and against all Losses, as incurred, to the extent
arising out of or based solely upon: (i) such Holder’s failure to comply with
the prospectus delivery requirements of the Securities Act or (ii) any untrue or
alleged untrue statement of a material fact contained in any Registration
Statement, any Prospectus, or any form of prospectus, or in any amendment or
supplement thereto or in any preliminary prospectus, or arising out of or
relating to any omission or alleged omission of a material fact required to be
stated therein or necessary to make the statements therein not misleading (A) to
the extent, but only to the extent, that such untrue statement or omission is
contained in any information so furnished in writing by such Holder to the
Company specifically for inclusion in such Registration Statement or such
Prospectus or (B) to the extent that such information relates to such Holder’s
proposed method of distribution of Registrable Securities and was reviewed and
expressly approved in writing by such Holder expressly for use in a Registration
Statement (it being understood that each Holder has approved
Annex A
hereto for
this purpose), such Prospectus or such form of Prospectus or in any amendment or
supplement thereto or (C) in the case of an occurrence of an event of the type
specified in
Section
4(c)(iii)-(v)
, the use by such Holder of an outdated or defective
Prospectus after the Company has notified such Holder in writing that the
Prospectus is outdated or defective and prior to the receipt by such
Holder of the Advice contemplated in
Section
7(c)
. In no event shall the liability of any selling Holder
hereunder be greater in amount than the dollar amount of the net proceeds
received by such Holder upon the sale of the Registrable Securities giving rise
to such indemnification obligation.
(c)
Conduct of Indemnification
Proceedings
. If any Proceeding shall be brought or asserted against any
Person entitled to indemnity hereunder (an “
Indemnified
Party
”), such Indemnified Party shall promptly notify the Person from
whom indemnity is sought (the “
Indemnifying
Party
”) in writing, and the Indemnifying Party shall have the right to
assume the defense thereof, including the employment of counsel reasonably
satisfactory to the Indemnified Party and the payment of all fees and expenses
incurred in connection with defense thereof;
provided
, that the failure of
any Indemnified Party to give such notice shall not relieve the Indemnifying
Party of its obligations or liabilities pursuant to this Agreement, except (and
only) to the extent that it shall be finally determined by a court of competent
jurisdiction (which determination is not subject to appeal or further review)
that such failure shall have prejudiced the Indemnifying Party.
An
Indemnified Party shall have the right to employ separate counsel in any such
Proceeding and to participate in the defense thereof, but the fees and expenses
of such counsel shall be at the expense of such Indemnified Party or Parties
unless: (i) the Indemnifying Party has agreed in writing to pay such
fees and expenses; (ii) the Indemnifying Party shall have failed promptly to
assume the defense of such Proceeding and to employ counsel reasonably
satisfactory to such Indemnified Party in any such Proceeding; or (iii) the
named parties to any such Proceeding (including any impleaded parties) include
both such Indemnified Party and the Indemnifying Party, and counsel to the
Indemnified Party shall reasonably believe that a material conflict of interest
is likely to exist if the same counsel were to represent such Indemnified Party
and the Indemnifying Party (in which case, if such Indemnified Party notifies
the Indemnifying Party in writing that it elects to employ separate counsel at
the expense of the Indemnifying Party, the Indemnifying Party shall not have the
right to assume the defense thereof and the reasonable fees and expenses of no
more than one separate counsel shall be at the expense of the Indemnifying
Party). The Indemnifying Party shall not be liable for any settlement
of any such Proceeding effected without its written consent, which consent shall
not be unreasonably withheld or delayed. No Indemnifying Party shall,
without the prior written consent of the Indemnified Party, effect any
settlement of any pending Proceeding in respect of which any Indemnified Party
is a party, unless such settlement includes an unconditional release of such
Indemnified Party from all liability on claims that are the subject matter of
such Proceeding.
Subject
to the terms of this Agreement, all reasonable fees and expenses of the
Indemnified Party (including reasonable fees and expenses to the extent incurred
in connection with investigating or preparing to defend such Proceeding in a
manner not inconsistent with this Section) shall be paid to the Indemnified
Party, as incurred, within ten Trading Days of written notice thereof to the
Indemnifying Party, provided that the Indemnified Party shall promptly reimburse
the Indemnifying Party for that portion of such fees and expenses applicable to
such actions for which such Indemnified Party is judicially determined to be not
entitled to indemnification hereunder.
(d)
Contribution
. If
the indemnification under
Section 6(a)
or
6(b)
is unavailable
to an Indemnified Party or insufficient to hold an Indemnified Party harmless
for any Losses, then each Indemnifying Party shall contribute to the amount paid
or payable by such Indemnified Party, in such proportion as is appropriate to
reflect the relative fault of the Indemnifying Party and Indemnified Party in
connection with the actions, statements or omissions that resulted in such
Losses as well as any other relevant equitable considerations. The relative
fault of such Indemnifying Party and Indemnified Party shall be determined by
reference to, among other things, whether any action in question, including any
untrue or alleged untrue statement of a material fact or omission or alleged
omission of a material fact, has been taken or made by, or relates to
information supplied by, such Indemnifying Party or Indemnified Party, and the
parties’ relative intent, knowledge, access to information and opportunity to
correct or prevent such action, statement or omission. The amount
paid or payable by a party as a result of any Losses shall be deemed to include,
subject to the limitations set forth in this Agreement, any reasonable
attorneys’ or other fees or expenses incurred by such party in connection with
any Proceeding to the extent such party would have been indemnified for such
fees or expenses if the indemnification provided for in this
Section 6
was
available to such party in accordance with its terms.
The
parties hereto agree that it would not be just and equitable if contribution
pursuant to this
Section 6(d)
were
determined by pro rata allocation or by any other method of allocation that does
not take into account the equitable considerations referred to in the
immediately preceding paragraph. Notwithstanding the provisions of
this
Section
6(d)
, no Holder shall be required to contribute, in the aggregate, any
amount in excess of the amount by which the net proceeds actually received by
such Holder from the sale of the Registrable Securities subject to the
Proceeding exceeds the amount of any damages that such Holder has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission, except in the case of fraud by such Holder.
The
indemnity and contribution agreements contained in this
Section 6
are in
addition to any liability that the Indemnifying Parties may have to the
Indemnified Parties.
7.
Miscellaneous
.
(a)
Remedies
. In
the event of a breach by the Company or by a Holder of any of their respective
obligations under this Agreement, each Holder or the Company, as the case may
be, in addition to being entitled to exercise all rights granted by law and
under this Agreement, including recovery of damages, shall be entitled to
specific performance of its rights under this Agreement. The Company
and each Holder agree that monetary damages would not provide adequate
compensation for any losses incurred by reason of a breach by it of any of the
provisions of this Agreement and hereby further agrees that, in the event of any
action for specific performance in respect of such breach, it shall not assert
or shall waive the defense that a remedy at law would be adequate.
(b)
Compliance
. Each
Holder covenants and agrees that it will comply with the prospectus delivery
requirements of the Securities Act as applicable to it in connection with sales
of Registrable Securities pursuant to a Registration Statement.
(c)
Discontinued
Disposition
. By its acquisition of Registrable Securities,
each Holder agrees that, upon receipt of a notice from the Company of the
occurrence of any event of the kind described in
Section 4(c)
, such
Holder will forthwith discontinue disposition of such Registrable Securities
under a Registration Statement until it is advised in writing (the “
Advice
”)
by the Company that the use of the applicable Prospectus (as it may have been
supplemented or amended) may be resumed. The Company will use its
best efforts to ensure that the use of the Prospectus may be resumed as promptly
as it practicable. The Company may provide appropriate stop orders to
enforce the provisions of this
Section
7(c)
.
(d)
Amendments and
Waivers
. The provisions of this Agreement, including the provisions of
this sentence, may not be amended, modified or supplemented, and waivers or
consents to departures from the provisions hereof may not be given, unless the
same shall be in writing and signed by the Company and the Holders of
at least a majority
of the then outstanding
Registrable Securities. If a Registration Statement does not register all of the
Registrable Securities pursuant to a waiver or amendment done in compliance with
the previous sentence, then the number of Registrable Securities to be
registered for each Holder shall be reduced
pro
rata
among all Holders and
each Holder shall have the right to designate which of its Registrable
Securities shall be omitted from such Registration Statement. Notwithstanding
the foregoing, a waiver or consent to depart from the provisions hereof with
respect to a matter that relates exclusively to the rights of Holders and that
does not directly or indirectly affect the rights of other Holders may be given
by Holders of all of the Registrable Securities to which such waiver or consent
relates;
provided
,
however
, that the
provisions of this sentence may not be amended, modified, or supplemented except
in accordance with the provisions of the immediately preceding
sentence.
(e)
Notices
. Any and all
notices or other communications or deliveries required or permitted to be
provided hereunder shall be delivered as set forth in the Purchase
Agreement.
(f)
Successors and
Assigns
. This Agreement shall inure to the benefit of and be binding upon
the successors and permitted assigns of each of the parties and shall inure to
the benefit of each Holder. The Company may not assign its rights (except by
merger) or obligations hereunder without the prior written consent of Holders
holding at least a majority of the then outstanding Registrable Securities. Each
Holder may assign their respective rights hereunder in the manner and to the
Persons as permitted under the Purchase Agreement.
(g)
Execution and
Counterparts
. This Agreement may be executed in two or more
counterparts, all of which when taken together shall be considered one and the
same agreement and shall become effective when counterparts have been signed by
each party and delivered to the other party, it being understood that both
parties need not sign the same counterpart. In the event that any
signature is delivered by facsimile transmission or by e-mail delivery of a
“.pdf” format data file, such signature shall create a valid and binding
obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such facsimile or “.pdf”
signature page were an original thereof.
(h)
Governing
Law
. All questions concerning the construction, validity,
enforcement and interpretation of this Agreement shall be determined in
accordance with the provisions of the Purchase Agreement.
(i)
Cumulative
Remedies
. The remedies provided herein are cumulative and not
exclusive of any other remedies provided by law.
(j)
Severability
. If any
term, provision, covenant or restriction of this Agreement is held by a court of
competent jurisdiction to be invalid, illegal, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired
or invalidated, and the parties hereto shall use their commercially reasonable
efforts to find and employ an alternative means to achieve the same or
substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be
the intention of the parties that they would have executed the remaining terms,
provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.
(k)
Headings
. The
headings in this Agreement are for convenience only, do not constitute a part of
this Agreement, and shall not be deemed to limit or affect any of the provisions
hereof.
(l)
Independent Nature of
Holders’ Obligations and Rights
. The obligations of each
Holder hereunder are several and not joint with the obligations of any other
Holder hereunder, and no Holder shall be responsible in any way for the
performance of the obligations of any other Holder hereunder. Nothing
contained herein or in any other agreement or document delivered at any closing,
and no action taken by any Holder pursuant hereto or thereto, shall be deemed to
constitute the Holders as a partnership, an association, a joint venture or any
other kind of entity, or create a presumption that the Holders are in any way
acting in concert with respect to such obligations or the transactions
contemplated by this Agreement. Each Holder shall be entitled to
protect and enforce its rights, including without limitation the rights arising
out of this Agreement, and it shall not be necessary for any other Holder to be
joined as an additional party in any proceeding for such purpose.
[signature
page follows]
IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as
of the date first written above.
|
PRESSURE BIOSCIENCES INC.
|
|
|
|
By:
|
|
|
|
Name:
|
Richard
T. Schumacher
|
|
|
Title:
|
President
and Chief Executive
Officer
|
[SIGNATURE
PAGE OF HOLDERS FOLLOWS]
[SIGNATURE
PAGE OF HOLDERS TO REGISTRATION RIGHTS AGREEMENT]
|
|
For Individuals
:
|
|
Name
of Holder:
|
|
|
|
Signature
of Holder:
|
|
|
For Entities
:
|
|
Name
of Holder:
|
|
Signature
of Authorized Signatory of Holder:
|
|
|
|
Name
of Authorized Signatory:
|
|
|
|
Title
of Authorized Signatory:
|
|
[SIGNATURE
PAGES CONTINUE]
ANNEX
A
Plan of
Distribution
Each
selling stockholder (the “
Selling
Stockholders
”) of the Registrable Warrant Shares and any of their
pledgees, assignees, and successors-in-interest may, from time to time, sell any
or all of their Registrable Warrant Shares on any stock exchange, market or
trading facility on which the shares of common stock are traded or in private
transactions. These sales may be at fixed or negotiated
prices. A Selling Stockholder may use any one or more of the
following methods when selling shares:
|
·
|
ordinary
brokerage transactions and transactions in which the broker-dealer
solicits purchasers;
|
|
·
|
block
trades in which the broker-dealer will attempt to sell the shares as agent
but may position and resell a portion of the block as principal to
facilitate the transaction;
|
|
·
|
purchases
by a broker-dealer as principal and resale by the broker-dealer for its
account;
|
|
·
|
an
exchange distribution in accordance with the rules of the applicable
exchange;
|
|
·
|
privately
negotiated transactions;
|
|
·
|
settlement
of short sales entered into after the effective date of the registration
statement of which this prospectus is a
part;
|
|
·
|
broker-dealers
may agree with the Selling Stockholders to sell a specified number of such
shares at a stipulated price per
share;
|
|
·
|
through
the writing or settlement of options or other hedging transactions,
whether through an options exchange or
otherwise;
|
|
·
|
a
combination of any such methods of sale;
or
|
|
·
|
any
other method permitted pursuant to applicable
law.
|
The
Selling Stockholders may also sell shares under Rule 144 under the Securities
Act of 1933, as amended (the “
Securities Act
”), if
available, rather than under this prospectus.
Broker-dealers
engaged by the Selling Stockholders may arrange for other brokers-dealers to
participate in sales. Broker-dealers may receive commissions or
discounts from the Selling Stockholders (or, if any broker-dealer acts as agent
for the purchaser of shares, from the purchaser) in amounts to be negotiated,
but, except as set forth in a supplement to the Prospectus, in the case of an
agency transaction not in excess of a customary brokerage commission in
compliance with NASDR Rule 2440; and in the case of a principal transaction a
markup or markdown in compliance with NASDR IM-2440.
The
Selling Stockholders and any broker-dealers or agents that are involved in
selling the shares may be deemed to be “underwriters” within the meaning of the
Securities Act in connection with such sales. In such event, any
commissions received by such broker-dealers or agents and any profit on the
resale of the shares purchased by them may be deemed to be underwriting
commissions or discounts under the Securities Act. Each Selling
Stockholder has informed the Company that it does not have any written or oral
agreement or understanding, directly or indirectly, with any person to
distribute the Registrable Warrant Shares. In no event shall any broker-dealer
receive fees, commissions and markups which, in the aggregate, would exceed
eight percent (8%).
The
Company is required to pay certain fees and expenses incurred by the Company
incident to the registration of the shares. The Company has agreed to
indemnify the Selling Stockholders against certain losses, claims, damages and
liabilities, including liabilities under the Securities Act.
Because
Selling Stockholders may be deemed to be “underwriters” within the meaning of
the Securities Act, they will be subject to the prospectus delivery requirements
of the Securities Act including Rule 172 thereunder. In addition, any
securities covered by the Prospectus which qualify for sale pursuant to Rule 144
under the Securities Act may be sold under Rule 144 rather than under the
Prospectus. There is no underwriter or coordinating broker acting in
connection with the proposed sale of the resale shares by the Selling
Stockholders.
The
Company has agreed to keep the Prospectus effective until the earlier of (i) the
date on which the shares may be resold by the Selling Stockholders without
registration and without regard to any volume limitations by reason of Rule 144
under the Securities Act or any other rule of similar effect or (ii) all of the
shares have been sold pursuant to this prospectus or Rule 144 under the
Securities Act or any other rule of similar effect. The resale shares
will be sold only through registered or licensed brokers or dealers if required
under applicable state securities laws. In addition, in certain states, the
resale shares may not be sold unless they have been registered or qualified for
sale in the applicable state or an exemption from the registration or
qualification requirement is available and is complied with.
Under
applicable rules and regulations under the Exchange Act, any person engaged in
the distribution of the resale shares may not simultaneously engage in market
making activities with respect to the common stock for the applicable restricted
period, as defined in Regulation M, prior to the commencement of the
distribution. In addition, the Selling Stockholders will be subject
to applicable provisions of the Exchange Act and the rules and regulations
thereunder, including Regulation M, which may limit the timing of purchases and
sales of shares of the common stock by the Selling Stockholders or any other
person. The Company will make copies of the Prospectus available to
the Selling Stockholders and have informed them of the need to deliver a copy of
the Prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule 172 under the Securities Act).
ANNEX
B
PRESSURE
BIOSCIENCES INC.
Selling
Securityholder Notice and Questionnaire
The
undersigned beneficial owner of Registrable Securities (as defined in the
Registration Rights Agreement) of Pressure BioSciences Inc., a Massachusetts
corporation (the “
Company
”),
understands that the Company has filed or intends to file with the Securities
and Exchange Commission (the “
Commission
”)
a registration statement (the “
Registration
Statement
”) for the registration and resale under Rule 415 of the
Securities Act of 1933, as amended (the “
Securities
Act
”), of the Registrable Securities, in accordance with the terms of the
Registration Rights Agreement (the “
Registration
Rights Agreement
”) to which this document is annexed. A copy
of the Registration Rights Agreement is available from the Company upon request
at the address set forth below. All capitalized terms not otherwise
defined herein shall have the meanings ascribed thereto in the Registration
Rights Agreement.
Certain
legal consequences arise from being named as a selling securityholder in the
Registration Statement and the related prospectus. Accordingly,
holders and beneficial owners of Registrable Securities are advised to consult
their own securities law counsel regarding the consequences of being named or
not being named as a selling securityholder in the Registration Statement and
the related prospectus.
NOTICE
The
undersigned (the “
Selling
Securityholder
”) hereby elects to include the Registrable Securities
owned by it in the Registration Statement.
The
undersigned hereby provides the following information to the Company and
represents and warrants that such information is accurate:
1. Name.
|
(a)
|
Full
Legal Name of Selling Securityholder:
|
|
|
|
|
(b)
|
Full
Legal Name of Registered Holder (if not the same as (a) above) through
which Registrable Securities are held:
|
|
|
|
|
(c)
|
Full
Legal Name of Natural Control Person (which means a natural person who
directly or indirectly alone or with others has power to vote or dispose
of the securities covered by the questionnaire):
|
|
|
|
2. Address
for Notices to Selling Securityholder.
|
|
|
Telephone:
|
Fax:
|
Contact
Person:
|
3. Broker-Dealer
Status.
|
(a)
|
Are
you a broker-dealer?
|
Yes
¨
No
¨
|
(b)
|
If
“yes” to Section 3(a), did you receive your Registrable Securities as
compensation for investment banking services to the
Company?
|
Yes
¨
No
¨
Note:
If no,
the Commission’s staff has indicated that you should be identified as an
underwriter in the Registration Statement.
|
(c)
|
Are
you an affiliate of a
broker-dealer?
|
Yes
¨
No
¨
|
(d)
|
If
you are an affiliate of a broker-dealer, do you certify that you bought
the Registrable Securities in the ordinary course of business, and at the
time of the purchase of the Registrable Securities to be resold, you had
no agreements or understandings, directly or indirectly, with any person
to distribute the Registrable
Securities?
|
Yes
¨
No
¨
Note:
If no,
the Commission’s staff has indicated that you should be identified as an
underwriter in the Registration Statement.
4.
|
Beneficial
Ownership of Other Securities of the Company Owned by the Selling
Securityholder.
|
Except as
set forth below in this Item 4, the undersigned is not the beneficial or
registered owner of any securities of the Company other than the
securities.
|
(a)
|
Type
and amount of other securities beneficially owned by the Selling
Securityholder:
|
|
|
|
|
|
|
|
(b)
|
Shared
or sole ownership? If shared, please indicate the name and
relationship of the party with whom ownership is
shared:
|
|
|
|
|
|
|
5. Relationships
with the Company.
Except as
set forth below, neither the undersigned nor any of its affiliates, officers,
directors or principal equity holders (owners of 5% of more of the equity
securities of the undersigned) has held any position or office or has had any
other material relationship with the Company (or its predecessors or affiliates)
during the past three years.
|
State
any exceptions here:
|
The
undersigned agrees to promptly notify the Company of any inaccuracies or changes
in the information provided herein that may occur subsequent to the date hereof
at any time while the Registration Statement remains effective.
By
signing below, the undersigned consents to the disclosure of the information
contained herein in its answers to Items 1 through 5 and the inclusion of such
information in the Registration Statement and the related prospectus and any
amendments or supplements thereto. The undersigned understands that
such information will be relied upon by the Company in connection with the
preparation or amendment of the Registration Statement and the related
prospectus.
IN
WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice
and Questionnaire to be executed and delivered either in person or by its duly
authorized agent.
Dated:
|
|
|
|
|
|
Beneficial
Owner
:
|
|
|
|
|
For Individuals
:
|
|
|
|
|
|
Signature:
|
|
|
|
|
|
|
|
Name:
|
|
|
|
|
|
For Entities
:
|
|
|
|
|
|
|
By:
|
|
|
|
|
|
|
|
Name:
|
|
|
|
|
|
|
|
Title:
|
|
|
PLEASE
FAX A COPY OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN
THE ORIGINAL BY OVERNIGHT MAIL, TO:
[INSERT
CONTACT DETAILS]
FOR
IMMEDIATE RELEASE
Investor
Contacts:
Richard
T. Schumacher, President & CEO
|
Pressure
BioSciences, Inc.
|
R.
Wayne Fritzsche, Chairman
|
(508)
230-1828 (T)
|
Pressure
BioSciences, Inc. Announces Completion of Private Placement
South
Easton, MA, February 18, 2009 – Pressure BioSciences, Inc. (NASDAQ: PBIO) (“PBI”
or the “Company”) today announced that it has received $1.8 million from the
sale of 156,980 units in a private placement that closed on Thursday, February
12, 2009. Each unit was priced at $11.50 and consists of (i) one
share of non-voting Series A Convertible Preferred Stock, (ii) a warrant to
purchase, at the purchaser’s election, either 10 shares of the Company’s common
stock at $1.25 per share, or one share of Series A Convertible Preferred Stock
at $12.50 per share, expiring 15 months from the closing, and (iii) a warrant to
purchase 10 shares of the Company’s common stock at $2.00 per share, expiring 30
months from the closing. Each share of Series A Convertible Preferred
Stock is convertible into 10 shares of common stock at a conversion price of
$1.15 per common share. The 30-day average closing price of PBI shares of common
stock as reported on the NASDAQ Capital Market as of the close of business on
Wednesday, February 11, 2009, the day before the closing of the private
placement, was $0.82 per share. The units were issued in a
private placement without registration under the Securities Act of 1933, as
amended (the “Securities Act”), in reliance upon the exemption from registration
set forth in Rule 506 of Regulation D promulgated under the Securities
Act.
In
connection with the private placement, prior to the closing, the Company
received $200,000 from one of its distributors to be held in the private
placement escrow account. The distributor requested, and the Company
agreed, that the $200,000 be used as payment for anticipated future purchases of
the Company’s pressure cycling technology (PCT) instrument and consumables
products, and not for an investment in the private placement.
Mr.
Richard T. Schumacher, President and CEO, commented: “We believe that we now
have the financial resources to continue to aggressively address our clearly
stated business goals throughout all of 2009, and into
mid-2010. These goals include (i) a sharpened focus on the large mass
spectrometry market where our collaborators and customers continue to publish
and present data that support the significant competitive advantages of PCT, and
(ii) a sales effort focused on additional but specific PCT product areas where
market penetration and customer purchases have begun, primarily in biomarker
discovery, soil and plant biology, counter-bioterror applications, and tissue
pathology.”
Mr. R.
Wayne Fritzsche, Chairman of the Board of Directors of PBI, commented: “We want
to thank the investors who participated in this financing, including all of the
Company’s officers and a majority of the members of the Board of
Directors. We believe that the combination of funds received,
cash-on-hand, and on-going sales of PCT instruments and consumables, will be
sufficient to support our continuing operations through the second quarter of
2010. We further believe that this is sufficient time to make
measureable progress on our very focused and specific business
goals.”
About
Pressure BioSciences, Inc.
Pressure
BioSciences, Inc. (PBI) is a publicly traded company focused on the development
of a novel, enabling technology called Pressure Cycling Technology
(PCT). PCT uses cycles of hydrostatic pressure between ambient and
ultra-high levels (up to 35,000 psi and greater) to control bio-molecular
interactions. PBI currently holds 13 US and 6 foreign patents
covering multiple applications of PCT in the life sciences field, including such
areas as genomic and proteomic sample preparation, pathogen inactivation, the
control of chemical (enzymatic) reactions, immunodiagnostics, and protein
purification. PBI currently focuses its efforts in the areas of mass
spectrometry and biological sample preparation.
Forward
Looking Statements
Statements
contained in this press release regarding the Company's intentions, hopes,
beliefs, expectations, or predictions of the future are "forward-looking''
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Forward looking statements include statements regarding the sufficiency of
the Company’s cash resources to fund its planned operations through the second
quarter of 2010, the Company’s ability to achieve its business goals, the effect
of the Company’s decision to focus primarily on the application of PCT-enhanced
protein digestion for the mass spectrometry market and the advantages of PCT in
this market, and the use of PCT in biomarker discovery, soil and plant biology,
counter-bioterror, and tissue pathology applications. These statements are based
upon the Company's current expectations, forecasts, and assumptions that are
subject to risks, uncertainties, and other factors that could cause actual
outcomes and results to differ materially from those indicated by these
forward-looking statements. These risks, uncertainties, and other factors
include, but are not limited to: possible difficulties or delays in the
implementation of the Company's strategies that may adversely affect the
Company's continued commercialization of its PCT System; changes in customer’s
needs and technological innovations; the Company’s sales force may not be
successful in selling the Company’s PCT product line because scientists may not
perceive the advantages of PCT over other sample preparation methods,
particularly in the mass spectrometry market; scientists may not be able to
duplicate the results achieved at particular laboratories having already used
PCT; and if actual operating costs are higher than anticipated, or revenues from
product sales are less than anticipated, the Company will need additional
capital sooner than the second quarter of 2010. Further, the Company
expects that it will need additional capital to fund its continuing operations
beyond the second quarter of 2010. Additional risks and uncertainties that could
cause actual results to differ materially from those indicated by these
forward-looking statements are discussed under the heading "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended December 31, 2007, and
other reports filed by the Company from time to time with the SEC. The Company
undertakes no obligation to update any of the information included in this
release, except as otherwise required by law.
Visit us
at our website
http://www.pressurebiosciences.com